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Although CD4 lymphocytes have been identified as the principal target of
the human immunodeficiency virus (HIV), the extent to which infection of other cell
types of the immune system contributes to the observed impairment in the immune
response is unknown. This study investigated the cell types infected with HIV in
peripheral blood, and the relation of virus load in different cell subsets with disease
progression. Two magnetic cell separation techniques were used to purify cell
subsets from 34 HIV seropositive individuals at different stages of disease
progression. HIV proviral sequences within these separate cell populations were
quantified by limiting dilution nested polymerase chain reaction (PCR). HIV-1
DNA was detected in CD4 and CD8 lymphocytes, monocytes, natural killer cells
and dendritic cells. The contribution to total proviral load by different subsets of
peripheral blood mononuclear cells (PBMCs) was estimated by quantitative PCR
combined with measurements of their relative frequency in peripheral blood. This
analysis revealed that CD8 T lymphocytes are a major reservoir of HIV within the
peripheral blood of individuals with AIDS.
Further independent evidence for in vivo infection of CD8 lymphocytes was
obtained by sequence comparisons of the V3 region of the envelope gene.
Numerous sequences were obtained from each purified cell subset and initial
sequence comparisons indicate that different virus populations may be present in
CD4 and CD8 lymphocytes. The functional significance of this will remain unclear
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until such variants can be characterised virologically. A PCR based method was
developed to detect spliced HIV mRNA transcripts whose presence within cells
indicates active viral replication, and differentiates these from cells containing an
inactive provirus. High levels of mRNA expression were detected in CD4
lymphocytes, CD8 lymphocytes and in one case in monocytes. This evidence
indicates that mature CD8 lymphocytes can be actively infected with HIV-1 in vivo
even although they do not express CD4.
This study provides evidence for widespread infection of CD4-negative cells
within the peripheral blood of HIV seropositive individuals, indicating that HIV-1
has a broader cell tropism for different cell types in vivo than described previously.
Active infection of not only CD4 T lymphocytes, but also CD8 T lymphocytes,
natural killer cells and dendritic cells may contribute to the observed decline of these
cell subsets upon disease progression and provide novel mechanisms underlying the
immunodeficiency observed in HIV-infected individuals.
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In 1981 there were reports of an unusually high number of young
homosexual males presenting with immunological abnormalities, often accompanied
by opportunistic infections, neurological disorders, and unusual forms of cancer.
Epidemiological studies suggested that an infectious agent was transmitted through
intravenous drug use, blood transfusion, blood products, vertically from mother to
child and during sexual intercourse. A retrovirus was isolated from lymph node
cells of a patient with lymphadenopathy, lymphadenopathy associated virus (LAV)
(Barre-Sinoussi et al., 1983). In the following year a virus described as HTLV-III
(Human T-lymphotropic virus type III) was isolated from patients with acquired
immunodeficiency syndrome (AIDS) (Gallo et al., 1984). In 1985 a lentivirus,
STLV-III (Simian T-lymphotropic Virus type III) was isolated from captive Asian
macaques with an AIDS like disease (Daniel et al., 1985). It was demonstrated by
electron microscopy that LAV and HTLV-III were morphologically similiar to
members of the lentivirus genus of the family Retroviridae. Comparisons of
genome sequences suggested these viruses were related to Antiviruses of other
animals. LAV and HTLV-III were renamed human immunodeficiency viruses
(HIV). For the AIDS associated virus in macaques the designation simian
immunodeficiency virus (SIV) was adopted. Two distinct types of HIV have been
recognised, HIV-1 and HIV-2.
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The Retroviridae comprise a large family of viruses, and comparison of
nucleotide sequence relationships and genome structure suggest that they belong in
seven distinct genera (Table 1.1) (reviewed in Coffin, 1996). Retroviruses have
several unique features including a diploid RNA genome that encodes the enzyme
reverse transcriptase (RNA-dependent DNA polymerase).
Table 1.1 : Retrovirus Genera
Genus Examples
Av ian-leukos is-sarcoma Rous sarcoma virus (RSV)
Avian myeloblastosis virus (AMV)
Avian erythroblastosis virus (AEV)
Avian myelocytomatosis virus (MC)
Rous-associated virus (RAV)
Mammalian C-type Moleney murine leukemia virus (Mo-MlV)
Harvey murine sarcoma virus (Ha-MSV)
Abelson murine leukemia virus (A-MuLV)
Feline leukemia virus (FeLV)
B-Type viruses Mouse mammary tumor virus (MMTV)
D-Type viruses Mason Pfizer monkey virus (MPMV)
HTLV-BLV group Human T-cell leukemia (or lymphotropic virus)
(HTLV)-l and -2
Lentivirus Human immunodeficiency virus-1 and -2
Simian immunodeficiency virus (S1V)
Feline immunodeficiency virus (BIV)
Spumavirus Simian foamy virus (SFV)
Human foamy virus (HFV)
Feline Syncytium-forming virus (FeSV)
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Their life cycle involves conversion of the genomic RNA into a double stranded
DNA intermediate by the virion-associated reverse transcriptase followed by
mandatory integration of the viral DNA into the host chromosome, a step carried
out by the viral integrase. HIV-1, HIV-2, and SIV belong to the genus lentiviruses.
This genus includes complex exogenous viruses responsible for a variety of
neurological and immunological diseases, but not directly implicated in
malignancies.
HIV infection involves firstly an acute phase including a transiently high
viral load and in some cases a flu-like seroconversion illness. Antibody (Ab) can
be detected from 1 to 10 weeks following exposure. Following seroconversion there
is generally a sharp reduction in the level of virus that can be detected in the plasma.
Seroconversion is followed by virus dissemination in lymphoid tissues and by
continuous virus replication in infected cells. During infection there is a correlation
between disease progression and the presence of increasing amounts of infectious
virus, in the number of infected cells that express viral gene products and a decline
in CD4 lymphocytes. This asymptomatic phase can last for several months to
more than 15 years. Eventually almost all individuals become immunodeficient
presumably because of the low levels of CD4 T cells. This stage of the disease,
AIDS, is associated with immune abnormalities, opportunistic infections,
neurological disorders, weight loss and unusual forms of cancer.
6
1.2 Classification of human immunodeficiency viruses (reviewed in
Luciw, 1996)
Independent isolates of HIV-1 display the greatest sequence variation in the
env gene, which encodes the viral envelope glycoprotein. Based on env gene
sequences, nine subtypes (clades) of HIV-1 (A through I) and five subtypes of HIV-
2 have been classified. Within each subtype there is a high degree of variability.
Although mutation is a major factor responsible for viral variation, recombination
has been postulated to occur in individuals infected with viruses from different
clades of HIV-1 and HIV-2. Some areas of the world harbor predominantely a
single subtype, whereas two or more subtypes may be prevalent in certain other
populations. Molecular epidemiological surveys indicate that the current global
distribution of subtypes is due to viral migration rather than to viral mutation.
HIV-1 viruses are found in several regions of Africa, Asia, Europe, and
both North and South America. HIV-2 is a distinct but genetically related virus
prevalent in West African countries. Although both cause AIDS, individuals
infected with HIV-2 exhibit a longer period of clinical latency and lower morbidity.
At present, the origins of HIV-1 and HIV-2 infection in man remain unclear,
although it is possible that both of these viruses arose from zoonotic transmissions
from nonhuman primates.
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1.3 Clinical Aspects of HIY-1 Infection
Infection with HIV-1 results in a range of clinical conditions from
asymptomatic infection to severe immunodeficiency resulting in opportunistic
infections and neoplasms. A number of classification systems for HIV-1 related
illnesses have been proposed. The most recent Centres for Disease Control (CDC)
system classifies the manifestations of HIV-1 into three clinical categories, A, B,
and C (table 1.2) (reviewed in Hirsch et al., 1996).
Table 1.2 : 1993 revised classification system for HIV infection and















(1) >500/pl Al B1 CI
(2) 200-499/pl A2 B2 C2
(3) < 200/jj.I (Aids
Indicator)
A3 B3 C3
a PGL : Persistent generalised lymphadenopathy
b CD4 T-cell categories correspond to CD4 T lymphocytes per pi blood.
(i) Acute Primary Infection Syndromes (Clinical category A)
Some HIV-1 seroconversions are asymptomatic while others are associated
with a self-limited mononucleosis or influenza-like syndrome characterised by fever,
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rigors, arthralgias, myalgias, malaise, lethargy, anorexia, nausea, diarrhoea, sore
throat and a urticarial or vesicular rash. Neurological symptoms including
headaches, a stiff-neck, irritability and depression may also be evident. This illness
may last 2 to 3 weeks but usually results in recovery. Incubation periods ranging
from a few days to 3 months have been described. During primary infection
plasma HIV-1 titres increase generally for a few weeks until a specific antibody
response is mounted.
(ii) Asymptomatic Infection and Persistent Generalised Lymphadenopathy
(Clinical Category A).
In adults the mean period of asymptomatic infection before the development
of AIDS has been estimated at 10 years in the absence of therapy. Within the HIV-
1 seropositive population CD4 lymphocyte counts give an indication of the degree
of immunosuppression and predict the risk of developing AIDS. Evidence suggests
that the risk of developing AIDS in individuals with CD4 counts less than 200/pl
is much greater than in those individuals with higher CD4 counts. More recently
plasma viral load measurements have become more accurate due to the development
of PCR techniques and these measurements are also useful in predicting disease
progression. CD4 counts and viral load measurements have also proved effective
in determining an individuals response to anti-retroviral therapy.
9
Figure 1.1 : The HIV-1 virion structure (Modified from Fields Virology, 1996)






(iii) Symptomatic HIV Infection (Clinical Categories B and C)
After a variable period of asymptomatic HIV-1 infection a variety of
symptoms indicate clinical deterioration including chronic fevers, night sweats,
diarrhoea, weight loss, herpes zoster, oral thrush (OC), hairy leukoplakia,
cytomegalovirus disease, encephalopathy, or pneumonocystis carinii pneumonia
(PCP). The term AIDS-related complex (ARC) is used when two or more
symptoms or two or more laboratory findings are indicative of immune dysfunction.
Once the diagnosis of AIDS has been made, survival is often less than two years,
although considerable variability exists depending on various factors such as age and
therapy.
1.4 Virion Structure
The HIV-1 virion is spherical in shape with a diameter of approximately 110
nm (figure 1.1) (reviewed in Levy, 1993; Luciw, 1996). A lipid bilayer envelope
surrounds a cone shaped nucleocapsid which is connected at the narrow end to the
lipid bilayer. The region between the viral envelope and nucleocapsid has been
termed the paranucleoid region, core shell, or lateral body. Each mature virion
contains two molecules of single-stranded RNA genome encapsulated by proteins
that have been proteolytically processed from the Gag precursor polypeptide.
These proteins are: the matrix protein (MA), located between the nucleocapsid and
the virion envelope; the major capsid protein (CA) which forms the capsid shell;
and the nucleocapsid protein (NC) which binds tightly to the RNA genome. The
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5' ends of the genome are base paired. A transfer RNA (tRNA) molecule is
positioned near the 5' end of each genomic RNA strand and serves as the primer for
initiation of negative strand viral DNA synthesis by reverse transcriptase (RT).
Several enzymes derived from the pol gene precursor polypeptide are also packaged
into virions; protease (PR), reverse transcriptase (RT), and integrase (IN). Viral
protein R (Vpr) (and Vpx for SIV and HIV-2) are small proteins associated with
the nucleocapsid.
HIV particles have approximately 72 heterodimers of the envelope
glycoprotein (Env gp), each of these is composed of a surface subunit (gpl20) that
interacts with the transmembrane subunit (gp41) through noncovalent bonds.
1.5 Viral Genome Structure and Organisation (reviewed in
Levy, 1993; Coffin, 1996; Luciw, 1996)
Infectious virions of HIV and SIV contain two copies of single stranded
RNA of positive polarity in respect to translation. In the early steps of replication
the virus RNA is converted into double stranded DNA which is then integrated into
the host genome. The reverse transcription and synthesis of double stranded DNA
results in the formation of two identical long terminal repeats (LTRs) flanking the
viral genes. Therefore HIV and SIV have two genetic forms, single stranded RNA
in virions and double stranded DNA (provirus) within the cell.
Most retroviruses contain three long, continous open reading frames (ORFs)
coding for the Gag, Pol and Env proteins. However, the genomic organisation of
11
Figure 1.2 : Genomic Organisation of HIV-1 and HIV-2/SIVMAC (From Fields


























lentiviruses, including HIV-1, is more complex (figure 1.2) and through the use of
ribosomal frame shifting, alternative splice sites, and bicistronic RNAs, the HIV
genome encodes three structural proteins Gag, Pol, and Env, and six auxiliary
proteins, Tat, Rev, Vif, Vpr, Vpu, and Nef. Expression of the HIV-1 genome is
mediated by three classes of mRNA: unspliced (9.0 kb), single-spliced (4.5 kb) and
multiply spliced, (1.8-2.2 kb). The structural protein precursors Gag and Pol are
produced from unspliced RNAs, while Env, Vif, Vpr and Vpu proteins are encoded
by singly spliced mRNA. Other regulatory genes are expressed from multiply
spliced mRNAs.
Mutations affecting either Tat or Rev severely impair viral replication but
mutations affecting the other auxiliary proteins do not generally perturb the viral
replication kinetics, at least in vitro and are usually referred to as accessory gene
products.
1.6 Viral Proteins (Reviewed in Levy, 1993; Coffin, 1996; Luciw, 1996)
(i) Core/Capsid Proteins
The gag gene is translated into a polyprotein precursor (p55) from an
unspliced mRNA and is subsequently cleaved by the viral protease into the mature
non-glycosylated capsid proteins of HIV, matrix (MA, p 17), capsid (CA, p24), p2,
nucleocapsid (NC, p7), pi and p6.
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(a) Matrix (MA, pi 7)
Mature MA contains about 130 amino acids, with a molecular weight of 17
to 18 kDa and is located in the matrix between the virion capsid and the envelope.
The MA protein has a close association with the viral membrane and can be cross-
linked to lipid, and has a stretch of basic amino acids resembling the nuclear
localisation signals of nucleophilic proteins. MA may be part of the viral
nucleoprotein complex produced after reverse transcription and may mediate nuclear
import of this pre-integration complex. Deletions in MA also impair envelope
glycoprotein incorporation into virions resulting in defective virus particles.
(b) Capsid Protein (CA, p24)
The capsid protein (CA) is released from the central portion of the Gag
polyprotein by two cleavages mediated by the viral protease. The mature form of
CA contains about 240 amino acids (molecular weight of 24 to 27 kDa), has a high
degree of hydrophobicity, and is a major subunit of the capsid shell. The domain
governing nucleocapsid assembly is located in the C-terminal portion of CA.
Specific interactions of CA with the viral RNA genome and other Gag proteins may
also play a role in CA function during capsid assembly.
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(c) Nucleocapsid (NC, p7)
Viral protease-mediated cleavage of the C-terminal portion of Gag produces
the nucleocapsid (NC) a protein of about 70 amino acids with a molecular weight
ranging from 7 to 9 kDa. This basic, hydrophilic protein binds viral genomic RNA
in the nucleocapsid and may condense the RNA genome for packaging into capsids.
A cysteine-histidine motif present in NC is similiar to the metal-binding finger
domains of several proteins that interact with nucleic acids. The cysteine-histidine
motif may also influence transfer RNA (tRNA) annealing to the viral genome. NC
may be involved in the early stages of viral replication such as virus uncoating and
reverse transcription since it is an intrinsic part of the nucleocapsid. P6, acts later
in replication and contains sequences required for efficient release of newly budded
virions from the infected cell.
(ii) The Viral Enzymes
The viral enzymes protease (PR, plO), reverse transcriptase (RT) and RNase
H (p66/p51) and integrase (IN, p32), are produced by cleavage of the Gag-Pol
polyprotein (pl60). In HIV the gag and pol genes overlap by 241 nucleotides with
the the pol gene is in a -1 reading frame with respect to gag. Expression of the pol
gene is facilitated by a ribosomal frameshift which occurs at a low frequency and
is directed by a short sequence located in the overlap between the two genes that
allows a 'slip-back' of the ribosome into the -1 position. This results in relatively
large amounts of gag transcripts and smaller quantities of the pol transcripts.
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(a) Protease (PR)
The mature form of the protease (PR) is 99 amino acids in length (molecular
weight 10 kDa). For processing, the Gag-Pol polyprotein dimerizes in the
infected cell, and the mature PR dimer is released by autocatalytic cleavage. The
fully active PR dimer has multiple specificity and targets five cleavage sites in Gag,
and seven in the Gag-Pol polyproteins. Site specific mutagenesis demonstrates that
PR is essential for replication.
(b) Reverse transcriptase (RT) and RNase H
P66 is cleaved from the Gag-Pol polyprotein and forms a homodimer.
Subsequently, one subunit of p66 is cleaved by PR to yield a heterodimer composed
of p51 and p66. Both the heterodimer and p66 homodimer display RNase H and RT
activity . RT is an RNA-dependent DNA polymerase which produces DNA from
both RNA and DNA templates and requires an oligonucleotide primer. RNase H
cleaves RNA in RNA DNA hybrids and is necessary for the synthesis of double
stranded DNA.
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(c) Integrase (IN, p32)
The Gag-Pol precursor polypeptide is proteolytically processed by viral PR
to produce a 32 kDa integrase. An integrase domain near the N-terminus contains
pairs of histidine and cysteine residues that adopt a structure similiar to the metal-
finger motif of DNA binding proteins. Integrase possesses both DNA cleavage and
joining (or strand-transfer) activities and mediates covalent linkage of linear double
stranded viral DNA into the host cell genome.
(iii) The envelope glycoprotein
A spliced transcript of the HIV-1 genome encodes both Vpu and the
precursor polyprotein for the envelope glycoprotein. This bicistronic mRNA is
synthesised at a late stage of viral replication and its expression is dependent on the
post-transcriptional function of the viral rev gene. Extensive glycosylation of the
Env precursor polyprotein in the endoplasmic reticulum (ER) and golgi apparatus
during synthesis produces gpl60. Intracellular cleavage of gpl60 yields a 550
amino acid N-terminal subunit (gpl20), and a 330 amino acid C-terminal subunit
(gp41). The processed Env oligomers are directed out of the golgi compartment
and into the plasma membrane.
The envelope glycoprotein is a heterodimer consisting of the gpl20 and
gp41 subunits held together by noncovalent bonds which are themselves organised
into an oligometric complex. High resolution electron microscopy of virions reveals
trimeric symmetry of the envelope glycoprotein spikes.
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(a) The external envelope glycoprotein (gpl20)
gpl20 is a highly glycosylated, hydrophilic protein positioned on the external
surface of virion membranes as well as on the plasma membranes of infected cells.
HIV-gpl20 contains 24 potential sites for N-linked glycosylation (Asn-X-Ser/Thr)
and 17 of these are modified with carbohydrate side chains. Therefore very few
regions of the peptide backbone protrude from the carbohydrate mass. HIV-gpl20
has 18 cysteine residues, that are highly conserved in the glycoproteins of diverse
HIV-1 and HIV-2 or SIV strains and are presumed to play a critical role in its
structure and function. A model for the gpl20 subunit, based in part on
biochemical analysis, shows nine intra-chain disulphide bonds. This disulphide
bonding pattern delineates gpl20 into several different regions which include five
conserved domains (C1-C5), five hypervariable domains (V1-V5), and a
conformation dependent domain that interacts with the CD4 receptor.
(b) The trasmembrane envelope glycoprotein (gp41)
gp41 is a relatively hydrophobic protein that traverses the lipid bilayer
membranes of both virions and cells and is classified as a type 1 integral membrane
protein. The gp41 sequence contains four potential glycosylation sites and three
cysteine residues. A stretch of about 20 amino acids at the N-terminus of gp41 are
hydrophobic and are required for the fusion of the virion membrane with the cell
plasma membrane during virus entry. A second hydrophobic domain spans the lipid
bilayer and enables gp41 to serve as an anchor for gpl20. The region between
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these two hydrophobic domains is external to the membrane and contains a highly
conserved sequence similiar to the leucine zipper motif implicated in protein-protein
interactions of a variety of viral and cellular proteins.
(iv) Essential Auxiliary Proteins
The relative levels of different HIV-1 mRNAs are controlled by the viral
regulatory factors Tat and Rev, as well as by cellular factors.
(a) Tat (Transcription activator)
Tat is encoded by two exons, one 5' and one within the env gene. Tat is a
transactivator of LTR-directed gene expression and functions through a cis-acting
sequence, designated the Tat response element (TAR), which is located in the repeat
(R) portion of the LTR. TAR is present in transcripts and folds into a characteristic
stem-loop structure. Several different mechanisms of the Tat/TAR interaction have
been proposed. These include bypassing of a transcriptional termination site,
stimulation of transcription initiation by simultaneous interaction with the nascent
RNA and transcription factors, or combinations of these mechanisms. Tat has also




Viral gene expression is modulated during HIV replication such that early
in infection only multiply spliced mRNA species accumulate within the cytoplasm
of infected cells while unspliced and incompletely spliced viral mRNAs remain
confined to the nucleus. Only late in infection do the incompletely spliced RNAs
accumulate within the cytoplasm and become translated into the viral structural
proteins.
Like tat, the rev gene is composed of two exons, one 5' and one within the
env gene. The Rev protein binds to a cis-acting RNA target sequence, the Rev
responsive element (RRE), so preventing the nuclear sequestration of incompletely
spliced viral transcripts. Rev therefore increases the cytoplasmic levels of unspliced
and partially spliced HIV-1 mRNAs, resulting in the efficient expression of the viral
proteins.
(v) Accessory Proteins
(a) Vif (Viral Infectivity Factor)
The gene encoding Vif is located immediately downstream of the poi gene.
Vif, a cytoplasmic protein, is synthesised from an open reading frame encoding 193
amino acids (molecular weight 23 kDa). Virions generated in its absence are as
much as 1000 times less infectious. In comparison, cell-to-cell infection is only
slightly impaired in the absence of Vif, indicating that the defect lies primarily in
the progeny virions. Studies have failed to document a notable difference in either
19
the quantity, processivity, or the apparent molecular weight of envelope and other
viral proteins from virions generated in the absence of Vif and the reverse
transcriptase from these virions was capable of efficiently initiating DNA synthesis.
Vif may therefore act late during virion assembly and be necessary for the proper
packing of the viral nucleoprotein core.
(b) Vpr (Viral Protein R)
Vpr is a 14 kDa virion-associated protein translated from a singly spliced
mRNA, the product of which is dependent on Rev function and thus accumulates
at late times in infection. In mature virions, Vpr is associated with the
nucleocapsid and may play a role in an early step of the virus life cycle such as
nuclear localisation of the viral pre-integration complex. Vpr-positive strains grow
faster and produce moderately higher levels of virus than their Vpr-negative
counterparts. This is more pronounced for infection of primary macrophages but
not in primary T cells, suggesting that Vpr function may be important in specific
target cells. Vpr may influence viral gene expression by altering a host cell
regulatory mechanism.
A strong sequence homology exists between the viral protein Vpx of HIV-2
and Vpr of HIV-1. Vpx is also packaged into mature virions and confers a rapid
growth advantage.
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(c) Vpu (Viral Protein U)
Vpu is a 16kDa protein translated from a singly spliced mRNA dependent
on Rev function and produced at late times in infection. The reading frame for Vpu
overlaps the 5' end of env but in a different reading frame. The absence of Vpu
results in virions containing multiple cores and virus budding into vacuolar
compartments as opposed to the plasma membrane. Vpu has been demonstrated to
degrade CD4 in the endoplasmic reticulum (ER). In infected cells, CD4 is also
trapped by the Env gp in the ER and produces gpl60-CD4 complexes.
Consequently, surface expression of CD4 is downregulated, and cleavage of gpl60
to gpl20 and gp41 is reduced. By decreasing the stability of intracellular CD4, Vpu
reduces the formation of gpl60-CD4 complexes and thereby increases the rate of
gpl60 processing.
(d) Nef (Negative Factor)
Nef, like Tat and Rev, is expressed early in the viral replication, however
its function is not essential in vitro. The nef gene of HIV-1 extends from the 3' end
of env into the U3 domain of the 3' LTR. Nef is translated from two multiply
spliced early transcripts that are independent of the post-transcriptional function of
Rev. Initial studies characterised Nef as a down regulator of viral gene expression,
but later reports found no Nef mediated transcriptional inhibition of HIV-1
replication, and kinetic studies indicated a positive effect of Nef. Expression of
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HIV nef genes in CD4 T cells is also associated with a reduction in the level of
CD4 receptor on the cell surface.
1.7 The life cycle of HIV-1 (Reviewed in Levy, 1993; Luciw, 1996)
(i) Attachment, Entry and nuclear transport.
Attachment and Entry.
HIV-1 binds to the surface of cells expressing the cellular receptor for HIV-
1, CD4 (Dalgleish et al., 1984; Maddon et al., 1986; Klazmann et al., 1984).
Sattentau and Moore (1991) demonstrated that when a soluble recombinant form of
CD4 complexes with gpl20 conformational changes are induced within the envelope
glycoprotein oligomers resulting in increased exposure of gp41 epitopes, including
the hydrophobic amino terminus of the transmembrane envelope glycoprotein (gp41)
allowing entry of the virus into the cytoplasm (Levy 1993). (see section 3.1).
Two studies investigating the crystal structure of the gp41 ectodomain, have
revealed a triple-stranded alpha-helical coiled coil region with the amino terminus
at its tip within the core. A carboxy-terminal alpha-helix packs against the outside
of the coiled coil, placing the amino and carboxy termini near one another at one
end of a rod like molecule. The helical regions are separated by an
immunodominant region which contains a short loop held together by an intra¬
molecular disulphide bond (Weissenhorn et al., 1997; Chan et al 1997). The crystal
structures show that three molecules of each peptide fragment are present in the
stable configuration, suggesting that the glycoprotein complex on the HIV-1
envelope is trimeric (Chan et al., 1997). The structure of gp41 is similiar to the
low pH induced conformation of influenza hemagglutinin (HA), however unlike
influenza viruses HIV-1 fuses at the plasma membrane without a pH change, in a
process that involves binding of the virus to CD4 and a chemokine co-receptor
(Alkhatib etal., 1996; Choe et al., 1996; Deng et al., 1996; Doranz et al., 1996;
Dragic et al., 1996; Feng et al., 1996) (section 3.2).
These crystallized helices represent a post HIV-cell fusion structure,
however the pre-fusion structure can be inferred. Binley and Moore (1997)
compared the pre-fusion structure to a mousetrap. The helical peptide fragments
represent the two halves of the trap, separated by a disulphide loop at the "hinge".
A "needle" (the fusion peptide) is attached to one end under tension. Binding to the
CD4 receptor brings both helices together and fires the fusion peptide down into the
target cell membrane initiating fusion of viral and cell membranes. The binding
of HIV-1 to soluble CD4 is enough to cause conformational changes in the viral
envelope (Sattentau and Moore, 1991) but these changes create or expose the co-
receptor binding sites on gpl20 allowing the fusion peptide to reach the cell
membrane (Wu et al., 1996; Trkola et al., 1996).
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Nuclear Transport: The role of vpr and pi 7 in nuclear transport in non
dividing cells and vpr in cell cycle arrest.
After infection, the preintegration complex (PIC) of HIV-1 is rapidly
transported to the nucleus using the host cell active transport processes obviating the
requirement of host cell division in establishment of the integrated provirus
(Bukrinsky et al., 1992). The ability of HIV-1 to replicate in non-dividing cells is
partly due to the karyophilic properties of the uncoated PICs. (Bukrinsky et al.,
1993), reflected by the presence of nuclear localisation signals (NLSs) on at least
two of its components MA, and Vpr (Bukrinsky et al., 1993; Goldfarb, 1995; von-
Schwedler et al., 1995; Mahalingarn et al., 1997).
The HIV-1 MA protein is a viral membrane protein, myristic acid is a
primary determinant of Gag protein-membrane interactions (Spearman et al., 1997).
MA is also involved in the nuclear import of PICs, this requires the transfer of some
MA molecules to the maturing core particle during virus assembly (Goldfarb, 1995).
Phosphorylation of Gag MA on tyrosine and serine prior to and during virus
infection facilitates its dissociation from the membrane (Bukinskaya et al., 1996),
IN binds the tyrosine phosphorylated C terminus of a subset of MA proteins,
thereby recruiting these molecules into the virion core and subsequently into the
uncoated viral nucleoprotein complex (Gallay et al., 1995 a and b).
MA contains in its proximal portion a stretch of basic residues that act as a
NLS recognised by the importin/karyopherin pathway (Gallay et al., 1996;
Bukrinsky et al., 1993). In the absence of a functional vpr gene, MA NLS mutant
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viruses fail to replicate efficiently in macrophages (Bukrinsky et al., 1993; von-
Schwedler et al., 1995), and cannot establish a stable infection in quiescent T
lymphocytes (von-Schwedler et al., 1995). The MA NLS is recognised by RchI a
member of the karyopherin-alpha family. Evidence suggests that a member of this
family participates in docking the HIV-1 nucleoprotein complex at the nuclear pore
(Gallay et al., 1996).
The vpr gene product of HIV-1 is a virion-associated protein that is essential
for efficient viral replication in monocytes and macrophages. Vpr is packaged
efficiently into viral particles through interactions with the p6 domain of the Gag
polyprotein p55Gag. Vpr regulates the nuclear import of HIV-1 by binding to
karyopherin alpha and increasing its affinity for viral NLSs, including the NLS of
MA. Virion-packaged Vpr can also arrest infected T cells in the G2 phase. HIV-1
does not replicate in quiescent (GO) T lymphocytes, however it can productively
infect T cells arrested in either Gl-S or G2 phase of the cell cycle (reviewed in
Bukrinsky et al., 1997). Mahalingam et al (1997) revealed that nuclear import,
virion incorporation and cell cycle arrest are mediated by distinct functional domains
of Vpr.
In an early study, Burkrinsky et al (1992) reported that HIV-1 integrase was
not required for nuclear import. However, in a more recent study, Gallay et al
(1997), demonstrated that the integrase enzyme can connect the HIV-1 PIC with the
cell nuclear import machinery via a NLS-mediated recognition of IN by members
of the important/karyopherin-alpha family.
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(ii) Reverse Transcription
(a) Synthesis of Minus Strand DNA
Viral particles are partially uncoated immediately after entry into cells to
produce a large nucleoprotein complex. HIV-1 has a characteristic molecule of
tRNA base paired to the primer binding region near the 5' end of the genome, and
reverse transcription is initiated from this primer (figure 1.3). In vitro the most
prominent early product is strong stop DNA, which is a copy of the short region
consisting of R and U5 lying between the primer binding site and the 5' end of the
genome. The strong stop DNA, still attached to the tRNA pimer, must transfer,
with the reverse transcriptase, to the other end of the genome in order for DNA
synthesis to continue. The driving force for "jumping" may be the affinity of the
reverse transcriptase enzyme for the template RNA, and the capsid structure rather
than sequence complementarity may play a major role in ensuring correct strand
transfer. The RNase H activity of reverse transcriptase is also an essential factor
in strand transfer as it removes the newly reverse transcribed RNA, leaving the
DNA free to pair with the R sequence at the 3' end. Minus strand DNA synthesis
then continues on the viral RNA template by the viral RT to the 5' end of the viral
RNA genome. Elongation of the growing DNA chain on the RNA template occurs
simultaneously with degradation of the template by the RNase H activity of the RT
enzyme.
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Figure 1.3 : Mechanism of viral DNA synthesis. Thin lines depict RNA; medium
lines, minus-strand DNA; thick lines plus-strand DNA. (From Fields Virology 1996)
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(b) Synthesis of Plus-Strand DNA
For synthesis of plus strand DNA, HIV like other lentiviruses requires two
primers; a polypurine track (PPT) which is a run of at least nine A and G residues
and borders the U3 domain in the 3' LTR and a central PPT (cPPT) located at the
end of the pol gene sequence. The PPT sequence avoids digestion by RNase H,
and its 3' end primes plus-strand DNA synthesis. Following initiation plus strand
DNA is elongated to the end of the minus strand DNA template to produce plus
strand strong-stop DNA. A second strand transfer then occurs so the tRNA primer
binding site in the plus strand viral DNA is base paired with the 3' end of the minus
strand strong stop DNA. RT continues, elongating the plus strand DNA to the
central termination signal (CTS) located immediately 3' to the cPPT. In addition,
plus strand DNA initiated at the cPPT is elongated to the end of the minus strand
DNA template. About 100 nucleotides of plus strand DNA, between the cPPT and
the CTS, are displaced. Cellular enzymes remove the displaced sequences and seal
the plus strand to yield double-stranded linear DNA which has an LTR at each end.
The primer RNAs are removed from the 5' ends of each strand. The diploid
genome is not necessary for reverse transcription and diploidy may provide a means
for repairing physical damage to the genome by allowing recombination during
reverse transcription.
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(ii) Integration of Viral DNA
Integration is a process unique to retrovirus replication. Following viral
DNA synthesis, the core structure containing linear DNA, the CA, the integrase
enzyme (IN) and possibly RT and NC proteins, enters the nucleus. Evidence would
suggest that nuclear localisation signals are present in the matrix protein and/or
Vpr. Once in the nucleus HIV is integrated into the host genome in its linear form,
flanked by both the 5' and 3' LTRs. The ends of the LTR contain "att" sites which
provide a signal for integration which is catalysed by the viral IN enzyme. In order
for integration to occur the 3' terminal two bases at either end of the viral DNA are
removed by the cleavage reaction of the IN, leaving a 3'-OH end. The 3' ends of
the viral DNA are joined to previously nicked sites in the host DNA. The
integration reaction leaves single-stranded gaps and two mismatched nucleotides at
each 5' terminus. Host cell enzymes remove the mismatched nucleotides, fill the
gaps, and nick-seal the remaining ends.
(Hi) Transcription
Once the provirus is integrated into cellular DNA, the next stages of
replication occur utilising cellular systems. Cellular RNA polymerase II synthesises
viral RNA from the proviral DNA, similiarly to cellular mRNA. The provirus is
transcribed into a single RNA precursor, which is subsequently processed by
polyadenylation at the 3' end of R to yield a genome-length molecule and by
splicing to generate subgenomic mRNA species.
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The LTRs are identical in nucleotide sequence but functionally different.
Only the 5' LTR is active for transcription initiation and it is likely that the 3' LTR
configuration is not open to transcription factors. The U3 domain of HIV contains
basal promoter elements, including a TATAA box for initiation by host cell RNA
polymerase II, and sites for binding the cellular transcription factor SP1.
Immediately upstream of the core promoter and TATAA box, HIV contains one
or more copies of the 10 bp sequence (GGGACTTTCC) that are recognised by the
T-cell enhancement factor NF-kB. This may be significant in HIV infection as cell
activation is required for HIV replication and T cells are generally quiescent.
(iv) Processing of Viral Transcripts
(a) Capping Group
A m7GPPP capping group is attached to the 5' end of viral mRNAs during
synthesis by the cellular transcription machinery. This structure may be important
for translation.
(b) Internal Methylation
Retroviral genomes are posttranscriptionally modified by occasional
methylation on the 6 position of A residues. It has been suggested that methylation
is important for the regulation of splicing.
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(c) Polyadenylation
Termination of transcription does not occur in the 5' LTR but only in the 3'
LTR, perhaps due to differences in the secondary structures of the LTRs. Most
primary transcripts are then processed by splicing and 3' -end maturation to yield
mRNAs. Primary transcripts are endonucleolytically cleaved and then a poly(A)
tail of 200 to 300 nucleotides is added by the poly(A) polymerase. Signals in U3
and R regions of the 3' LTR (AAUAAA and a downstream GU-rich element) are
recognised by cellular functions which add poly-A tails to the 3' ends of viral
transcripts. Poly(A) at the 3' end of mRNAs is implicated in stability,
translatability, and in translocation from the nucleus to the cytoplasm.
(d) Splicing
Full-length HIV transcripts serve three roles: firstly as genomic RNA in
progeny virions, second as mRNA for translation of Gag and Gag-Pol polyproteins
in the cytoplasm and third as precursors for alternatively spliced mRNAs that are
also translated in the cytoplasm to produce Env gp and accessory proteins. The
ratio of spliced to unspliced viral mRNA is controlled by the regulator of viral gene
expression Rev functioning through a Rev-responsive element (RRE) (For splicing
see section 4.1 to 4.3). The transactivating protein Tat and the regulatory protein
Rev are expressed from multiply spliced RNAs and accumulate early after infection.
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Later as the regulatory proteins increase in amount, the amount of gag-pol and env
mRNA would increase rapidly.
(v) Translation
The translation of retrovirus mRNA apparently follows a standard scanning
model in which ribosomal subunits bind initially to the capping group and move
along the RNA until the gag AUG initiation codon is encountered. A shift of
reading frame must occur for read-through into the next coding region. There is
apparently an occasional slippage of the ribosome to the -1 frame. As a
consequence only 1/10 or 1/20 as much Pol as Gag is made. This ensures a proper
ratio of proteins to one another and provides the pro and pol proteins in association
with gag so they can be incorporated into virions.
Unlike the translation of gag and pol, which takes place on free
polyribosomes using full length RNA; the env protein product, like other cell
surface proteins, is synthesized on polyribosomes associated with the rough
endoplasmic reticulum using spliced subgenomic RNA.
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(vi) Virion assembly
The first event in virion assembly is the formation of nucleoprotein
complexes composed of p55 Gag as well as the Gag-Pol polyprotein (pi60), and
genomic viral RNA. Cleavage of Gag-containing polyproteins during assembly is
mediated by the viral protease to produce a mature nucleocapsid composed of fully
processed Gag (MA, CA, NC, p6, PI, and P2) and Pol products (PR, RT, RNAse
H, and IN) as well as two molecules of single-stranded RNA genome. Oligomers
of Env gp are inserted into the plasma membrane, and the MA domain of p55 Gag
is presumed to interact with the cytoplasmic tail of the transmembrane subunit in
the Env oligomer during virion assembly. The viral nucleoprotein complex extrudes
or buds through the plasma membrane to produce a virion with a nucleocapsid
surrounded by a lipid bi-layer membrane which contains oligomers of Env gp.
Selected host cell proteins are also incorporated into mature virus particles.
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1.8 Anti-retroviral Therapy (reviewed in Skowron, 1996).
It is estimated that, in HIV-1 infection, about 10'° virions are produced
daily and about 109 CD4 cells are destroyed and produced daily (Ho et al., 1995).
An inhibitor of viral replication could prevent this cell loss, however several factors
in the HIV replication cycle are themselves challenges. First integration means
proviruses can remain latent or can be expressed at low levels. Second HIV
infection occurs throughout the body, including lymph nodes and the central nervous
system. Thus delivery of an antiviral agent to all target cells is difficult. Third,
reverse transcription does not involve a proof reading reaction , therefore variant
genomes including anti-viral resistant strains are readily generated.
The first treatment available was Zidovudine (ZDV/AZT), a nucleoside
analogue reverse transcriptase inhibitor. Nucleoside analogues are structurally
similiar to the natural dideoxynucleosides that the HIV RT incorporates into
complementary DNA strands. Nucleoside analogues are incorporated into growing
DNA strand and prevent subsequent elongation. Unfortunately it became clear that
individuals treated with AZT only benefit transiently before resistant viral strains
emerged. Multiple mutations in the RT gene were seen in 90% of late-stage and
30% of early-stage patients after 1 year of AZT therapy. More recently protease
inhibitors have become available for the treatment of HIV infection. These antiviral


































































































































HIV replication by inhibiting proteolysis of Gag-Pol polyproteins, rendering
progeny virus non-infectious. Twelve or more antiviral agents may be available
for use, alone or as components in double or triple therapy (table 1.3). These
include nucleoside analogue and non-nucleoside reverse transcriptase inhibitors, and
protease inhibitors.
The advantages of combination therapy in HIV infection include an additive
or synergistic effect on antiviral activity and a delay or avoidance of drug resistance.
In many cases after the use of a protease inhibitor in combination with AZT and
3TC, no virus was detectable in peripheral blood (Ho, 1997). However, from
antigen and HIV antibody tests of PBMCs or plasma isolated from treated
individuals it is not possible to speculate whether or not the virus has been cleared.
It may be that virus is still detectable in the lymphoid tissue of these individuals and
when therapy is ceased the viral load may recover.
Before therapy is prescribed for a particular individual it is necessary to first
evaluate the risk of disease progression against possible adverse effects of therapy
and therefore to assess risk factors for each drug. Once a course of treatment has
been decided it is essential to monitor the response by following general health, the
CD4 count, and the plasma viral load. It is also important that a course of therapy
that is best tolerated by each individual is used, and that the emergence of resistant
viral strains is monitored throughout treatment.
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20 to 30 mis of whole blood were collected in ethylenediaminetetraacetic
acid (EDTA) blood tubes (Sarstedt, Leicester, UK) from 34 HIV-1 seropositive
individuals. The individuals were from two study groups, the Heterosexual
Transmission Study (The City Hospital, Edinburgh) (table 2.1) and those attending
Genito-Urinary Medicine (The Royal Infirmary, Edinburgh) (table 2.2).
Immunological and virological information on disease progression was available for
all but two individuals (tables 2.1 and 2.2). Risk factors for infection included
intravenous drug use and sexual contact with an HIV-positive individual. Only five
individuals were receiving or had received antiviral treatment in the previous six
months.
CD4, CD8 and total lymphocyte counts were available for the samples
studied and at monthly or two monthly intervals during the previous 12 months.
Average CD4, CD8 and lymphocyte counts over a 6 month period previous to the
study were calculated. Using cell counts from 12 months before the study, the
percentage cell loss was calculated for CD4 and CD8 lymphocytes. CD4 counts
ranged from less than one to more than 980 CD4 lymphocytes per p.1. 21 of the
patients had CD4 counts associated with late stage disease (CD4 count <200/|il),
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whereas the other 11 had no symptoms and a CD4 count of more than 200/pl. Of
the individuals with CD4 count less than 200, 5 had an AIDS defining illness.
Absolute CD8 counts ranged from 70 to 2732/pl and monocytes from 120 to
740/pl. p24 antigen levels were measured in 24 samples using a commercial kit
(Coulter, Miami, USA) according to the manufacturers instructions.
(ii) Determination of individual absolute cell counts.
Absolute cell counts were determined by flow cytometry in the HIV
Immunology laboratory, The Royal Infirmary Edinburgh. An Ortho Trio patient
summary report (Ortho-Clinical Diagnostics, Herts, UK) was produced illustrating
the CD3-positive T cells, CD4-positive T cells, CD8-positive T cells, CD 19-
positive B cells, CD16-positive, CD3-negative natural killer cells as cells per
microlitre of whole blood. A further study involved 40 HIV-1 positive individuals.
The number of CD4 and CD8 memory and naive cells were determined using a
panel of antibodies against CD4, CD8, CD45RA (naive cells), and CD45RO
(memory cells). (FACS analysis carried out by Helen Mason).
(Hi) Isolation of Peripheral Blood Mononuclear Cells (PBMC)
Blood samples were diluted with an equal volume of phosphate buffered
saline (PBS) (GIBCO BRL, Paisley, UK) and slowly layered over a ficoll-hypaque
density gradient, Lymphoprep (Nycomed, Oslo, Norway). 3 mis of lymphoprep
37
were used for every 10 mis of diluted whole blood. Samples were then spun for 30
minutes at 2100 rpm (500xg) with no brake. PBMCs and platelets collected on top
of the gradient because they had a lower density and red blood cells, which have a
higher density pelleted below the gradient. The top layer of plasma was removed,
aliquoted and stored in liquid nitrogen. The PBMC layer was removed and washed
twice with PBS for 10 minutes at 1000 rpm (lOOxg) removing any ficoll-hypaque
and platelets. Viable cells were counted by means of a haemocytometer, with
trypan blue exclusion. 2 aliquots of 2xl05 PBMCs were pelleted and frozen in
liquid nitrogen for DNA and RNA extractions. The remaining PBMCs were
resuspended in PBS for subsequent cell separations.
For each HIV-positive cell separation, negative PBMCs supplied by the
Edinburgh and South East Scotland Regional Transfusion Centre (RTC) were run
in parallel as negative controls. It was essential to show that none of the cell
separation techniques used interfered with the polymerase chain reactions (PCR)
carried out later.
(iv) Isolation of T Cells Using Rosetting Procedure.
For 17 samples, a rosetting procedure was used to isolate T and non-T cells
from PBMCs. 20 mis of sheep red blood cells (SRBCs) in Alsevers solution
(Scottish Antibody Production Unit [SAPU], Lanark, UK) were washed twice at
2100 rpm (500xg) for 10 minutes in PBS. 1 ml of the SRBC pellet was incubated
with 1 unit of neuraminidase (Sigma, Dorset, UK) in PBS for 1 hour at 37°C. The
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SRBCS were washed twice with PBS then resuspended in 49 mis of RPMI
(GIBCOBRL, Paisley, UK).
No more than 2xl07 patient PBMCs were washed and resuspended to a final
volume of lxlO7 PBMCs/ml in PBS For every ml of PBMCs 2 mis of FCS and
neuraminidase-treated -SRBCs were added and the mixture was incubated at 37°C
for 10 minutes. The cells were then loosely pelleted by spinning at 800 rpm (70xg)
for 5 minutes and the pellet was incubated for 1 hour on ice.
The SRBC, FCS and PBMC mixture was resuspended and layered over
ficoll-hypaque as previously described . The top layer of cells, non-T cells were
washed twice, counted and used for further cell separations. The SRBCs bound the
CD2 receptor found on T cells, forming rosettes, which formed a loose pellet below
the ficoll-hypaque. After removing the gradient, the SRBCs were hypotonically
lysed and the T cell fraction was washed twice with RPMI and resuspended in PBS
for further separations.
(v) Magnetic separation of E-rosette positive and negative cells.
CD3, CD4, CD8, CD14 and CD19 monoclonal antibodies were supplied by
SAPU. The CD21 monoclonal was obtained from The Binding Site, Birmingham,
UK, HLA-DR from The American Tissue Culture Collection, Maryland, USA, and
CDllb was donated by Peter Beverly, University College, London, UK.
100 pi (1 mg) of magnetic beads coated with antibody to mouse
immunoglobulin (IgG) (Immunotech, Marseilles, France) were incubated with 5 pg
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of each mouse monoclonal antibody. The beads and antibody were annealed
overnight in a small volume (50 pi) at 4°C and then washed twice with PBS to
remove any unbound antibody.
T cells and non-T cells were serially incubated with these antibody coated
beads for 30 minutes and the cells which bound to the beads were removed using
a neodymium-iron-boron magnet (Dynal). The E -rosette positive fraction was
incubated first with anti-CD4 to select T helper cells and then with anti-CD8 to
select CD8 lymphocytes. Non-T cells or the E- rosette negative fraction were
incubated with anti-CD3 to remove any contaminating T cells, and then monocytes
were isolated by means of ant-CD 1 lb and anti-CD 14 beads. B cells were depleted
with anti-CD19 and 21, from the E-rosette negative monocyte depleted fraction.
Dendritic cells were isolated from the fraction depleted of T cells, monocytes and
B cells using anti-CD4 and HLA-DR. Samples of each depleted fraction were taken
for flow cytometer analysis. Unfortunately these beads were too large for the flow
cytometer so the positively selected cells could not be directly analysed. Viable cell
counts for positively selected cells were calculated by counting depleted cells at each
selection step.
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(vi) Magnetic separation using the miniMACS (monoclonal antibody cell
sorter)
For 15 of the isolated PBMCs an alternative cell separation procedure was
used. Direct MACS (monoclonal antibody cell sorter) microbeads (Miltenyi Biotec
Ltd, Camberly, UK) conjugated to antibodies directed against CD 14, CD4, CD8,
and CD56 were used. MACS beads are only 50 nm in diameter and neither change
the scatter properties of the cells in the flow cytometer nor do they influence the
light microscopic appearance of the cell. Therefore positively selected cells could
be directly counted and analysed by flow cytometry using this method.
A miniMACS magnet was used allowing the separation of a few hundred to
2xl08 cells. PBMCs were resuspended carefully to ensure a single cell suspension
in 180 pi of PBS. Then 40 pi of each directly conjugated magnetic beads were
added sequentially and the cells were incubated for 15 minutes at 6-12°C. A
separation column was placed in the miniMACS magnet and washed by running
through 500 pi of PBS. The magnetically labelled cells were applied to the column
in a 500 pi volume. The column was then rinsed three times with 500 pi of PBS.
The effluent was collected as a negative fraction. The negative fraction was spun
at 100 rpm (lOOxg) for 5 minutes to pellet the cells and the whole procedure was
repeated for the next antibody. For the positive cell fraction the separation column
was removed from the magnet and the cells flushed out using 1 ml of PBS and a
plunger supplied with the column. Aliquots of each cell fraction were used for flow
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cytometry in order to monitor the cell purity and viable cell counts were made at
each step.
The PBMCs were incubated twice with anti-CD 14 to remove all the
monocytes. Then they were incubated with anti-CD4 to isolate CD4 T
lymphocytes, dendritic cells, and T cells expressing CD4 and CD8. Natural killer
cells were then removed using anti-CD56 and finally CD8 lymphocytes were
selected using CD8 coated MACS beads.
(vii) Isolation of CD4 and CD8 positive lymphocytes using Dynabeads
Four samples, two HIV-positive and two negative controls were separated
using magnetic Dynabeads (DYNAL UK Ltd,Wirral, UK) conjugated with anti-CD4
and anti-CD8. Monocytes were first depleted by plastic adherence. Briefly PBMCs
were incubated overnight at 37°C in a plastic tissue culture flask with Iscoves
medium (GIBCOBRL, Paisley, UK). Any monocytes adhere to the plastic surface.
Anti-CD4 and CD8 Dynabeads were washed twice with PBS using a magnet
then resuspended to a final bead concentration of 2xl07 per ml. Beads were added
to the monocyte depleted cell fraction to give a final concentration of at least lxlO7
dynabeads/ml. The cells were incubated for 20 minutes at 4°C with gentle rotating
and the selected cells removed by means of a magnet. The cells were first incubated
with anti-CD4 beads then the depleted fraction was treated with anti-CD8 beads.
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(viii) Storage of selected cell subsets.
For every sample 1 ml aliquots of plasma were stored in liquid nitrogen.
Each cell fraction was stored in three aliquots. Two were snap frozen as cell pellets
in liquid nitrogen for RNA and DNA extractions. The other aliquot was
resuspended in 0.5 mis of freezing medium containing 50% RPMI, 40% foetal calf
serum (FCS), and 10% DMSO (dimethyl sulphoxide). This aliquot was frozen
slowly and then stored in liquid nitrogen so these slow frozen cells could be used
in cell culture.
(ix) Purity of isolated cell subsets.
The process of isolating subsets of mononuclear cells by antibody-coated
magnetic beads (Immunotech) prevented analysis of the selected cells by
fluorescence-activated cell sorting (FACS) techniques. However, the purity of cell
fractions could be inferred by measurement of the frequencies of different cell types
in the residual cells after removal of a particular fraction. The small size of MACS
microbeads allowed direct staining of the magnetically labelled cells with
fluorochrome conjugated antibodies and subsequent analysis by flow cytometry.
Cell populations were stained with mouse monoclonal antibodies conjugated
to fluorescein isothiocyanate or phycoerythrin for FACS (Becton-Dickinson,
Cowley,UK). Cells were stained with a panel of monoclonal antibodies including,
anti-CD3, CD4, CD8, CD14, CD16, CD19, CD21, and HLA-DR. Cells were
incubated with 10 pi of each conjugated antibody for 30 minutes on ice, in the dark.
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Any unbound antibody was removed by washing twice with PBS. The cells were
resuspended in FACS fix (2% paraformaldehyde) then analysed by flow cytometry.
Unstained control cells and positive control cells were run in parallel with each
sample. Flow cytometry was carried out under the supervision of Donald Innis,
Kings Buildings, Edinburgh.
2.2 Extraction of nucleic acid
Nucleic acid was isolated from cell pellets and 100 pi plasma by incubation
in TNE buffer [0.11 M sodium chloride, 55 mM Tris pH8, 0.55% sodium dodecyl
sulphate (SDS)](BDH Laboratory Supplies, Poole, UK) and 1 mg/pl proteinase K
(Boehringer Mannheim, Sussex, UK) for 30 minutes at 37°C in the presence of
poly A (Boehringer Mannheim) precipitant (40 pgmpl) in a total volume of 500 pi.
450 pi of water saturated phenol (Rathburn Biochemicals, Walkerburn,UK) was
added and the samples shaken vigorously for 5 minutes. After centrifugation at
15000 rpm (14000xg) (Heraeus benchtop centrifuge) for 5 minutes the aqueous layer
was transferred to 450 pi Chloroform/iso-amyl alcohol (50:1) (BDH Laboratory
Supplies) and placed on a shaker for 2 minutes. The centrifugation step was
repeated and the aqueous layer transferred to a fresh eppendorf containing 40 pi
sodium acetate (pH 5.2) (Sigma) and 800 pi ethanol (-20°C) (Rathburn
Biochemicals). After thorough mixing the nucleic acid was precipitated overnight
at -20°C. The nucleic acid was collected by centrifugation at 15000 rpm (14000xg)
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at 0°C. The pellet was washed twice with 80% ethanol and resuspended in 25 pi
nuclease free water.
2.3 Quantification of HIV proviral sequences.
Proviral sequences were quantified using a previously described limiting
dilution and nested PCR approach (Simmonds et al., 1990b). The double PCR was
performed as two sequential PCR reactions. The initial reaction contained the DNA
to be amplified together with a sense and antisense primer spanning the V3 and gag
regions. The nucleotide sequences of the primers and the position of the 5' base in
the HXB2 genome (Myers et al., 1991) are given in table 2.3.
Table 2,3; Primer sequences










V3 primers provided equivalent quantitation to primers in the gag region
(Donaldson et al., 1994a). This reaction was carried out in a 50 pi volume of PCR
buffer containing 0.4 units DNA Taq polymerase (Promega), 50 mM KC1, 10 mM
Tris-HCl pH 9.0, Triton X-100, 1.5 mM MgCl2, 30pM each of dGTP, dATP,
dTTP,dCTP and 0.25pM of each of the outer nested primers. PCR was performed
on serial ten fold dilutions of DNA over 25 heat cycles.
The reaction conditions were, denaturation 94°C for 40 seconds, primer
annealing 50°C for 50 seconds and an extension step at 72°C for 90 seconds.
Following initial amplification with outer primer pairs, 1 pi of the product was
transferred to a second tube containing 20 pi of reaction buffer, Taq polymerase
(0.015 U/pl) and a pair of primers lying within one of the outer primer pairs used
in the first reaction. Product DNA was amplified for a further 25 heat cycles using
the same program as before. The product of the second PCR reaction was
visualised by electrophoresis on a 1% agarose gel (Sigma) and by ultra-violet
transillumination in the presence of ethidium bromide.
After preliminary quantifications using serial ten fold dilutions of DNA and
subsequently (using V3 primers), on two fold dilutions in quadruplicate around the
end-point, between 10 and 20 replicates were then carried out at the end-point in
order to more accurately determine the virus load.
In addition to the selected subsets (CD4 T cells, CD8 T cells, B cells,
monocytes and dendritic cells) PCR quantitation was also used to determine the
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provirus load in PBMCs and the residual E-rosette positive populations after CD4
and CD8 cell depletions of seven patients. Residual cells from this fraction could be
unselected cytotoxic T cells (CTLs) or T helper cells in which CD4 was down-
regulated by infection with HIV. Quantification results were expressed as proviral
copies per 106 cells. All separations, extractions and amplifications were carried out
with parallel samples of PBMCs isolated from buffy coats derived from HIV
negative blood to serve as negative controls.
2.4 Analysis of quantification results.
The relative frequencies of CD4 T lymphocytes, CD8 lymphocytes,
monocytes and B cells in the original mononuclear cell populations were estimated
by FACS analysis. Numbers of dendritic cells were estimated by cell counting
before and after depletion of the E-rosette negative population by anti-CD4 and
HLA-DR coated magnetic beads. To estimate the numbers of cells used for PCR
cell counts taken at each depletion with specific monoclonal antibodies were used.
The only exception were samples from individuals with CD4 counts less than 200
per pi of whole blood, where the low level of cells lost during magnetic separation
greatly exceeded the numbers of selected cells. For these samples we therefore used
the absolute CD4 counts derived from FACS analysis of the original blood samples
to estimate cell numbers.
For each cell subset a final PCR reaction was carried out with 20 replicates
at the determined end-point. Using the volume of extracted nucleic acid used in the
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end-point PCR reaction and the number of cells extracted, the number of provirus
copies per lxlO6 cells was estimated. In order to determine the actual number of
provirus copies/106 cells we used the Poisson distribution to calculate the frequency
of target sequences per replicate, using the following formula: / = -log( 1 -p)ld
(where/ = the frequency of infection, p = proportion of positive samples and d =
dilution). To ensure that all proviral sequences were accounted for by this method
of analysis, we compared the total number of provirus-bearing cells from
unfractionated PBMCs with the sum of each of the component subsets analysed. For
example, the frequency of provirus in PBMCs from p26 was 8 copies/106 cells. In
this particular case, the contribution to the proviral sequences in the CD8 cells was
58 copies per million CD8 cells, multiplied by their frequency in the total PBMC
population (70 000 CD8 cells/ml in a total mononuclear cell concentration of 600
000/ml: 11.6%). Therefore CD8 cells contribute 6.8 proviral copies/ml to the
mononuclear cell virus load. The contributions of CD4 lymphocytes (2.1 copies/106
mononuclear cells), from monocytes (1.1 copies/106 mononuclear cells) and DCs
(1.3/106 mononuclear cells) were calculated similarly. The total of these individual
contributions was 11.3 copies /106 cells, close to the virus load measured by PCR
on unfractionated mononuclear cells (8 copies/106 cells). These observations
independently validated the methods used for quantitation of cells and provirus. This
analysis was carried out on a total of seven patients and yielded a total PBMC
proviral load/total of the subsets load ratio of between 0.4 to 1.56. These values are
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consistent with the accuracy of the methods used for cell counting and quantification
of HIV sequences.
In order to illustrate that virus detected in a cell subset was not due to
contamination of the cell fraction with other cell types, the levels of contaminating
cells were determined by FACS analysis. These values could then be used in
parallel with the PCR results to show that for example CD4 contamination of the
CD8 fraction could not account for the detected provirus.
2.5 DNA sequencing of PCR product
(i) Biotinylated PCR for solid-phase sequencing
For patients p2, p5 S4, S6, and S25, single molecules of HIV DNA
obtained by limiting dilution PCR were used for sequencing the V3 region of the
envelope gene. It was necessary to sequence single molecules as the heterogeneity
of the env gene means that a consensus sequence would be impossible to interpret.
For positive reactions the secondary reaction was repeated in a 100 pi volume using
the inner sense primer and a biotinylated anti-sense primer.
(ii) Dynabeads for solid-phase sequencing.
Streptavidin coated Dynabeads (Dynal) were used to isolate biotin-labelled
target molecules. The Dynabeads were supplied as a suspension of 6.7x10s beads
per ml (10 mg/ml) in PBS pH 7.4. 20 pi of beads were removed per biotinylated
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PCR product and washed twice with BW (10 mm Tris HCL pH 7.5, 1 mM EDTA,
2.0M NaCl) (BDH Laboratory Supplies) using magnetic apparatus. The beads were
then resuspended in 40 pi of BW per reaction and incubated for 20 minutes at room
temperature with 40 pi of biotinylated PCR product. After washing twice with
BW the DNA was denatured with a 10 minute incubation in 0.15 M sodium
hydroxide (NaOH) (Sigma) leaving only the biotinylated strand bound to the beads.
The beads were then washed with 0.15 M NaOH, BW and TE (Tris HC1 pH 7.5,
ImM EDTA) and were resuspended in 20 pi TE.
(iii) Solid-phase sequencing
Nucleotide sequencing was carried out using the Sequenase-2 kit (United
States Biochemicals) with [35S| dATP (Amersham, Buckinghamshire, UK) according
to the instructions of the manufacturer. Briefly, 0.5 pmol of primer, 2 pi 5X
sequenase reaction buffer and 5 pi DNA bound to Dynabeads were incubated at
65°C for 5 minutes then allowed to cool slowly to room temperature. 5 pi of this
annealing mix was then added to an extension mix containing 0.1 pi labelling mix,
1 pi 0.1 M dithiothreitol (DTT), 3.25 units Sequenase enzyme and 5 pCi |35S|
dATP. 3 pi of the extended sequencing reaction were added to 2.5 pi of
termination mix for each of the nucleotides G, A, T, and C. 4 pi of stop solution
(95% formamide, 20 mm EDTA, 0.05% Bromophenol blue, and 0.05% xylene
cyanol FF ) were added to each of the termination mixes.
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(iv) Acrylamide gel electrophoresis
The sequencing reactions were run on a 6% acrylamide gel. The gel mix
contained 21 g urea (BAH Laboratory Supplies)), 6 mis of long ranger liquid
acrylamide/Bisacrylamide (FMC Bioproducts, Rockland USA), 5 mis lOx TBE
(0.089 M Tris, 0.089 M Boric acid, 0.02 M EDTA), 0.05 g ammonium persulphate
(Sigma) and 20 pi TeMed (Sigma). The gel mix was then dissolved in a final
volume of 50 mis with distilled water.
Glass plates were cleaned with 70% (v/v) ethanol then acetone. The plates
were then assembled with flat spacers. The gel was poured taking care to avoid
bubbles and left to polymerise. The gel was pre-run at 75 volts for 10 minutes
using lx TBE as the electrophoresis buffer. The samples were heated to 95°C for
7 minutes then loaded on the gel. The gel was dried and exposed to X-ray film for
1-3 days. No fix step was required with the brand of arylamine used.
(v) Analysis of sequencing gels.
Sequencing gels were read and aligned using a sequencing package
developed in the department (Simmonic Software). Sequences were then analysed
using the package MEGA (Molecular Evolutionary Genetics Analysis).
Phylogenetic trees were constructed to compare patient cell subset sequences. A
rooted tree was constructed with the HIV HXB2 sequence as an outgroup and the
Jukes Cantor method to account for multiple substitutions. The bootstrap re-
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sampling method (100 replicates) was used to assess the confidence of each node
in the tree constructed.
2.6 Extraction of RNA
(i) Creating a Ribonuclease-Free environment
In order to prevent RNase contamination proper microbiological sterile
technique was used and gloves were changed regularly. Reagents and utensils were
set aside specifically for RNA work. Sterile disposable plastic ware was used which
did not require pretreatment to inactivate RNases. Solutions used were treated with
0.05% diethyl pyrocarbonate (DEPC) overnight at room temperature and were
autoclaved to remove any residual DEPC. The laboratory area used was first
treated with RNase away (Molecular Bio-Products Inc, San Diego, USA)). All the
reaction steps and reagents were stored or carried out on ice.
(ii) Stratagene RNA isolation kit.
RNA was extracted using the Stratagene RNA isolation kit according to the
manufacturers instructions. Lysis solution A (Table 2.4) was prepared and the
extraction protocol followed using the volume of reagents described in table 2.5
depending on the number of cells.
The cells to be extracted were centrifuged at 1000 rpm (lOOxg) for 5 mins
and the supernatant removed. 100 n 1 of lysis solution and the correct volume of
mercaptoethanol (p-ME) was added for every IxlO6 cells processed. A volume of
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2 M sodium acetate (NaOAc) (pH 4.0), water saturated phenol, and
chloroform:isoamyl alcohol were added and the mixture was and vortexed. The
tube was mirofuged for 5 mins at 15000 rpm (14000xg) so two phases were clearly
visible. The upper phase was transferred making sure not to take any of the
interface layer, to a sterile RNAse-free microcentrifuge tube. The lower level
containing phenol, proteins and DNA was discarded.
Table 2.4 : Lysis solution for RNA extraction
Total volume 50 mis 25 mis 10 mis 5 mis
Guanidinium Thiocynate 23.64 g 11 •82g 4.8g 2.364g
(Sigma g-6639)
ImM Na Citrate (pH 7) 1.25 mis 0.625 mis 0.25 mis 0.125 mis
Sarcosyl (Sigma L-5125) 0.5 g 0.25 g 0.1 g 0.05 g
Table 2.5: Volume of reagents used in RNA extraction protocol(ftl)
Cell
Amounts
lxlO6 2x10" 3xl06 4xl06 5xl06
Solution A 100 200 300 400 500
P-ME 0.72 1.44 2.16 2.88 3.6
2M 10 20 30 40 50
NaOAC
Phenol 100 200 300 400 500
Chloro:Iso 20 40 60 80 100
Isopropanol 100 200 300 400 500
75% Wash 200 400 600 800 1000
DEPC H90 25 50 75 100 125
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If less than 1 x 106 cells were used the procedure for 1 x 106 cells was
followed and the RNA was precipitated with 1 yul glycogen. A volume of
isopropanol was added to the RNA solution and mixed well. The sample was
microfuged at 15000 rpm (14000xg) for 30 minutes after 1 hr at -70°C. The
supernatant was removed and the pellet washed with 75% ethanol:25% DEPC-
treated water, and the pellet dried. The pellet was resuspended in 20pl DEPC
treated water containing 1 unit of RNasin (Promega) and stored in liquid nitrogen.
(Hi) Isolation of mRNA
As an alterative to total RNA extraction, mRNA was extracted with the
Mini-Message Maker (R and D Systems, Abingdon, UK) according to the
manufacturers instructions. Briefly, 1 ml of the supplied lysis buffer was added
to the cell pellets (no more than 107 cells) and DNA was sheared by passing the cells
through a fine pipette tip. The cells were then microfuged at 15000 rpm (14000xg)
for 3 minutes and the supernatant was transferred to a fresh tube. The supernatant
was made to 1.5 mis with lysis buffer and 50 pi of oligo-dT latex beads were added.
The tube was inverted ten times, incubated for 10 minutes at room temperature, and
spun at 15000 rpm (14000xg) for 5 minutes. The pellet was resuspended in 350 pi
of lysis buffer and transferred to a spin column. The spin column was spun at
15000 rpm (14000xg) for 2 minutes and the eluate discarded. The mRNA was
eluted with 100 pi elution buffer at 70°C by spinning at 15000 rpm (14000xg).
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(iv) DNase treatment
Purified RNA was treated with RQl-RNase free DNase (Promega) in order
to degrade any contaminating DNA. The RNA pellet was resuspended in 0.4 mis
of DNase buffer (0.005M MgCl2, 0.01M Tris pH 7.4) and 5 pi of DNase (50 U)
were added. The RNA was incubated at 37°C for 30 minutes then at 97°C for 10
minutes to inactivate the DNase enzyme.
2.7 Detection of env messenger RNA.
(i) cDNA synthesis
cDNA was synthesised using 0.5 units AMV (Avian Myeloblastosis Virus)
reverse transcriptase enzyme (Promega), lx RT buffer (50 mm Tris HC1 pH 8.3,
50 mM MgCl2, 5mM DTT,5mM EDTA, 50pg/pl bovine serum albumin, 50 mm
KC1), 0.8 mM dNTPs, 10% DMSO, 0.75 units RNasin, O.lpM outer antisense
primer and 5 pi of RNA in a final volume of 20 p\. The reaction mix was
incubated at 42°C for 1 hour and stored at -70°C. Mock RT reactions were also
prepared in order to determine whether DNA contamination was present.
(ii) Primary PCR Amplification.
Reaction mix was prepared as described in table 2.6 in a total volume of 50
pi.
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Taq DNA pol buffer 10X IX 5
dNTPs 3 mM 0.03 mM 0.5
s5326 (antisense primer) 10 pM 0.25 pM 1.25
NARS (sense primer) 10 pM 0.25 pM 1.25
cDNA IX 0.1X 5
Taq DNA pol (Promega) 10 U/pl 0.05 U/pl 0.25
The PCR heat cycle was as follows; 94°Cx5min for 1 cycle, 58°Cx5min for
1 cycle, 72°Cxl.5min, 94°Cx35sec and 58°Cx40sec for 30 cycles, followed by
72°Cxl0min and 22°C for 1 cycle of 30 minutes.
Primers were selected so the sense primer was complementary to a sequence
in the LTR region and the antisense was complementary to the env region (see
figures 4.1 and 4.2). Only the spliced products vif, vpr, tat exon 1, and vpu-env
were detected using the primers listed below:
NARS 5' GAGATCGTCACCGCGGGCTTGTCCC 3' (position 627 HXB2)
S5236 5' CCCATAATAGACTGTGACCCA 3' (position 6327 HXB2)
Half the volume of the amplified product was loaded a 1.5 % metaphor gel.
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(in) Secondary PCR Amplification.
Reaction conditions were the same as those for the primary reaction. 0.1 p\
of primary product was transferred to a thin walled tube and reaction buffer added
in a final volume of 20 |il.
The following inner primers were used:
T5480 5' TGAGCCGAACGACTTCGC 3' (position 678 HXB2)
S5237 5' TCCCAAGGAGCAWGRTGCCCC 3' (position 6273 HXB2)
The amplified product was loaded on a 1.5% metaphor gel. The expected
size of the products were; vif 1424 base pairs (bp) , vpr 905 bp, tat exon 1 514 bp,
and vpu-env 314 bp.
(iv) Quantitative RT-PCR
RT-PCR only provides an answer as to whether or not a transcript is being
expressed. Relative quantitation was carried out by running an actin message RT-
PCR in parallel with the HIV env PCR. Every cell should express actin message
so this PCR acted as an internal control to monitor RNA loss and RT efficiency
between different reactions.
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2.8 Detection of actin mRNA by RT-PCR
(i) cDNA synthesis
mRNA was annealed to an oligo (dT)15 primer and cDNA synthesis as
described for env mRNA.
(ii) PCR Amplification.
5 pi of RNA was added to reaction mix as described in table 2.7.








Taq DNA pol buffer 10X IX 2
dNTPs 3mM 0.03mM 0.2
antisense primer and 25uM lwM 0.8
sense primer
(Stratagene)
cDNA IX 0.1X 2
Taq DNA pol lOU/pl 0.05U/pl 0.1
(Promega)
PCR reaction conditions were as for env mRNA. 1 pi of primary product
was transferred to a fresh tube and the PCR reaction repeated using secondary
primers. The primers used were as follows:
Primary PCR Reaction
p-Actin-sense 5' TGACGGGGTCACCCACACTGTGCCCATCTA 3'
p-Actin-antisense 5' CTAGAAGCATTTGCGGTGGACGATGGAGGG 3'
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Secondary PCR Reaction
p-Actin-sense 2 5' GCCCTGGACTTCGAGCAAGAGATGGCCAC 3'
p-Actin-antisense 5' CTAGAAGCATTTGCGGTGGACGATGGAGGG 3'
2.9 Detection of RNA bv Access RT-PCR
The Access RT-PCR system (Promega) is designed for RT and PCR
amplification in one reaction step. The reaction mix was prepared on ice: IX
AMV/T/i {Thermus flavus) buffer, 0.2 mM each dNTP, 1 mM outer sense and
anti-sense primers, 1 mM MgS04, 0.1 U/pl AMV-RT, 0.1 U/pl Tfi DNA
polymerase, 10 pi RNA and to a final volume of 50 pi with nuclease free water. Tfi
polymerase is a thermostable DNA polymerase from Thermus flavus. Also supplied
were positive control RNA, primers and a negative control. The reaction conditions
were as follows (table 2.8):
Table 2.8 : Reaction conditions for Access RT-PCR
Reverse
Transcription
1 Cycle 48°C 45 minutes
RT Inactivation
and Denaturation
1 Cycle 94°C 2 minutes
Denaturation 94°C 30 seconds
Primer Annealing 40 Cycles 56°C 1 minute
Extension 70°C 2 minutes
Final extension 1 Cycle 70°C 7 minutes
Soak 1 Cycle 4°C 10 minutes
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1 pi of primary PCR product was used in a secondary reaction and the
product visualised using a 2% agarose gel stained with ethidium bromide.
2.10 Cell Culture
(i) Cell Medium
Medium was prepared in a sterile still air cabinet. Sterile plastic pipettes and
autoclaved tips were used. All plastic cell culture flasks were sterile. For most cell
culture complete RPMI was prepared as follows: 100 mis RPMI 1640 (GIBCO
BRL), 1% penicillin (GIBCO BRL), 1% streptomycin (GIBCO BRL), L-glutamine
1 % (GIBCO BRL), 100 pi interleukin-2 (IL-2) (MRC), 10 mis heat inactivated
foetal calf serum (GIBCO BRL) and 30 pi phytohaemaglutinin (Murex, Dartford,
England). Cell conditioned medium was also prepared by removing the supernatant
from cultured cells and spinning at 2000 rpm (500xg) to remove any cell debris.
(ii) PBMCs
PBMCs were isolated by ficoll-hypaque centrifugation (See section 2.1) from
a whole uninfected blood pack supplied by the Edinburgh and South East Scotland
RTC. The washed cell pellet was resuspended in complete RPMI (lml/106 cells).
After incubation at 37°C for 72 hours in a plastic cell culture flask, the cells were
split and more medium added when required.
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(iii) CD4 Lymphocytes
CD4 lymphocytes were isolated using miniMACS beads (see section 2.1) as
described and were cultured as for PBMCs. The cells were FACs analysed before
and after culture.
(iv) CD8 Lymphocytes
CD8 lymphocytes were isolated with miniMACS beads as described (section
2.1) and were suspended in cell conditioned medium (lxlO6 cells/ml). The cells
were then treated as for PBMC culture. The cells were analysed before and after
culture.
(v) Dendriric cells
Dendritic cells were isolated after E-rosetting as described (section 2.1) and
were resuspended in complete iscoves medium (GIBCO BRL) in place of RPMI.
The cells were cultured as described for PBMCs and were analysed by light
microscopy in order to detect any characteristic dendritic cell morphology.
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CHAPTER 3 : The Distribution of HIV-1 Within
Peripheral Blood Cell in vivo.
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INTRODUCTION
3.1 The CD4 Receptor
The cluster determinant (CD4) molecule is a T-cell co-receptor that increases
the affinity of a helper T cell for an antigen presenting cell through its interactions
with major histocompatibility (MHC) class II molecules. CD4 has also been
implicated in signal transduction pathways essential for T-cell activation. Many
studies indicate that infection of target cells with human immunodeficiency virus
type-1 (HIV-1) is dependent on surface presentation of CD4, which serves as
specific virus receptor (reviewed in Levy, 1993; Bour et al., 1995; Bachelder et al.,
1996). Early reports that HIV-1 infection in vivo was restricted to the CD4
expressing subset of T lymphocytes were followed by studies showing that anti-CD4
monoclonal antibodies (mAbs) could block both infection of CD4-positive target
cells and subsequent formation of syncytia. CD4 serves as a receptor for HIV-1,
HIV-2 and simian immunodeficiency viruses (SIV).
The CD4 molecule is a transmembrane glycoprotein of 58 kDa and consists
of an extracellular region of 370 amino acids, a transmembrane region of 25 amino
acids, and a cytoplasmic tail of 38 amino acids at the C terminal end. The
extracellular portion of CD4 is folded into 4 distinct domains (D1-D4). The N-
terminal D1 domain shares extensive structural and sequence homology with the
variable region of immunoglobulin (Ig) light chains, and is composed of three
hypervariable regions called complementarity-determining regions (CDRs). The
other three domains are less closely related to Ig molecules at the level of primary
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structure but fold similarly to Ig family domains, confirming that CD4 is a member
of the Ig-like superfamily.
The HIV-1 envelope external glycoprotein (gpl20) binding site is located
in the D1 and D2 domains of CD4. Four charged residues (Lys-29, Lys-35, Lys-
46, and Arg-59) and one hydrophobic phenylalanine at position 43 were essential
for gpl20 binding. These five amino acids are predicted to form a hydrophobic
pocket by folding of the four charged amino acids around the hydrophobic
phenylalanine residue, a structure that may be involved in direct contact with gpl20.
The MHC II and gpl20 binding sites on CD4 are distinct but overlapping.
The HIV envelope precursor, gpl60, is cleaved to yield gpl20 and gp41 as
mature envelope proteins. The HIV-1 gpl20 envelope protein has a complex
secondary structure stabilised by disulphide bonds between conserved cysteine
residues. Extensive variability is apparent in five discrete gpl20 domains termed
V1-V5. More conserved amino acid sequences termed C1-C5 separate these
hypervariable regions. Several of these domains interact with each other to form
the complex secondary structure of gpl20. Consequently, probing the CD4-binding
site by amino acid deletions and substitutions in gpl20 is often impeded by the
extensive structural changes caused by the mutations. However, it has been
established that the major regions of gpl20 important for CD4 binding consist of
residues 256 to 262 in the C2 domain, residues 368 to 389 in the C3 domain, and
residues 421 to 457 in the C4 domain. Additional residues in the C5 domain have
been reported to also contribute to the formation or stability of the CD4 binding
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site. The C2 and C5 domains of gpl20 are poorly exposed at the surface of the
molecule (reviewed in Bour et al., 1995) . It is thus likely that residues within these
domains contribute to the structure of the CD4 binding site but are not involved in
direct contact with CD4. In contrast, the C4 domain and most of the C3 domain
protrude from gpl20 and may be of particular importance for interactions with
CD4.
HIV entry has been shown to be efficient at a neutral pH. In a model for
virion entry into lymphoid cells, it is thought that conformational changes are
induced in both gpl20 and the transmembrane glycoprotein, gp41, after virions
attach to cell surface CD4. The interaction of CD4 with the envelope glycoprotein
promotes dissociation of the gpl20 subunit from the gp41 subunit resulting in
exposure of the hydrophobic fusion peptide at the N-terminus of gp41. After
exposure by dissociation of gpl20, the fusion peptide inserts into the lipid bilayer
of the cell plasma membrane and thereby initiates fusion of the viral and cell
membranes. Cell surface proteins other than CD4 may also induce conformational
changes in the envelope glycoprotein.
Conformational changes in cell surface CD4 have also been reported
following attachment of HIV (reviewed in Levy, 1993; Bour et al., 1995). CD4
conformational change may be involved in T cell activation events important for
virus transcription. A number of antibodies specific for domains of CD4 that do not
participate in HIV binding have been shown to inhibit HIV replication in CD4 T
cells. Antibodies against CDR3 loop of extracellular domain 1 have been shown to
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inhibit HIV infection of CD4 cells without blocking either HIV binding or HIV
entry into CD4 cells. The HIV neutralising activity of these antibodies was shown
to be a consequence of their ability to inhibit virus transcription. Thus, certain
epitopes within the CDR3 loop of CD4 appear to be important in the delivery of
HIV-induced T-cell activation signals essential for HIV transcription. The
identification of these novel HIV-neutralising antibodies has been central in
establishing that CD4 acts as an essential signalling molecule in HIV infection.
3.2 Alternative receptors.
The T cell surface antigen CD4 is the principal binding site for the HIV
virus, but alone is insufficient to allow entry of the virus into the cell (reviewed in
Levy, 1993). This was first demonstrated when it was shown that mouse cells
expressing human CD4 were not permissive for viral entry. Several alternative cell
surface receptors have been implicated in virion attachment and entry into certain
neuronal and colorectal tumour cell lines as well as several other cell types, all
lacking detectable CD4. HIV-1 gpl20 binds to galactosyl ceramide which is found
on glial cell lines as well as colon cell lines. Complement receptors, such as Fc
(fragment, crystalline) receptors offer another potential mechanism for viral
attachment and internalisation. It is most likely that these adhesion molecules
facilitate cell-to-cell contact during infection rather than functioning as true
receptors which, by definition, must interact with a virion surface component.
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Chemokine receptors as co-receptors for HIV entry
Immune cell trafficking comprises circulation, homing, adhesion, and
recirculation of discrete populations of leukocytes between the blood vessels, lymph
and lymphoid organ, and tissues. The molecular regulation of trafficking is
complex, involving the interactions not only of cellular adhesion molecules such as
selectins and integrins, but of an entire superfamily of chemoattractant cytokines
(chemokines) and their receptors.
Chemokines can be classified into four families (C, CC, CXC, CXXXC)
according to the number and location of cysteines and disulfide linkages (reviewed
in Premack et al., 1996). The most abundant are CC and CXC families which
include macrophage inflammatory proteins (MlP-la and MIP-1P) ,RANTES (CC)
and stromal cell-derived factor-1 (SDF-1) and IL-8 (CXC). Structural distinctions
of the different branches of the superfamily have been shown to parallel general
distinctions in the biological activities of chemokines. For example, most CXC
chemokines generally are chemoattractants for neutrophils but not monocytes,
whereas CC chemokines generally attract monocytes, lymphocytes, basophils and
eosinophils but not neutrophils. The C chemokine appears to be lymphocyte
specific. PCR and blotting analyses suggest that most of the shared receptors are
broadly distributed among leukocyte classes, but clear definition of tissue
distribution of the receptors awaits wider availability of specific monoclonal
antibodies.
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Recently the first HIV co-receptors have been identified as members of the
chemokine receptor family (Alkhatib et al., 1996; Choe et al., 1996; Deng et al.,
1996; Doranz et al., 1996; Dragic et al., 1996; Feng et al., 1996). They are all
seven transmembrane receptors from the large family of G protein coupled
receptors, and include, CCR5, fusin, CCR3, and CCR2b. These co-receptors are
responsible for bringing the surface membranes of the host cell and the virus
together to allow fusion of the membranes and viral entry.
CCR5 is the chemokine which binds RANTES, MlP-la and MIP-ip and
is thought to be a co-receptor for macrophage tropic strains of HIV-1 (Deng et al.,
1996; Dragic et al., 1996). A complex of gpl20 of macrophage-tropic primary
HIV-1 and soluble CD4 interacts specifically with CCR5 and inhibits the binding
of the natural ligands. The apparent affinity of the interaction between gpl20 and
CCR5 was dramatically lower in the absence of soluble CD4. These results suggest
that HIV-1 attachment to CD4 creates a high-affinity binding site for CCR5 leading
to membrane fusion and virus entry (Trkola et al., 1996; Wu et al., 1996). The
initial description of the CCR5 gene suggested that its expression is limited to
granulocyte precursors, and absent in PBMCs. However, CCR5 transcripts were
recently detected in both the monocyte/macrophage and macrophage depleted cell
fractions of PBMCs (Deng et al., 1996).
The fusin molecule is the co-receptor for T cell tropic strains of HIV.
Fusin is a heterodimeric G protein coupled receptor and is related to the chemokine
receptors (Berson et al., 1996; Feng et al., 1996). The sequence of fusin shows
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greatest similarity with the CXC chemokine IL-8 receptor. Due to this homology,
the term CXCR4 has been proposed for fusin, in keeping with current chemokine
receptor terminology. The ligand for CXCR4 is SDF-1, which can inhibit HIV
infection and the formation of syncytia by blocking the co-receptor (Oberlin et al.,
1996).
CCR3 is the receptor for the recently cloned chemokine eotaxin. Expression
of the receptor CCR3 is more restricted than CCR5, being present on eosinophils,
monocytes and T cells. Eosinophils also express CD4 and are permissive to HIV
entry. Eotaxin was shown to inhibit CCR3 mediated HIV entry (Choe et al., 1996;
Doranz et al., 1996).
Classification according to T cell tropic syncytium inducing strains of HIV-1
using CXCR4 and non-syncytium inducing macrophage tropic strains using CCR5
now appears to be over simplified (reviewed in Premack et al., 1996).
Macrophage-tropic strains may also use CCR3, while dual-tropic strains use
CCR5, CCR3, CCR2b and CXCR4. Tropism of the virus may change with disease
progression which may be to avoid suppressive activity of chemokines and to
broaden the number of cells the virus can infect.
Subsequent to the discovery of CCR5 as a HIV co-receptor, Samson et al
(1996) described a polymorphism in the gene for CCR5. The mutation is a 32 base
pair deletion from the coding region and results in a frame shift. The gene product
is a non-functional receptor that does not support membrane fusion or infection by
HIV. The mutant allele of CCR5 is expressed at a high frequency in Caucasian
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populations but is absent in black populations from Western and Central Africa and
Japanese populations. In a cohort of HIV-1 infected Caucasian subjects, no
individual homozygous for the mutant was found, and the frequency of
heterozygotes was 35% lower than in the general population. White blood cells
from an individual homozygous for the null allele were found to be highly resistant
to infection by macrophage-tropic HIV-1 viruses, confirming that CCR5 is the
major co-receptor for primary HIV-1 strains.
It has been known for some time that certain CD4-negative cell lines may
be infected with HIV if large concentrations of the virus are used. In view of the
interaction between certain chemokine receptors and gpl20 it is possible that a
high-titre virus stock is enough to allow the selection of variants that are better
adapted to viral entry and replication in the absence of CD4 using a second
receptor.
3.3 The immune response to HIV-1 infection
Primary HIV-1 infection is characterised by extremely high levels of viral
replication. After the initial burst of viraemia viral titres decline dramatically, often
as much as 10-100 fold. Immunological control of viral infection has been ascribed
to multiple components of the immune response. Evidence exists to suggest that
protection from infection or clearance of viraemia, or both, is mediated by natural
killer cells that are non-specific for virus, virus specific antibodies, and cytotoxic
T lymphocytes.
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(i)Humoral immune response to HIV infection
The host defences against free virus particles involve neutralisation of
infectivity, and occur either by antibody blocking HIV attachment or entry into a
cell or by blocking uncoating of the virus (reviewed in Levy, 1993). Antibodies are
also effective in mediating the destruction of virus-infected cells. This can occur
by antibody mediated activation of the complement system, however this requires
a high density of viral antigens at the cell membrane to prove effective. In contrast,
antibody dependent cell mediated cytotoxicity (ADCC) (see below) mediated by
natural killer (NK) cells can recognise as few as 103 IgG molecules in order to bind
and kill the infected cell. Virus infected cells can also be destroyed via antibody-
dependent cell-mediated cytotoxicity by macrophages and neutrophils.
The HIV envelope is the major target for humoral antibody responses. The
viral proteins believed to be primarily involved in antibody neutralisation have been
localised to the envelope gpl20 and the external portion of gp41. Antibodies to the
p 17 core protein have also been reported to show neutralising activity. The
presence of anti-HIV neutralising antibodies in infected individuals has been
reported by several investigations and in general infected individuals have
consistently demonstrated strong neutralising activity against their homologous
strain. In general HIV-1 sera can neutralise HIV-1 but not HIV-2 strains. In
contrast, sera from HIV-2 infected individuals have been reported to cross react
with and neutralise some HIV-1 strains.
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Most studies indicate that at least six regions of the viral envelope could be
involved in HIV neutralisation (reviewed in Levy, 1993). A conserved domain
within gp41 has been suggested and studies with hypervariable deletion mutants
have also shown that domains in VI or V2 and in V4 and V5 of gpl20 could induce
neutralising antibodies. An important neutralising domain of gpl20, the principal
neutralising domain (PND) is found in the central portion of the third variable
region (V3 loop). Although V3 is a variable region, the PND is a linear epitope
conserved among many strains or differing only slightly in amino acid structure.
The V3-loop directed neutralisation does not involve the CD4-binding domain.
The V3 loop can have both neutralising and non-neutralising epitopes, since sera
with high-titre antibody to V3 peptides do not always neutralise the homologous
HIV-1 strain. Moreover, work with escape mutants has indicated that regions
within or outside the V3 loop can be involved in efficient antibody neutralisation.
These sites outside of V3 can apparently alter the conformation of the V3 loop,
permitting virion escape from neutralisation. Thus the V3 region can be both a
linear and a conformational determinant for antibody recognition. Another major
neutralising region on gpl20 is in the CD4-binding domain, antibodies that cross-
neutralise a large number of different strains, including those with different V3
regions, are directed against this region. The determinant is generally conformation
dependent.
The clinical relevance of these antibodies remains uncertain. AIDS patients
can have substantial titres of neutralising antibodies yet the virus would appear to
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replicate unchecked. The virus may change under immunologic responses to escape
neutralisation. However in the early stages of infection, antibodies can provide a
major barrier to virus spread between cells and tissues and are important in
restricting free virus in the plasma.
(ii) ADCC
Antibodies (IgGl isotypes) to both the gpl20 and gp41 envelope proteins
induce ADCC. In this process, the antibody-antigen-coated cells are recognised by
effector NK cells or monocytes Fc receptors and killed by a cytotoxic mechanism,
most probably by perforins and secreted lysosomal enzymes. Only certain epitopes
on HIV proteins induce this response, since not all anti-e«v antibodies produce this
activity and they can be distinguished from neutralising antibodies. One detrimental
effect of ADCC in HIV infection could be the release by cell destruction of large
quantities of infectious particles with subsequent spread in the host.
(Hi) Cell mediated immune response to HIV
(a) CD4 T lymphocytes
Antigen-specific T helper cells play an important role in retroviral infections
(Levy, 1993). Indeed, they provide help for B-cell activation and antibody
production and for clonal expansion of cytolytic lymphocytes. Upon antigen-
derived activation, these cells release the appropriate lymphokines that induce clonal
expansion of specific B cells and cytotoxic T lymphocytes (CTL). Activation of T
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cells depends on recognition of antigenic peptides displayed by specialized antigen
presenting cells (APCs), monocytes/macrophages, DCs and B cells. T helper cells
are also involved in the recruitment and activation of macrophages at the sites of
virus infection.
CD4 T cells can be separated into Thl and Th2 subsets (Clerici et al., 1994;
Clerici et al., 1997). Thl cells secrete IL-2 and interferon-gamma (IFN-y): Th2
cells produce 1L-4, IL-6 and IL-10. Since the Thl cells produce IL-2 and other
cytokines that help in enhanced CD8 cell activity, this subset could also be
important in the cellular immunological control of HIV infection and prevention of
AIDS. A Th2 response results in B-cell activation and the secretion of high levels
of IL-10 by the Th2 cells can lead to suppression of Thl function. It has been
demonstrated that Thl responses are found primarily in healthy asymptomatic
individuals and in high risk individuals who do not show evidence of HIV infection.
Some investigators suggest that this type of response that helps induce cell-mediated
immunity could be protective for an individual.
(b) CD8 Cytotoxic T Cells
Another cell type that commonly reacts with virus-infected cells is the CD8
cytotoxic T lymphocytes (CTL) (reviewed in Johnson et al., 1994). Classically, this
response is major histocompatibility complex (MHC) dependent and requires cell-to-
cell contact. CD8 lymphocytes are an important feature of the immune response
against HIV, eliminating virus infected cells. Resting CD8 lymphocytes are induced
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to full effector function when presented with a variety of viral antigens, particularly
to epitopes within the gag, reverse transcriptase, nef, and env proteins. CD8
cytotoxic T lymphocytes typically recognise short HIV peptide fragments expressed
on the surface of infected cells in the context of a major histocompatibility class I
(MHC-I) molecule and the target cell is killed. The target cell can be destroyed by
inserting perforin pores in the cell membrane allowing the entry of enzymes called
granzymes which leads to apoptosis or, if the target cell expresses the Fas molecule
on its surface, the CTL may employ a Fas ligand to trigger apoptosis. On
recognition of antigenic cells CD8 T cells secrete x-interferon which induces
resistance to virus in neighbouring cells and stimulates the activity of phagocytic
cells.
(C) Anti-HIV suppressing activity of CD8 cells
CD8 T cells can also control HIV infection without killing the infected cells.
This non cytotoxic cellular immune response involves suppression by CD8 cells of
HIV replication (Levy et al., 1996). This antiviral activity is not MHC restricted
and is mediated at least in part by soluble factors. Infected individuals who were
asymptomatic and whose cultured PBMCs did not yield HIV were studied and when
CD8 cells were removed high levels of virus were released from the CD4 cells
remaining in culture. Further observations indicated that the CD8 cells could
suppress virus production without affecting activation markers on CD4 cells or
killing the virus-infected cells. A soluble factor produced by the CD8 cells is
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involved in this CD8 antiviral response. The presence of the factor can be shown
by adding supernatants from CD8 cultures directly to infected CD4 cells. CD8 cells
inhibit HIV replication before RNA transcription.
(d) Natural killer cells
NK cells mediate two forms of cytotoxicity: (i) lysis of virus-infected cells
in a non-MHC restricted manner and without prior sensitization, (ii) Through
CD16, NK cells can lyse IgG antibody-coated target cells; this mechanism is known
as antibody dependent cellular cytotoxicity (Levy, 1993). NK cells may provide the
first line of defence against viruses before activation of specific humoral and cellular
immune mechanisms.
(e) Dendritic cells
Dendritic cells (DCs) are antigen presenting cells found in all tissues and
organs of the body. Antigenically naive T cells are not widely distributed through
the tissues, and are mainly found in the blood and lymphoid organs. DC are the
principal antigen presenting cells (APC) involved in primary immune responses:
their major function is to obtain Ag in tissues, migrate to lymphoid organs, and
activate T cells. DCs are required for the stimulation of naive CD4 T cells, the
development of potentially protective cytotoxic T lymphocytes, and furthermore, are
more potent stimulators of secondary immune responses than monocytes (Caux et
al., 1995). Highly purified DCs can also stimulate a strong antibody response
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against both the envelope and core proteins. In contrast, addition of adherent
macrophages did not induce an HIV-specific antibody response (Roberts et al.,
1994).
3.4 Immunological abnormalities in AIDS
Infection with HIV-1 is persistent and associated with the development of
profound immunosuppression. The principal immunological defect observed upon
disease progression is the loss of CD4 T helper cells that play a role in all pathways
of the adaptive immune response to pathogens. Uninfected individuals show a mean
level of 1100 CD4 T cells/pl whole blood, while in AIDS CD4 T cell counts can
as low as less than 1/pl. Theories about the causes of the observed loss of CD4
cells range from direct destruction or dysfunction by cytopathic infection with HIV-
1 to apoptosis resulting from defects in antigen presentation (reviewed in Levy,
1993). Direct killing could be due to a cytolytic effect of the virus or to immune
attack on virus infected cells. HIV can cause direct cytopathic effects in activated
CD4 T cells in culture, either in single cells or by syncytium induction. Syncytia
are giant multi-nucleated cells and may include as many as 500 CD4 expressing
cells. These syncytia produce large quantities of virus for a short period of time and
then die. By incorporating non-infected cells into syncytia, a single gpl60
expressing cell can eliminate many uninfected CD4 cells. HIV-expressing cells
will also be killed by HIV-specific cytotoxic T cell responses, which are the normal
mechanism for eliminating virus infected cells. Antibody-dependent, complement
77
mediated cytotoxicity and other humoral immune effects may also help to remove
HIV infected cells (reviewed in Weiss, 1993).
It has recently been demonstrated that the number of CD4 lymphocytes
destroyed and replenished each day in HIV infection is of the order of 109, which
was close to estimates of the total number of HIV-1 RNA expressing lymphocytes
in the body (Ho et al., 1995; Wei et al., 1995). It may be that CD4 lymphocyte
loss is primarily a consequence of the destruction of these cells induced by HIV
while the gradual decline in CD4 and CD8 lymphocytes upon disease progression
represents a failure of the host to adequately replace cells lost by infection (Ho et
al., 1995; Wei et al., 1995).
Amongst indirect mechanisms, it has been demonstrated that in vitro HIV
infection of lymphocyte cultures leads to a higher degree of apoptosis than normal
(Finkel et al., 1995; Gougeon et al., 1996). If this also occurs in vivo it could
account for T helper cell depletion. However it has been reported that the major
cell type in the peripheral blood of HIV seropositive individuals undergoing
apoptosis are uninfected CD8 T lymphocytes (Carbonari et al., 1995). The
depletion of CD4 T cells in AIDS patients shows similarities to the T-cell depletion
that occurs following superantigen activation. Superantigens can bind
simultaneously to a region of the T cell receptor and to a MHC class II molecule on
an antigen-presenting cell. Uninfected cells which bind soluble gpl20, may
provide the necessary activation signal to initiate programmed cell death (Frost et
al., 1996).
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The finding that the blood and lymph of AIDS patients contains large
quantities of soluble gpl20 is the basis for several other hypotheses to account for
the depletion of uninfected CD4 T cells (reviewed in Levy, 1993). The
noncovalent interaction of gpl20 and gp41 is unstable, allowing large quantities of
free gpl20 to be shed into the surrounding fluid in vitro. If this phenomenon occurs
in vivo, gpl20 may bind to CD4 molecules on normal, uninfected CD4 T cells,
thus blocking the interaction of CD4 with class II MHC molecules on antigen-
presenting cells preventing the subsequent transduction of part of the activating
signal. However very large quantities of soluble gpl20 would be necessary to
measurably block T cell function. Another possibility is that binding of soluble
gpl20 to CD4 membrane molecules may induce destruction of uninfected T cells by
antibody-plus-complement lysis or by ADCC. Since numerous other cell types
express CD4, these mechanisms might be expected to cause their destruction as
well. However depletion of other CD4-bearing cells is much lower. The probable
explanation of this difference lies in the density of CD4 molecules, which is
considerably higher on CD4 T cells than macrophages or dendritic cells. Except for
CD4 T cells, the density of CD4 molecules most likely is too low to induce ADCC
or antibody-plus-complement lysis of other CD4-expressing cells. Binding of
soluble gpl20 to CD4 on an uninfected, activated T cell might result in receptor
mediated endocytosis of gpl20. The internalised gpl20 might then be processed
and presented together with class II MHC molecules on the cell membrane of the
uninfected CD4 T cell. Although T cells that are CD4 and MHC class II restricted
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generally function as helper cells, small numbers exhibit cytotoxic activity instead.
These cytotoxic CD4 T cells as well as CD8 lymphocytes and natural killer cells
could then selectively deplete these uninfected CD4 T cells.
Depletion of T cells normally induces T cell maturation within the thymus
to restore the peripheral T cell numbers. Some researchers have suggested that
soluble gpl20 in AIDS patients binds to CD4 on thymocytes, thus interfering with
the positive selection of class II MHC-restricted cells that occurs during T-cell
maturation. T cell precursors in the thymus or peripheral pools may be infected
with HIV and therefore fail to proliferate and replenish the mature T helper cell
population (Schulzeosthoff et al., 1993). It has also been suggested that defective
antigen presentation by monocytes or dendritic cells would inhibit T cell
proliferation (Knight, 1994).
It has been postulated that the T-cell homeostasis mechanism may fail
preceding AIDS. Given the high rate of T-cell turnover in HIV infection, blind T
cell homeostasis, where a constant number of lymphocytes is maintained without
regard to CD4 or CD8 phenotype, if it exists would have important implications for
HIV pathogenesis. This would account for the gradual shift in HIV infection from
predominantly circulating CD4 lymphocytes to CD8 lymphocytes. The failure of
T-cell homeostasis preceding AIDS would account for the depressed levels of total
T cells (Margolick et al., 1997).
The decline in CD4 lymphocytes and the initial increase in total CD8
counts in most HIV infected individuals is well documented (Pantaleo et al., 1993).
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However recent research has shown that CD8 naive cells are depleted during the
asymptomatic stage of HIV infection and that this loss can parallel that seen in CD4
lymphocytes (Rabin et al., 1995; Roederer et al., 1995). CD4 naive lymphocytes
are also lost preferentially as total CD4 counts fall. In individuals with CD4 counts
less than 200 per p.1, memory T cells were reported to account for 80% of T cells
whereas they form only 15% of the CD4 population in uninfected individuals.
Naive cells are required for all new T cell mediated immune responses and are
memory precursors. Their loss, which precedes the eventual loss of memory cells,
may contribute substantially to the eventual loss of the total CD4 and CD8
population. Loss of naive cells has important consequences for the development of
immune responses in HIV infected individuals. As naive subsets disappear, there
is a progressive inability to mount responses to novel antigens, which may well
result in high susceptibility to opportunistic infections. This loss would also
compromise the hosts ability to deal with the constantly mutating virus; novel strains
which are immunogenetically unique will encounter less resistance from the host
immune response than early in the progression of disease.
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Even with a vigorous virus-specific CD8 response there is still the
persistence of HIV viraemia, and high levels of CTL activity to HIV peptides does
not prevent the development of disease. It is possible that virus infected cells are
not recognised and conceivably, suppression of virus expression by the non-
cytotoxic CD8 cell antiviral factor could contribute to this lack of recognition by
CTL. Some recent reports suggest that HIV can escape the CTL response and this
mechanism could be involved in progression to disease (reviewed in Johnson and
Walker, 1994). A decline in the number of circulating CD8 lymphocytes, a
reduction in the cytotoxic response and loss of CD8 T cell function have been
reported in patients with more developed disease status (Edwards, 1972). The cell
loss and decline in cell function can be observed in healthy seropositive individuals
and occurs over time as the individuals CD4 count decreases and the disease
progresses. This loss of immune function may contribute to the rapid fall in
lymphocytes observed as an individual approaches AIDS (CD4 <200/pl).
A major component of cellular immunity is the NK cell, which recognises
and kills virus-infected cells in a non-MHC-directed manner. Impaired NK cell
activity and the decline in NK cell numbers is one of the many immunological
defects observed in patients with AIDS (Mitchell et al., 1994; Brenner et al., 1997).
A block in the capacity of DC from the peripheral blood to stimulate T-cell
proliferation after exposure to HIV is a feature of cells from HIV-infected persons.
DCs from asymptomatic HIV-seropositive individuals showed a reduced capacity
to stimulate either naive or memory T-cell responses as assessed from stimulation
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of allogenic mixed leukocyte reactions and recall responses in autologous T cells.
Findings indicate that both naive and memory T cells and monocytes were
functioning normally in these individuals and pinpointed the defects to signalling
through the DCs (Macatonia et al., 1990). The later appearance of T cell defects
is compatible with the thesis that they may be secondary to loss in the function of
DCs.
The decline of CD4 T helper cells in AIDS patients eventually affects the
functioning of B cells in the humoral response (Lane et al., 1983). As AIDS
progresses, patients are increasingly unable, from lack of T helper cells to mount
a humoral antibody response to new antigens. This may be important in relation to
the antigenic drift of HIV. As the virus mutates in HIV infection, late stage
individuals may not mount an adequate antibody response against the new HIV
variant.
3.5 Evidence for in vivo and in vitro infection of different cell subsets
with HTV-1.
It has until very recently been generally accepted that the cellular tropism of
HIV is determined almost exclusively by the distribution of CD4, the cell surface
receptor for HIV-1. CD4 is expressed on T helper cells, monocytes and peripheral
blood dendritic cells (Freudenthal et al., 1990) but not on mature cytotoxic T cells,
natural killer cells or B lymphocytes.
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(i) Infection of CD4 and CD8 lymphocytes with HIV-1.
HIV-1 infection of CD4 lymphocytes has been reported both in vitro and in
vivo (Schnittman et al., 1989). In fact CD4 lymphocytes are thought to be the
major reservoir of HIV-1 infection within the peripheral blood of seropositive
individuals. Early reports indicated that from 1 to 0.01% of CD4 T Cells
contained viral DNA, (Psallidopoulos et al., 1989; Schnittman et al., 1989).
However a more recent study using a sensitive PCR technique has suggested that at
least 10% of CD4 lymphocytes within the peripheral blood harbour HIV-1 in vivo
(Hsia et al., 1991).
Mature CD8 lymphocytes in the peripheral blood do not express CD4 at their
cell surface, however numerous studies have reported the infection of CD8
lymphocytes in vitro (Tsubota et al., 1989; De Maria et al., 1991; Mercure et al.,
1993). De Maria et al demonstrated that CD8-positive, CD4-negative lymphocyte
lines derived from infected individuals express HIV proteins and generate reverse
transcriptase activity (De Maria et al., 1991; De Maria et al., 1994). Infection was
confirmed at a single cell level by immunoelectron microscopy and two colour
immunohistochemistry. Seven days after establishing such cultures approximately
5 % of lymphocytes co-expressed CD4 and CD8. The basic requirements for HIV
infection of CD8 lymphocytes was the presence of CD4 cells. PCR of sorted
cells revealed that the CD8 cells harboured HIV-1 proviral DNA and stimulation of
these cells resulted in virus replication and infection of CD4 cells. This study
indicated that CD8 lymphocytes of patients with late stage AIDS may be infected
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with HIV-1 but the findings were not published. Mercure et al found that CD8 cells
can be productively infected when co-cultured with HIV-1 infected CD4 positive
cells. However direct infection of purified CD8 lymphocytes with isolated virus
was not possible (Mercure et al., 1993).
Infection of lymphoid CD4 and CD8 cells by SIV has been demonstrated
by DNA PCR and by cell sorting and virus isolation by co-culture (Dean et al.,
1996). In this study as many as 19.4% of the positively selected CD8 cells also
expressed CD4, indicating that SIV provirus may reside in dual positive cell
populations and that this may provide a mechanism of entry for HIV into CD8-
positive, CD4-negative cells in vivo. Semenzato and colleagues reported that
CD8 lymphocytes in the lung of AIDS patients harbour HIV-1. PCR of lung CD8
lymphocytes retrieved by bronchiolar lavage showed that they harboured and
expressed HIV-1 (Semenzato et al., 1995). Although there was a lack of membrane
CD4 reactivity it was demonstrated that the lung CD8 cells could express CD4
RNA.
Possible mechanisms for HIV infection of CD8 lymphocytes in vitro include:
(a) Viral transmission through cell-to-cell contact. This has already been reported
between monocytes or dendritic cell and CD4 lymphocytes and between CD4
lymphocytes (Valentin et al., 1990; Cameron et al., 1992; Levy, 1993; Cameron
et al., 1997). It has also been demonstrated that the minimum requirement for
infection is the presence of CD4 cells, (b) CD8 T cell activation by PHA may up
regulate CD4 expression at the cell surface allowing infection. An increase in
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double positive lymphocytes upon PHA stimulation has been reported (Flamand et
al., 1997). (c) A CD4 independent mechanism using a chemokine receptor for
virus entry.
(ii) Macrophages
Monocytes/macrophages which express the CD4 receptor for HIV, are often
considered an important reservoir of this virus in infected patients. HIV does not
replicate as actively as in CD4 T lymphocytes and HIV DNA rather than RNA can
be detected (Levy, 1993).
In the spleen HIV is found mostly in CD4 lymphocytes and trapped on the
surface of follicular DCs, while macrophages are not the major target population.
The results obtained in the spleens of HIV patients are comparable to those obtained
in the peripheral blood. Infection of macrophages was 20-100 times lower than in
CD4 T lymphocytes, which contained practically all the viral load of the
unseparated mononuclear cell populations (Mcilroy et al., 1996).
Although peripheral blood monocytes express CD4 and the activation marker
HLA-DR there is little evidence for their extensive infection with HIV (Collman et
al., 1990; Valentin et al., 1991; Levy, 1993). Estimates of the frequency of
infected monocytes ranged from zero to 100/106 cells (Schnittman et al., 1989;
Innocenti etal., 1992; Bagasra et al., 1993; Hsia et al., 1995). Such results have
collectively led to the view that the ability to support HIV replication increases as
monocytes differentiate into macrophages even though CD4 surface expression
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decreases with such differentiation. Evidence that differentiation into macrophages
is required for productive infection was obtained by comparing monocyte culture in
suspension rather than adherance to plastic and by the increased susceptibility to
HIV-1 that occurs on culture of monocytes in the presence of the maturation inducer
granulocyte-macrophage colony stimulating factor (GM-CSF) (Valentin et al.,
1991).
Separate studies have suggested that monocytes are either susceptible to HIV
in the absence of detectable CD4 on their surface or express CD4 on only a small
proportion of cells which are then susceptible to infection. In one study, CD4
antibody completely inhibited HIV infection of alveolar macrophages indicating that
CD4 although expressed at a low level appeared to be critical to HIV infection of
alveolar macrophages (Lewin et al., 1996). However, Sonza et al (Sonza et al.,
1995) concluded that the susceptibility of human monocytes to HIV-1 infection in
vitro is not dependent on their level of CD4 expression. Observations suggest that
the differing susceptibility of monocytes and monocyte-derived macrophages to
infection with HIV is not simply proportional to the level of surface CD4
expression.
The reasons why monocytes are resistant to HIV-1 infection are unknown.
CD4 on monocytes is reportedly identical to that on lymphocytes and thus gpl20
binding properties should be the same (Stewart et al., 1986). However, the CD4
molecule on monocytes has been has been found to have reduced binding affinity
for gpl20, when compared with binding of gpl20 to CD4 on macrophages
87
(Finbloom et al., 1991). Binding to an accessory receptor, such as CCR5, the
expression of which increases with culture may contribute to viral attachment and
entry, thereby facilitating infection of the cultured cells. There is currently no
evidence available to support this theory.
(iii) Dendritic cells
Although dendritic cells and macrophages share a bone marrow origin, these
cells were long assumed to differentiate via discrete pathways. DCs have now been
shown to develop from myeloid lineage precursors, and recent evidence suggests
that they may even differentiate from blood monocytes (Peters et al., 1996).
Purified fresh peripheral blood DCs lack the characteristic morphology, phenotype
and immunostimulatory function of mature DCs. The purified cells have the
appearance of medium sized lymphocytes and express substantial levels of CD4,
but lack the T cell molecules CD3, CD8, and T cell receptor (TCR). When placed
in culture, the cells mature: the cells enlarge and exhibit many cell processes,
express much higher levels of MHC II and a panel of accessory proteins for T cell
activation, and become potent stimulators of the mixed leukocyte reaction. Among
the many changes during the maturation process is a fall in CD4 expression
(O'Doherty et al., 1993).
Peripheral blood dendritic cells can be infected in vitro with HIV-1.
However, increased levels of infection were produced on culture with the maturation
cytokines, GM-CSF and tumour necrosis factor-alpha (TNF-a), and more proviral
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copies than cells were obtained in the cultures. In common with monocytes, DCs
appear more susceptible to HIV infection as CD4 levels decline or are lost (reviewed
in Knight, 1996).
DC purified from human peripheral blood were inoculated with various
strains of HIV-1, and viral replication was demonstrated by detection of p24 Ag,
and by Southern and Northern blot analyses for the presence of HIV DNA and
RNA. Purified DC did not express detectable membrane CD4, although CD4
mRNA was detected by RT-PCR. The presence of anti-CD4 monoclonal antibodies
failed to block infection of DC by any of the HIV strains tested, suggesting the
existence of a CD4-independent alternative pathway of viral entry (Chehimi et al.,
1993).
Hsia et al (1995) were unable to detect HIV-1 DNA in 104 or 105 DCs.
Cameron et al detected HIV DNA in 5xl05 dendritic cells but these were thought
to be contaminated with demonstrable numbers of CD4 lymphocytes. However,
contradicting these findings, DCs have been isolated from the blood of individuals
in different clinical categories and HIV infection has been demonstrated (Patterson
et al., 1994). The frequency of cells harbouring HIV DNA in purified populations
of cells isolated from the spleen were quantified by limiting-dilution PCR. Directly
isolated DC in each case were 10-100 times less infected than CD4 lymphocytes.
DC seem to be infected, but HIV-DNA positive CD4 lymphocytes accounted for
the vast majority of infected mononuclear splenocytes (Mcilroy et al., 1995).
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Evidence suggests that DC become productively infected only as they mature
in vivo (Weissman et al., 1995). Within peripheral blood, three forms of DC at
different stages of maturation were observed by electron microscopy. These cells
ranged from those with short cytoplasmic projections, the majority of cells in the
peripheral blood exhibited this morphology, to the occasional completely veiled DC.
HIV was never detected in the more immature DCs but in the fully veiled cells,
electron microscopy revealed viruses budding from the cell membrane or in clusters
attached to the cell surface.
The rate and efficiency of key steps in the life cycle of H1V-1 was examined
in three primary cell types, T cells, DCs, monocytes (Langhoff et al., 1993). The
results show that viral DNA synthesis proceeds much more rapidly and efficiently
in primary DCs than in primary T cells or monocytes. In the subsequent phase of
viral expression the appearance of spliced viral mRNA products also occurred more
rapidly in cultures of DC. The increased efficiency of the early steps of HIV
replication in primary blood derived T helper DC than in other blood derived
mononuclear cells raises the possibility that these cells play a central role in HIV-1
infection and pathogenesis. The high level of virus produced by populations of DCs
is remarkable as these cells are terminally differentiated and do not proliferate in
culture. However other studies would suggest that any DCs may have latent or non¬
productive infection with virus, since a much higher proportion of DC contained
viral DNA than expressed viral RNA.
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(iv) Natural killer cells
Among other defects, patients with AIDS display abnormalities in NK cell
activity and NK cells decrease in HIV infection through a selective depletion of the
CD16-positive, CD8-positive, CD3-negative subset (Vuillier et al., 1989). Recent
results indicate that purified populations of NK cells, which express neither surface
CD4 nor CD4 mRNA, were susceptible to infection with various isolates of HIV-1
(Chehimi et al., 1991; Scottalgara et al., 1993). Viral replication was detected by
p24 antigen intracellularly and in culture supernatants, by the presence of HIV DNA
within infected cells. Infection of NK cells was not blocked by anti-CD4 suggesting
a CD4 independent mechanism of entry was involved. Infection was only detected
in the subset of NK cells expressing CD8.
It is possible that HIV infection of NK cells could be involved in the decline
in their number and function observed in AIDS patients. In order to investigate this
NK cells were compared from infected and uninfected cultures. NK cells from
HIV-infected and uninfected cultures were similar in their ability to lyse three
different target cells. However, considerable numbers of NK cells in the infected
cultures died, suggesting that the loss of NK cells in HIV infection is as a result of
virus replication but that reduced NK cell function involves another mechanism.
The possibility that NK cells serve as a potential reservoir for HIV-1 in vivo must
be considered (Chehimi et al., 1991).
NK cells were exposed to different strains of HIV-1. Illb and SF2 strains
were able to infect NK cells but less infection was observed when using a brain
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isolate. Two viruses isolated from lymphocytes of children with AIDS were able
to infect NK cells but 3 isolates from monocytes of children with AIDS were unable
to infect purified NK cells. Since the five isolates have not been fully characterised
it remains to be determined whether NK cells are differentially permissive to
lymphocyte-tropic or monocyte-tropic strains of HIV-1 (Chehimi et al., 1991).
3.6 Viral dynamics of HIY infection
In general retroviruses can productively infect only actively dividing cells.
In contrast, lentiviruses, including HIV-1 can establish a productive infection in
certain non-dividing cells (Watkins et al., 1990). It has been demonstrated that
HIV-1 can infect and establish a complete, stable form of viral DNA in primary
CD4 lymphocytes in vitro but is blocked from transcription in the absence of cell
activation. Thus quiescent T cells may be a major and inducible reservoir in
infected individuals (Spina et al., 1995).
It was show by virus quantitation and mutation fixation rates that the
composite lifespan of plasma virus and of virus-producing cells is remarkably short.
This holds true for patients with CD4 counts as low as 18 cell per pi and as high as
355 cells per pi. Investigations estimate that the rate of CD4 lymphocyte turnover
is on average, 2xl09 cells per day, or about 5% of the total CD4 lymphocyte
population, depending on clinical stage, which is close to the number of
lymphocytes expressing HIV mRNA in the body (Ho et al., 1995; Wei et al.,
1995). The data suggest that HIV-1 viraemia is sustained by a dynamic process
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involving continous rounds of de novo virus infection and replication and cell
turnover and not an 'innocent bystander' mechanism of cell killing whereby
uninfected or latently infected cells are indirectly targeted for destruction by
adsorption of viral proteins or by autoimmune reactivities .
3.7 How does HIV cause ALPS?
How does HIV cause AIDS? There are no definite answers but there are
numerous theories discussing how HIV may lead to AIDS and these are summarised
below (reviewed in Weiss, 1993).
It has been hypothesised that the chronic activation of the immune system
occurring throughout HIV infection is the mechanism responsible for the cell
deletion process. By the onset of AIDS antibody responses are low and APC had
little effect. This might reflect the significant T-cell depletion and dysfunction that
occurs with AIDS and thus a lack of T cell help. The immunological abnormalities
observed may be, in fact secondary to CD4 T helper cell loss, as these cells are
directly involved in many areas of the host immune response to viruses.
The powerful immune response enabling many patients to remain healthy for
years may finally be undermined by continuous mutation of the virus (Vazeux et
al., 1992). New viral variants may emerge that are able to evade the protective
forces some what. These features enable the virus to evolve in response to the
threats it encounters during the course of an individual infection. Mutants able to
evade immune attack to some degree appear and predominate until the immune
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system gathers the strength to quell them, but meanwhile new escape mutants begin
to multiply. Generation of mutants thus stimulate a continuous reduction in the
efficiency of the immune system. At some point, the diversity becomes too
extensive for the immune system to handle, and HIV escapes control. More
cytopathic variants of HIV may possibly arise as the immune system becomes
weaker increasing the rate of cell loss in AIDS.
The preferential loss of naive cells has important consequences for the
development of immune responses in HIV infected individuals (Schulzeosthoff et
al., 1993; Rabin et al., 1995; Roederer et al., 1995). As naive subsets disappear,
the host becomes less able to control opportunistic infections and new virus
variants. These naive cells are also precursors for the memory population and thus
their loss will inevitably lead to a reduction in the overall number of circulating T
lymphocytes. Given the high rate of T-cell turnover in HIV infection, blind T cell
homeostasis would account for a shift from CD4 to CD8 lymphocytes and a failure
of this mechanism would account for the depressed level of total T cells (Margolick
et al., 1997).
Specific cellular immune responses are driven by various cytokines.
Immunoregulatory cytokines are produced by T cells, monocytes/macrophages,
natural killer cells and B cells. A type 1 response is a strong cellular immune
response with normal or increased levels of IL-2, IL-12 and interferon-gamma
(IFN-y); and a type 2 response as a reduced or undetectable cellular response
accompanied by an increase in one or more B-cell activities and an increase in IL-4,
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IL-5, IL-6, IL-10 and/or IL-13. Recent studies indicate that type 2 cytokines are
increased in HIV infected individuals in the progression towards AIDS (Clerici et
al., 1994; Clerici et al., 1997). A dominant type 1 cytokine profile would be more
protective against disease progression than a dominant type 2 cytokine profile. It
has been shown that HIV-specific cellular immune responses, can be detected in
cohorts of individuals multiply exposed to HIV, many of whom do not appear to be
infected. Thus a type 1 to a more dominant type 2 response in HIV infection could
be instrumental in the failure of the immune response to cope with HIV replication
in the later stages of disease. A type 1 to type 2 switch has been noted with
progression to AIDS in some individuals.
Studies investigating the infection of DCs with HIV have suggested that DC
infection is in fact important in the development of AIDS (Knight, 1996). Studies
have revealed that DCs are functionally impaired during asymptomatic HIV
infection before the development of T-cell abnormalities. DCs from asymptomatic
HIV-seropositive individuals showed a reduced capacity to stimulate either naive or
memory T-cell responses as assessed from stimulation of allogenic mixed leukocyte
reactions and recall responses in autologous T cells. Loss or dysfunction of DCs
impairing the recruitment of T helper cells into the memory pool would contribute
to the progressive decline in CD4 lymphocytes. Loss of DC function may also be
important in other areas of immune abnormalities in AIDS. Examples of the
important roles of DCs which may be lost or impaired are the stimulation of a
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cytotoxic T cell response and their involvement in the development of an antibody
response (Roberts et al., 1994).
Interacting DC and helper CD4 lymphocytes form a micro environment
which is permissive for HIV-1 replication (Cameron et al., 1992; Cameron et al.,
1997). The virus need only be pulsed initially onto the DCs, which then transfer
HIV-1 to the lymphocytes that are responding to the presented antigens. Pulsing T
cells with HIV-1 results in much less of a subsequent infection than does pulsing the
DCs. Direct examination of the interacting DCs and T cells reveals extensive
production of p24 by many of the lymphocytes including syncytia. The majority of
the responding T cells die during the co-culture. Apoptosis accounts for much of
this death. Thus the micro-environment that is generated between antigen
presenting DCs and T cells reveals the cytopathic potential of HIV-1, because there
is such extensive and rapid death by apoptosis of the antigen-reactive T cells. These
observations could be important in the lymph node of infected individuals where
DCs come into close contact with many T cells.
DCs from the thymus may be infected with HIV as well as thymic T cells
(Knight, 1996). Changes in the function of DCs within the thymus could alter the
selection of T cells and be a factor in the loss of naive T cells that occurs in AIDS.
Failure of DC from infected individuals to stimulate proliferation of naive T cells
could underlie the loss of memory cells that also occurs. Within the spleen and
lymph nodes only low levels of infection of DCs have been described.
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Finally is it possible that immune dysfunction and the cell depletion observed
in AIDS is directly due to the cytopathic effects of HIV infection. Early reports
claimed the HIV infection was silent during the asymptomatic stage. However
recent reports would suggest that the asymptomatic stage is in fact far from silent
with the immune system battling to replace cells lost to HIV replication. It has been
demonstrated that the number of CD4 lymphocytes destroyed and replenished each
day is of the order of 109 which was close to estimates of the total number of HIV-1
RNA expressing lymphocytes in the body (Ho et al., 1995; Wei et al., 1995). It
may be that CD4 lymphocyte loss is a consequence of the destruction of these cells
induced by HIV.
Direct cell loss due to HIV replication is further supported by investigations
of lymph node infection (Embretson et al., 1993). Using in situ PCR it was
possible to visualise the distribution of HIV RNA and DNA in the lymph nodes and
to show that cells in the lymph nodes are infected at ten times the frequency of cells
in the peripheral blood. Because the lymphoid organs contain the majority of T
cells, while the peripheral blood contains only a small fraction (about 2% of all T
cells). Emberetson et al (1993) and showed that HIV is not only abundant, but also
active in the lymphoid tissue during the asymptomatic phase, even though the virus
in peripheral blood was inactive at this time. This offers an explanation for the loss
of CD4 cells during the asymptomatic phase when the number of infected cells in
the peripheral blood is relatively low. In the later stages of disease the architecture
of the lymph nodes collapses, and these organs loose their ability to trap the virus.
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The spillover from the lymphoid organs could partially explain the increase in viral
burden as the disease progresses.
3.8 Cell Separation
Results in vivo suggest that a much wider range of cells are infectable with
HIV than have been demonstrated in vivo. Previous studies have also demonstrated
that cells which do not express CD4 can be infected. Therefore the host cell range
of HIV-1 within the peripheral blood of seropositive individuals may be broader
than those cell types identified, that is CD4 T lymphocytes, monocytes, and
dendritic cells. The aim of this investigation was to determine the in vivo
distribution of HIV-1 proviral sequences in different cell subsets of PBMCs isolated
from seropositive individuals at different stages of disease progression. Cell subsets
were isolated using three different isolation methods, and HIV-1 DNA was
quantified in each fraction using primers complementary to the gag and V3 regions
of HIV-1.
The underlying problem with any investigations where individual cell types
are isolated from PBMCs is that cells are not a homogenous population and different
purification procedures may result in variations in the purities of the cells isolated.
The cell isolation procedures alone may cause cell activation or maturation altering
the cells from their in vivo state. In the main PBMCs are isolated by layering whole
blood onto ficoll hypaque, centrifugation and harvesting the cells from the interface.
Unfortunately this first step activates the monocytes present.
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Different groups have used various techniques to isolate DCs and these are
summarised below. Freudenthal et al (1990) separated T lymphocytes by rosetting
with neuraminidase-treated sheep erythrocytes followed by ficoll-hypaque
sedimentation. T cells were recovered from the pellet by lysing the erythrocytes
and washing twice in RPMI. The T-cell depleted (ER-ve) fraction was washed
twice in RPMI and cultured for 36 hours. By reculturing the cells twice for 30-40
minutes at 37°C on fresh dishes monocytes were depleted by attachment to plastic.
Non-adherent cells were then 'panned' once or twice on plastic dishes coated with
immunoglobulin to remove residual Fc fragment receptor (FcR)-bearing monocytes.
The monocyte and T-cell-depleted fraction was layered onto 2.5 ml columns of
hypertonic 14.5% metrizamide in 15 ml conical tubes and sedimented at 650 x g for
10 minutes at room temperature. The dendritic-cell-enriched interface was
separated from the B and natural killer (NK) enriched pellet.
Patterson et al (1994) incubated PBMCs overnight to provide plastic
adherent and non-adherent cells. The non-adherent cells were centrifuged over
13.5% weight/volume metrizamide to separate the lymphocytes and low density
cells (LDC). It was estimated that 10-40% of these LDCs were DCs. The LDCs
were incubated with a cocktail of monoclonal antibodies directed against CD3,
CD14, CD56, and CD19 (T cells, monocytes, natural killer cells, and B cells
respectively). Labelled cells were removed by panning on anti-mouse
immunoglobulin-coated flask. By flow cytometry it was estimated that the final DC
purification was 95 % pure.
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Chehimi et al (1993) concluded that differences in results might be explained
by the different methods used to purify DC. They found that the use of 14.5%
metrizamide yielded preparations contaminated by monocytes.
Initially a procedure was developed which involved the selection of CD4 T
cells, CD8 T cells, monocytes and B cells. Dendritic cells were then positively
selected from the depleted fraction. The use of metrizamide and cell culture
techniques were avoided. Lymphocytes were first isolated by resetting with
neuraminidase treated sheep red blood cells. The T cell fraction could then be
separated into CD4 T cells and CD8 T cells with monoclonal antibodies. E-rosette
negative (ER-ve) cells were incubated with a series of monoclonal antibodies, first
with CD14 (monocytes), then CD21 (B cells), and finally with CD4 and MHC-II
HLA-DR (Dendritic cells). Each monoclonal Ab was pre-bound to magnetic beads
so each cell type could be fractioned using a magnet after each incubation.
DCs are difficult to purify partly because they are present in such small
numbers, and because no DC-specific cell markers have been identified (Freudenthal
et al., 1990). Furthermore it has been reported that a population of DCs are lost
in the E-rosette positive fraction either because they directly bind sheep red blood
cells or because they cluster with T cells. Weissman et al (1995) isolated three
populations of dendritic cells using various techniques. Only one type of these
isolated DCs were infected with HIV. Thus discrepancies in findings of different
groups studying dendritic cell infection could be due to different isolation
procedures. Dendritic cell isolation proved to involve many disadvantages, most
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prominent was the level of cell loss that resulted from the E-rosetting procedure.
E-rosette positive cells were also found to contain natural killer cells which can
express CD2 and therefore bind to the SRBCS. Therefore in later cell isolation
procedures, the miniMACS cell separation method was used, the dendritic cell
fraction was not isolated and the methods used concentrated on the isolation of other
cell subsets.
Another disadvantage of the first technique was that the beads used could not
be directly FACS analysed so cell purity could only be inferred. The second cell
separation method involved the use of MiniMACS directly conjugated beads and
separation columns. MACS Microbeads are extremely small, only 50 nm in
diameter and can be directly analysed by FACS as they do not affect the light
scattering of labelled cells. The purity of the sorted fractions can be determined
directly after MACS separation by flow cytometry and labelled cells can be stained
simultaneously with fluorochrome conjugated antibodies. The size and composition
of these beads mean they are biodegradable and were therefore useful where cells
were required for cell culture as they do not alter the cell physiological function.
The MiniMACS system was already optimised and the manufacturer claimed that
typically isolated cells were of 95-99% purity. Monocytes, CD4-positive cells, and
natural killer cells were first isolated before anti-CD8 beads were used to purify
CD8 T lymphocytes. However, because the E-rosetting method was not used (in
order to limit cell loss during cell separation), T cells were not first isolated,
therefore the CD4 T lymphocytes population was contaminated with DCs.
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Finally CD4 and CD8 cells were isolated from four individuals using
Dynabeads. This study was carried out in order to further verify the PCR results.
In order to do this two positive and two negative samples were separated in an
independent lab (St Marys Hospital, London) and were numbered anonymously.
PCR reactions were then carried out blind.
RESULTS
3.9 Cell Separation and FACS Analysis
30 mis of whole blood were taken from 34 HIV seropositive individuals with
CD4 counts ranging from less than 1 to 938 /pi of blood. Of the individuals studied
19 had CD4 counts less than 200 and 12 had CD4 counts of greater than 200.
There was also an even distribution of individuals infected by heterosexual contact,
homosexual contact and intravenous drug use. Other virological and immunological
data for the individuals studied are given in tables 2.1 and 2.2. Cell subsets were
isolated from PBMCs using 3 purification methods; (i) Using an E-rosetting
technique, E-rosette positive cells were first incubated with anti-CD4 coated
magnetic beads to isolate CD4 T cells. The deleted fraction was then treated with
anti-CD8 in order to positively select CD8 T lymphocytes. Monocytes, B cells and
DCs were sequentially purified from the E-negative fraction using magnetic beads
coated with CD14, CD19 and CD21, and CD4 and HLA-DR. Blood samples from
17 individuals with CD4 counts ranging from < 1 to 938/pl blood, were treated in
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this manner (individuals coded P). None of these individuals were undergoing anti-
retroviral therapy or had received treatment in the previous six months (Table 2.1).
(ii) MiniMACS beads directly conjugated to anti-CD14, CD4, CD56 and CD8 were
used to select monocytes, CD4 lymphocytes, NK cells and CD8 T lymphocytes
respectively. This isolation method was carried out on 15 samples from individuals
with mean CD4 counts ranging from 3 to 420/pl blood. 5 of these individuals were
undergoing anti-retroviral therapy, (individuals coded S04-S26, Table 2.2) (iii)
In a blind study with two HIV positive (Anonl and 2) and two negative control
samples Dynabeads conjugated with ani-CD4 and CD8 were used to purify CD4 and
CD8 lymphocytes.
For each cell separation method negative control PBMCs were separated in
parallel. Aliquots of isolated cells were then FACS analysed using a panel of
monoclonal antibodies, in order to determine purity. For raw data see appendix.
The process of isolating subsets of mononuclear cells using indirect labelling
of magnetic beads (Immunotech) prevented analysis of the selected cells by FACS
techniques. However, the purity of cell fractions could be inferred by measurement
of the frequencies of different cell types in the residual cells after removal of a
particular fraction. Mean values for each cell fraction were calculated from FACS
data of three negative controls run in parallel with positive samples. The E
positive cells (T cell fraction) contained a mean frequency (3 samples) of 82.8%
CD3 cells (Table 3.1). Contaminating cells included B lymphocytes (0.9% CD19
cells) and natural killer cells (15.5% CD16 cells). The presence of NK cells was
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expected as they express CD2 which binds to SRBCs. Positive selection for CD4
cells was shown by a reduction of CD4-positive cells from a mean of 47.0% in the
E-rosette (ER) positive population to 1.7% in the depleted cells. There was also a
reduction in the number of CD3 positive cells from 82.8% to 54.4% and an
enrichment of CD8 positive cells. CD4-depleted cells consisted of 54.5% CD8
cells, which were then positively selected on CD8-coated beads. Residual cells after
CD8 depletion contained only 4.2% CD8 cells and 12.0% CD3 cells. There was
a small decline in NK cells from 14.5% to 12.7% as these cells can express low
levels of CD8. The remaining CD4-negative, CD8-negative, CD3-negative cells
contained NK cells, dead cells and any remaining SRBCs. ER-ve cells (non-T cells)
(table 3.1) contained less than 1% CD3-positive T cells. These cells were first
incubated with anti-CD3 coated beads to remove these residual T cells. Monocytes
were effectively removed by means of beads coated with CD lib and CD 14 (59.5%
to 3.7%). The remaining cells were depleted by use of CD19-coated and CD21-
coated beads to remove residual B cells. Less than 1 % of the resulting population
expressed CD3 while, 43.5% expressed CD4, and 53.2% HLA-DR, a phenotype
consistent with dendritic cells. Magnetic beads coated with anti-CD4 and anti-HLA-
DR coated magnetic beads were then used to isolate the dendritic cell fraction. DCs
express no cell surface markers (Freudenthal et al., 1990) so it is difficult to
determine their purity by FACS analysis. Therefore the purified DCs from
negative control samples were resuspended in cell culture medium and incubated at
37°C. The cultured cells were analysed by light microscopy and after 5 days cells
104
with a veiled morphology were detected. This morphology is characteristic of a
mature DC (Freudenthal et al., 1990).
When this E-rosetting technique followed by positive selection of cells using
monoclonal antibody coated magnetic beads was used, direct FACS analysis of the
positively selected cells was not possible and therefore the level of cell purity had
to be inferred from depleted cell fractions. The first method does not necessarily
prevent analysis of subset purity and the selection steps could be carried out using
miniMACS beads. However a further problem with the E-rosette technique was the
substantial cell loss observed, especially when lysing the sheep red blood cells.
Therefore the E-rosetting step was omitted in later procedures
CD 14, CD4, CD56 and CD8 positive cells from 15 individuals were purified
using directly coated MiniMACS beads and columns. FACS analysis was carried
out using six HIV positive samples and five negative control samples for monocytes,
CD4-positive cells and CD8-positive cells. Only three natural killer cell fractions
were analysed. For each purified cell fraction mean purity values were calculated
from the FACS data (table 3.2). MiniMACS beads directly conjugated to CD 14
were first used to isolate monocytes as these cells express Fc-receptors and are
generally adherent so could non-specifically bind to antibody coated beads for other
cell types. Monocytes contained a mean frequency (11 samples) of 0.3%
contaminating T cells (CD3 positive) and only 1.2% CD19 positive B lymphocytes
and 1.6% CD 16 positive NK cells. CD4 conjugated beads were then used to isolate
CD4 lymphocytes (as well as CD4 expressing DCs). CD4 selected cells were
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97.6% CD3 positive and 90.4% CD4 positive. However there were only 1.6%
contaminating CD8 cells, 0.1% B Cells and 1.0% NK cells. The percentage of
CD4 expressing cells may be higher but masked by bound CD4 MiniMACS beads.
In all individuals but three CD56 coated beads (Immunotech) were used to deplete
NK cells and reduce potential contamination to the CD8 lymphocyte fraction. In
the remaining three individuals a sample of CD56 coated MiniMACS beads were
used to positively select NK cells for FACS analysis and PCR. The NK cell
fractions were 93.5% CD16 positive and only 3.6 % CD3 positive. Finally anti-
CD8 coated MACS beads were used to positively select CD8 lymphocytes from the
CD14, CD4, CD56 depleted cell fraction. These cells were 95% CD3 positive
(mean 11 samples) and at least 93 % CD8 positive. Contaminating CD4 cells and
NK cells were only 1.6% of the cell population.
As well as allowing direct FACS analysis of cell subsets the miniMACs
method provided a rapid system which could be used to isolate cells. The time
taken to separate cells proved important in RNA work carried out using the purified
cells (chapter 4).
3.10 Detection of HIV-1 DNA in different cell subsets using nested-PCR
Once the cell fraction purity was determined nucleic acid was extracted and
proviral DNA was quantified in each cell type using a limiting dilution and nested-
PCR approach (Simmonds et al., 1990b). The quantitation was performed using
primers corresponding to the gag gene and the V3 region. A nested PCR approach
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was used because this method can detect one single molecule of target DNA, and
allow quantitation by dilution of DNA to an end-point. PCR product was visualised
on a 2% agarose gel containing ethidium bromide. Using cell counts from each
sample and the number of copies of provirus detected it was possible to express the
results as proviral copies per million cells. All separations, extractions, and
amplifications were carried out with parallel samples of mononuclear cells isolated
from buffy coat leucocytes derived from HIV-1 negative blood to serve as negative
controls. Serial dilutions of cells from HXB2 cultured cells with a known PCR cut
off were used as positive controls for extractions and PCR reactions.
HIV-1 DNA could be detected in CD4 T lymphocytes, CD8 T lymphocytes,
monocytes, DCs and NK cells (Tables 3.3 and 3.4). HIV DNA was never detected
in the negative controls or purified B cells. For negative samples the cut-off for the
assay depended on the number of cells isolated and available for extraction. Mean
CD4 counts taken over the previous six months were used as a marker of
immunosuppression and progression to AIDS. HIV DNA was detected in the CD4-
positive cell subset of 17 of the 19 individuals with CD4 counts less than 200, and
in 10 of the 11 individuals with CD4 counts greater than 200. Where the E-
rosetting technique was used CD4 lymphocytes were isolated and were found to be
infected with HIV in 8 of the 10 individuals with mean CD4 counts less than 200/pl
and in 6 of the individuals with CD4 counts greater than 200 (Table 3.3). When the
miniMACS method was used to isolate CD4 cells the cell fraction contained both
CD4 lymphocytes and CD4 expressing populations of DCs. Using this method
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HIV DNA was detected in all the individuals studied, 10 with CD4 counts less than
200 and 5 with CD4 counts greater than 200. CD4 lymphocytes were infected at all
stages of disease progression. The mean level (1071 proviral copies/106 cells) was
higher in individuals with CD4 counts less than 200 than for those with higher
counts (82 copies/106 cells) (table 3.5). Infection was detected in monocytes of
seven individuals with CD4 counts from <1 to 71 and in two individuals with CD4
counts of 286 and 382/pl. The mean frequency of infection in those individuals
with CD4 counts <200 was 184 proviral copies/106 cells and 27 copies/106 cells in
individuals with higher CD4 counts. Dendritic cell infection ranged from < 1 to
1099 proviral copies/106 cells in individuals at all stages of disease progression.
The frequency of infection of dendritic cells did not correlate with CD4 count
(p=0.490 Wilcoxon signed ranks test), and the individual with 1099 copies/106 DCs
had a CD4 count of 279/pl. HIV DNA was detected in the CD8 lymphocytes of
23 of the 34 individuals studied. These HIV positive CD8 lymphocytes included 6
individuals with CD4 counts greater than 200. The mean frequency of infection in
individuals with CD4 counts greater than 200 was 86 compared to 206 proviral
copies/106 cells in individuals with lower CD4 counts. In the three individuals
where NK cells fractions were extracted and PCR reactions carried out, HIV DNA
was detected in 3 of the cell isolates, from individuals with CD4 counts of 400 and
366/pl.
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Table 3.5 : Mean Cell Counts, Frequency of infection, and Distribution of
infection in PBMCs for HIV seropositive individuals with CD4 counts/ill of





Mean CD8 Counts 1051 625
CD4 Losse 5.5 32
CD8 Losse -1.4 19
Frequency infection CD4 T cells'7t 82 1071
Frequency infection CD4 T cells/DCsc/g 1109 500
Frequency infection CD8 T cellsc 80 238
Frequency infection monocytes1 29 95
Frequency infection DCsc 264 106
Distribution HIV in CD4 T cells'1 54 21
Distribution HIV in CD4 T Cells/DCsll 40 8
Distribution HIV in CD8 T cells'1 31 59
Distribution HIV in monocytesc 7 4
Distribution HIV in DCsc 18 23
Distribution HIV in NKsc 3 /
a For individuals with CD4 counts <200 the mean values are for 18 individuals, b The mean values for individuals with CD4
counts >200 were calculated using data from 14 individuals, c Frequencies of infection are in proviral copies/106 cells, d
Distribution values in each cell subset are given as a % of the total proviral load in the total PBMCs of each individual, e CD4 and
CD8 cell loss values are a percentage loss from a cell count taken 12 months prior to the sample, f CD4 infection=CD4 cells
separated by E-rosetting method, g CD4/DCs=CD4+ cells isolated using MiniMACS system. All calculations exclude individuals
receiving anti-retroviral therapy.
CD4 and CD8 cells were separated in an independent laboratory from
PBMCs of two control HIV negative individuals and two HIV seropositive
individuals. These samples were labelled anonymously and were analysed for the
presence of HIV DNA. HIV was detected in both the CD4 and CD8 cells isolated
from the HIV seropositive individuals but no HIV DNA was detected in the negative
control samples.
3.11 Analysis of quantification results
To investigate the relationship between the frequency of HIV infection of
CD4 T lymphocytes and CD4-positive cells containing DCs with disease
progression, mean CD4 counts/pl were plotted against the frequency of infection
of CD4 T lymphocytes (Figure 3.1) and CD4 cells isolated using the miniMACS
system (Figure 3.2). Although there was a wide variation in CD4 lymphocyte
infection ranging from 1 to almost 10000 copies/106 cells an inverse correlation
with mean CD4 number was observed (p= <0.001) No correlation was evident
between mean CD4 counts and the frequency of infection of CD4-positive cells
isolated without prior separation of T and non-T cells (p=0.463). The frequency of
infected CD8 lymphocytes was also variable ranging from 1 to 100 copies/106 cells
(Figure 3.3), with an observable tendency for an increase in the frequency of HIV
infection with declining CD4 count (p=0.03) .
The frequencies of HIV infection of CD4 and CD8 lymphocytes (HIV
copies/106 cells) were then plotted (Figure 3.4). There was a good correlation
109
Figure 3.1 : The Frequency of infection of CD4 lymphocytes (log10 copies/106 cells)
isolated by E-rosetting followed by positive selection with anti-CD4 coated magnetic
beads (Immunotech) vs the mean CD4 counts/pl whole blood calculated over a six
month period.
FrequencyInf ctioCD4Lymphocytes
Figure 3.2 : The Frequency of infection of CD4-positive cells including CD4 T cells
and Dendritic cells (log10 copies/106 cells) isolated by miniMACS vs the mean CD4
counts/pl whole blood calculated over a six month period.
FrequencyInfectioCD4Positiveells
Figure 3.3 : The Frequency of infection of CD8 lymphocytes (logi0 copies/106 cells)
isolated by E-rosetting followed by positive selection with anti-CD8 coated magnetic
beads and by miniMACS vs the mean CD4 counts/|il whole blood calculated over a six
month period.
FrequencyInfectioCD8Lymphocytes
Figure 3.4 : The Frequency of infection of CD4 lymphocytes (log10 copies/106 cells)
isolated by E-rosetting followed by positive selection with anti-CD4 coated magnetic
beads (Immunotech) vs the frequency of infection of CD8 lymphocytes (log10
copies/106 cells).
 
between the infection of CD4 T lymphocytes and CD8 T lymphocytes (p=0.002).
As the frequency of HIV infection in CD4 lymphocytes increases the frequency of
infection of CD8 lymphocytes increases. Less of a correlation was evident when
the frequency of CD8 infection was plotted against CD4 positive cell infection
isolated using the miniMACS method (p=0.312) (including CD4 lymphocytes and
DCs).
A total of 14 samples contained no detectable infection in monocytes, yet
were obtained from individuals with a wide range of CD4 counts. Apart from the
two individuals receiving anti-retroviral therapy the provirus load in monocytes was
less than 100 proviral copies/106 cells. No correlation between disease progression
and monocyte infection was apparent (p =0.139) (figure 3.5). The frequency of DC
infection was also plotted against mean CD4 count (figure 3.6). The level of
infection was generally higher than that in the monocyte population and there were
fewer negatives. The frequency of infection of DCs did not correlate with CD4
counts (0.).
The absolute cell counts for each cell fraction and the frequencies of
infection were combined to determine the contribution of HIV-1 DNA from each
cell subset to the proviral load in total PBMCs. Absolute cell counts were used to
calculate the proviral load of each cell subset per pi of whole blood. The
contribution of each cell subset to the overall proviral load in PBMCs (% total load
in PBMCs) were then illustrated as bar graphs with individual patients plotted along
the X-axis in ascending order according to mean CD4 counts (cells/pl). Separate
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Figure 3.5 : The Frequency of infection of monocytes (log10 copies/106 cells) isolated
by positive selection with anti-CD 14 coated magnetic beads (Immunotech and
miniMACS) vs the mean CD4 count calculated over a six month period.
FrequencyInf ctioMonocytes
Figure 3.6 : The Frequency of infection of Dendritic cells (log10 copies/106
cells) vs the mean CD4 count over a six month period.
FrequencyInfectioDCs
graphs were plotted for samples separated by the E-rosetting method (figure 3.7)
and those using the miniMACS technique (figure 3.8). Individual p25 appears
blank because a low level of virus was detectable in the total PBMCs it was not
possible to detect virus in any of the individual cell subsets. Individuals S15, SI9,
S24, S25, and S26 were all recieving anti-retroviral therapy. Looking at both
figures it is evident that there appears to be very little correlation between the
distribution of monocyte and dendritic cell infection with disease progression
(p—0.139 and 0.09 respectively). However as would be expected as the CD4 count
decreases so does the contribution of provirus from CD4 lymphocytes to the total
viral load in PBMCs. This also true for CD4 positive cells isolated using
miniMACS beads. This cell fraction contained DCs but because these cells are a
minor population (<1% of PBMCs) their presence may not affect the overall
contribution of CD4 lymphocytes.
It is also evident that as the disease progresses the contribution of CD8
lymphocytes increases, so in individuals with lower CD4 counts, CD8 lymphocytes
become a major reservoir of HIV infection in the peripheral blood. This increase
in the relative viral load in CD8 lymphocytes of late stage individuals is especially
clear in S8, P24, S9 and S7 where the individuals had CD4 counts of less than 20//d
and the CD8 lymphocytes contributed almost 100% of the total HIV population in
PBMCs.
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Figure 3.7 : The relative distribution of different cell subsets isolated by E-rosetting
and positive selection with monoclonal antibody coated beads (Immunotech) to proviral
load in peripheral blood mononuclear cells.
CD4 = CD4 lymphocytes; CD8 = CD8 lymphocytes; DC = Dendritic cells; mono =
Monocytes.
 
Figure 3.8 : The relative distribution of different cell subsets isolated by miniMACS
to proviral load in peripheral blood mononuclear cells.
CD4 = CD4 lymphocytes and dendritic cells; CD8 = CD8 lymphocytes; NK = Natural
killer cells; mono = Monocytes.
 
3.12 CD4 and CD8 cell loss with progression to AIDS
CD4 and CD8 cell loss over a twelve month period prior to the study were
calculated for each of the 34 individuals. CD4 loss and CD8 cell loss were plotted as
a percentage depletion in that cell type (figure 3.10). Therefore a positive value
represents cell loss, a value of zero means there was no change in the cell count and
a negative value represents an increase in the cell count for either CD4 or CD8
lymphocytes. From the graph it is evident that in the majority of individuals there was
a decrease in both the number of CD4 cells and CD8 lymphocytes. Five individuals
showed an increase in CD4 lymphocyte numbers and nine showed an increase in CD8
cell numbers, of which two were receiving anti-retroviral therapy. It is also evident
that the level of CD4 and CD8 loss correlate, that is where there is a high CD4 loss
CD8 loss is also high.
In order to investigate cell loss amongst memory and naive CD4 and CD8
lymphocytes, cells from 50 individuals were stained with monoclonal antibodies
directed against CD4, CD8 , CD45RA and CD45RO. These values were plotted
against CD4 counts (figure 3.11). In both cell subsets, CD4 and CD8 lymphocytes,
naive cells were lost in preference to memory cells. The majority of the cells expressed
CD45 RA, a naive cell marker, in individuals with CD4 counts of greater than 500.
However as CD4 counts fall to 200-500 cell per pi there is a sharp decrease in the
number of naive cells so the memory cell subset become the major cell population in
both CD4 and CD8 lymphocytes.
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Ffeure 3.9 : CD8 lymphocyte loss over a 12 month period (%) vs CD4 lymphocyte
loss over a 12 month period (%). Cell loss calculated from absolute cell counts
determined by FACS analysis.
CD4 Loss (%)
3.13 Effect of PHA stimulation on CD4 and CD8 lymphocytes
In a recent report it has been suggested that anti-CD3 or phytohaemagluttin
(PHA) may up regulate CD4 expression on the surface of CD8 T lymphocytes. In
order to investigate whether CD4 up regulation on CD8 T cells may be a possible
mechanism of infection of this cell subset, purified cells were FACS analysed for CD3,
CD4, and CD8. These cells were then stimulated with PHA, a plant derived T cell
mitogen. In all analysed cells the percentage of CD3 cells was at least 97.4% (table
3.6). Before stimulation 1.6% of CD4 cells expressed both CD4 and CD8 and after
stimulation this increased to 7.5%. In the purified CD8 lymphocyte population the
number of CD4, CD8 double positive cells increased from 0.4% to 21.7% after
stimulation. There was no increase in CD3-positive, CD4-positive, CD8-negative
lymphocytes in the stimulated CD8 cells, therefore it is possible that CD4 is up-
regulated on the surface of CD8 cells when stimulated with PHA.
DISCUSSION
3.14 Infection of a wide range of cell types within PBMCs in vivo by HIV
This study documents the infection of a wide range of different cell types within
the peripheral blood of seropositive individuals by HIV. HIV DNA sequences were
detected in CD4 T lymphocytes, monocytes, peripheral blood dendritic cells, CD8 T
lymphocytes and natural killer cells. There was remarkable individual variation in the

















































































































As previously described HIV infection of CD4 lymphocytes were detected
at all stages of disease progression (Schnittman et al., 1989). HIV-1 DNA was
only detected in the monocyte fraction in 7 of the 29 treatment naive individuals
and the level of infection detected was consistently low except in one individual
undergoing therapy. This is consistent with previous reports which suggested a low
level of monocyte infection in vivo and the requirement for differentiation into
macrophages for HIV infection (Schnittman et al., 1989; Innocenti et al., 1992;
Bagasra et al., 1993; Hsia et al., 1995). In the small study undertaken we were
able to detect HIV-1 infection of natural killer cells isolated directly from the
peripheral blood of infected individuals. This was a novel finding although purified
NK cells are infectable in vitro and this may explain why NK cell numbers and
function decrease with disease progression (Chehimi et al., 1991; Scottalgara et al.,
1993).
Previous reports of infection of DCs in vivo are contradictory. For example,
Hsia et al were not able to detect any HIV-1 DNA in 104 or 105 DCs isolated from
the PBMCs of seropositive individuals (Hsia et al., 1995), whereas Patterson et al
detected HIV provirus by PCR in lymphocytes and DCs of all the patients
investigated and found that in each case the viral load was similar for both cell
fractions (Patterson et al., 1994). This study would support the latter finding as
HIV infection of peripheral blood dendritic cells was detected at all stages of disease
progression. No correlation was observed between the frequency of DC infection
and disease progression. However, it was difficult to accurately determine the
114
frequency of infection of DCs as there was no way to determine how effective the
DC isolation was in each case and how many of the DCs were selected in the E-
rosette positive fraction. Any variation in results from investigating infection of
DCs may be due to different methods used to purify the cells. Weissman et al
isolated three populations of DCs from the peripheral blood using three different
purification methods and found only one of these isolated DC subsets to be
infectable with HIV (Weissman et al., 1995).
A surprising finding in this study was the frequent infection of CD8
lymphocytes in symptomatic and pre-AIDS individuals. HIV DNA was detected in
the CD8 lymphocytes of 23 of the 34 individuals studied. These HIV positive CD8
lymphocytes included 6 individuals with CD4 counts greater than 200 per pi. It
was not possible for contamination of the CD8 population with another cell type to
account for the levels of HIV-1 DNA detected, for example in S04 1400 copies
HIV/106 CD8 cells were detected compared to only 128 copies/106 CD4 cells and
from FACS analysis CD4 contamination of CD8 cells was only 1.6%. These
findings are inconsistent with previous reports which found that CD8 cells were
uninfected in vivo (Psallidopoulos et al., 1989; Schnittman et al., 1989). It is
difficult to identify the reason for the discrepancy, although a relatively insensitive
PCR was used in both of these earlier studies that may have been incapable of
detecting the low levels of infection found in some of the study group. However,
Semenzato et al recently been reported that CD8 lymphocytes recovered from the
lung tissue of AIDS patients show similar frequencies of infection to those in
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PBMCs reported here (Semenzato et al., 1995). Infection of peripheral blood CD8
cells has been reported with SIV and CD8 lymphocytes are susceptible to HIV-1
infection in vitro in the presence of CD4 T lymphocytes. De Maria et al
demonstrated that CD8-positive, CD4-negative lymphocyte lines derived from
infected individuals express HIV proteins and generate reverse transcriptase activity.
Infection was confirmed at a single cell level by immunoelectron microscopy and
two colour immunohistochemistry. The basic requirements for HIV infection of
CD8 lymphocytes was the presence of CD4 cells. PCR of sorted cells revealed that
the CD8 cells harboured HIV-1 proviral DNA and stimulation of these cells resulted
in virus replication and infection of CD4 cells (De Maria et al., 1991).
Following publication of the findings of this study Sleasman et al reported
that in children and neonates HIV-1 DNA could be detected in CD4 but not CD8
lymphocytes (Sleasman et al., 1996). However, only a small number of individuals
were studied, all of whom had CD4 counts greater than 200. A single round PCR
method was used and the maximum number of cells analysed was only 104. In most
pre-AIDS cases in this study HIV DNA would not have been detected in CD8
lymphocytes using the PCR method described. Most recently it has been reported
that proviral sequences were detected in CD8 lymphocytes from 10 of 12 HIV
infected individuals (Flamand et al., 1997). This study highlights HIV infection of
CD8 lymphocytes in vivo and suggests that reactive CTLs recruited to kill HIV
infected cells could, as a consequence of specific antigen activation, express CD4
and become targets for HIV infection.
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In general the frequency of CD4 lymphocyte and CD8 lymphocyte infection
increased with disease progression. However there appeared to be very little
correlation between the level of DC or monocyte infection with mean CD4 counts.
In order to get a clearer picture of HIV infection of different cell subsets with
disease progression the level of infection was expressed as a percentage of the total
HIV load in PBMCs. This analysis revealed that early in infection CD4
lymphocytes are the major cell type in the peripheral blood infected with HIV.
However as the disease progresses and the CD4 count decreases, CD8 lymphocytes
become a major reservoir of HIV in the peripheral blood. The significance of
widespread infection of CD4 negative, CD8 positive lymphocytes in late stage
disease remains to be determined and will be addressed in subsequent chapters. One
of the contributing factors of the high frequency is the loss of CD4 T cells which
effectively removes this population from circulation. The substantial increase in
CD8 T cell infection on disease progression may possibly be related to the
phenomenon by which HIV spreads to non-lymphoid tissue during the later stage of
disease, associated with the loss of immune control.
3.15 Possible mechanisms of HIV infection of CD4 negative cells.
If CD8 lymphocytes in the peripheral blood are infected then the mechanism
of HIV attachment and entry remain unclear. Early in T cell ontogeny, thymocytes
express both CD4 and CD8. As these T cells further differentiate, they loose either
CD4 or CD8 expression, and coincident with this acquire their functional
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capabilities. Occasional lymphocytes co-expressing the CD4 and CD8 antigens are
present in normal human blood peripheral lymphocytes (Lundberg et al., 1995).
Although these cells constitute less than 3% of the total circulating T cell population
in uninfected individuals, an increase in lymphocytes expressing both CD4 and CD8
antigens to 43% of total lymphocytes has been reported in an HIV infected patient
(Ribrag et al., 1993). Infection of these double positives CD8 lymphocyte
precursors may be a possible mechanism for CD8 infection with HIV using the
CD4 receptor. To investigate the levels of CD4 CD8 double positive lymphocytes
in circulation in HIV-1 positive individuals and negative controls FACS analysis was
carried out using a panel of anti-CD3, CD4, and CD8 monoclonal antibodies. In
the HIV-1 negative individuals studied only a low level of lymphocytes co-
expressing CD4 and CD8 were detected (mean value 0.3%). No increase in CD4
CD8 T cells was noted in PBMCs isolated from 40 HIV seropositive individuals
(Mason, 1997). This low level of CD4 expressing lymphocytes in circulation would
be unlikely to account for the level of infection detected, and in any case CD4 cells
were depleted first in all separation methods so any immature double positive
lymphocytes would be purified with the CD4 positive cells. It is possible however,
that HIV infects double positive precursors in the thymus. As these T cells further
differentiate they may loose CD4 expression and in this study these cells would be
isolated in the CD3 positive, CD4 negative, CD8 positive cell fraction. Thus the
peripheral CD8 cells we observed to be infected with HIV could have been infected
within the thymus while expressing CD4 during normal selection.
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Although mature CD8 lymphocytes do not express CD4, in vitro infection
of CD8 lymphocytes with HIV-1 has been achieved by co-culture with HIV-1
infected CD4 cells (De Maria et al., 1991). It is possible that the interaction
between CD4 and CD8 cells occuring in vivo as part of the aquired immune
response may transmit infection to CD8 lymphocytes. This would involve infection
via cell-to-cell contact, the most common opportunity for CD8 T lymphocytes to
come into close contact with HIV-1 infected CD4 cells in vivo is during their lysis
in lymphoid organs.
Another possible mechanism of CD8 infection using CD4 could involve
transient up regulation of CD4 expression on CD8 lymphocytes during antigenic
stimulation of the cell. This is supported by the finding that mature CD8
lymphocytes do not express CD4 at the cell surface but CD4 mRNA can still be
detected by RT-PCR in CD8 cells isolated both from PBMCs and cells collected by
bronchiolar lavage (Semenzato et al., 1995). In this study we were able to show
that PHA up-regulates CD4 expression on CD8 cells in vitro however this was a
very artificial way of examining T cell stimulation and may not reflect events in
vivo. A recent study reported that stimulation of CD8 lymphocytes through the T
cell receptor (TCR) complex with agonists, such as an anti-CD3 monoclonal
antibody, the bacterial superantigens, toxic shock syndrome toxin-1 (TSST-1) and
staphylococcal enterotoxin B (SEB), and phytohemagglutinin, leads to de novo
expression of the CD4 antigen on the cell surface which results in susceptibility of
CD8 T cells to HIV infection (Flamand et al., 1997). Conditioned media from
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PHA or SEB stimulated CD8 T cells were not found to induce CD4 on resting CD8
cells suggesting that a soluble factor released by activated cells is not responsible for
CD4 induction and that direct activation by an antigen or mitogen is required for
CD4 induction. CD4 mRNA could be detected in mature CD4 T cells but there
was no CD4 mRNA expression detected in the resting CD8 T lymphocytes. In
addition to these findings, activation of peripheral blood mononuclear cells from
HIV-infected individuals results in the appearance of T cells double-positive for
CD4 and CD8, which become infected by HIV isolated directly from infected
individuals.
Finally HIV-1 attachment and entry in CD8 lymphocytes and NK cells may
occur via a CD4 independent mechanism and involve one of the chemokine
receptors discussed earlier. CD8 lymphocytes, in common with CD4 lymphocytes,
and macrophages express the CCR5 receptor (M Dittmar, personal communication).
The mechanism of HIV entry into NK cells must occur without the use of
the CD4 cell receptor as they do not express CD4 nor mRNA for CD4 and infection
in vitro is not blocked by anti-CD4 (Scottalgara et al., 1993). HIV-1 may infect
NK cells as they bind infected target cells in order to destroy them via a lytic
mechanism. This immunological reaction requires the close apposition of the target
and effector cell to avoid the release of toxic molecules into sites where they could
do damage. Thus if lytic molecules are released from the NK cell to an HIV-1
infected target molecule then virus may be transmitted by cell-to-cell contact thus
gaining entry into the cell without CD4.
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3.16 The loss of immune function and immune cells in AIDS and HIV
infection.
The decline in CD4 lymphocytes and the initial increase in total CD8
counts in most HIV infected individuals is well documented (Pantaleo et al., 1993).
However recent findings have shown that CD8 naive cells are depleted during the
asymptomatic stage of HIV infection and that this loss can parallel that seen in CD4
lymphocytes. The increase in total CD8 counts in most HIV infected individuals
is primarily due to an expansion of the memory cells. We have shown in this study
that during the progression of HIV infection naive cells are preferentially lost both
in the CD4 and CD8 T cell subsets. It has also been shown that in individuals with
CD4 counts less than 200 per pi memory T cells were reported to account for 80%
of T cells whereas this figure was only 15% in uninfected individuals. This
selective decline in T cell subsets is very relevant in HIV infection and in AIDS as
naive cells are required for all new T cell mediated immune responses and are
memory cell precursors. Their loss, which precedes the eventual loss of memory
cells, may contribute substantially to the eventual loss of the total CD4 and CD8
population (Calabro et al., 1995; Rabin et al., 1995; Roederer et al., 1995).
Loss of naive cells has important consequences for the development of
immune responses in HIV infected individuals. As naive subsets disappear, there
is a progressive inability to mount responses to novel antigens, which may well
result in a greater susceptibility to previously unencountered opportunistic
infections. This loss would compromise the ability to deal with the constantly
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mutating virus; novel strains which are immunogenetically unique, will encounter
less resistance from T cell immunity than early in the progression of disease.
Recently it has been reported that among other defects, patients with AIDS
display abnormalities in NK activity and that NK cells decrease in HIV-1 infection
through the selective depletion of the CD16-positive, CD3-negative, CD8-positive
subset (Mitchell et al., 1994; Brenner et al., 1997). This is the subset of NK cells
reported to be infectable with HIV-1 in vitro. Purified DCs were reported to
stimulate a strong antibody response against both the envelope and core proteins,
however by the onset of AIDS antibody responses induced by DCs were low
(Roberts et al., 1994). DCs are also important antigen presenting cells and are
involved in the stimulation of T cells. Infection, depletion and impaired function
of DCs were shown to occur early in HIV infection (Macatonia et al., 1990).
The immunodeficiency observed in AIDS may be attributed to the
destruction of T helper cells, given its central role in all aspects of humoral and
cellular acquired immune responses. However, direct infection with cells other than
T helper cells contributes substantially to disease in AIDS (Watkins et al., 1990).
Ho et al (1995) examined the dynamics of CD4 T lymphocyte recovery after
treatment with anti-retrovirals and found a rapid rise in the number of circulating
lymphocytes. The findings suggested a high pre-treatment rate of CD4 lymphocyte
cell destruction in vivo and a continuous process of active replacement of lost
lymphocytes. The gradual decline in CD4 levels could be a failure of homoeostatic
mechanisms to adequately replace cells. Therefore, although a variety of
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mechanisms for cell depletion have been proposed, it is possible from the findings
reported here, that the observed decline in CD4 T cells, CD8 T cells, DCs and NK
cells may be a direct consequence of the cytopathic effect of HIV infection.
Furthermore it is possible that this direct infection may be responsible for the
impaired immune functions of each of these cells observed upon disease
progression.
It is also important to note the close interactions of different cell subsets
when mounting an immune response to a foreign antigen. If infection can occur by
cell-to-cell contact then the immune response to HIV infection may result in a
greater rate of transmission to uninfected cells. For example DCs efficiently
transmit HIV to CD4 T cells and may represent explosive sites of viral infection
resulting in the formation of syncytia.
Overall this study conclusively demonstrates that HIV has a broader tropism
for different cell subsets within the peripheral blood in vivo than previously
described. It may be that loss of these cells and their function in AIDS is a direct
effect of their infection with HIV-1 and is not secondary to the loss of T helper cell
function as previously postulated.
3.17 Future research
It has been reported that provirus containing lymphocytes in PBMCs are
generally transcriptionally inactive and infection may be defective or virus
expression may be inhibited. In order to determine whether different cell types are
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productively infected with HIV-1 and if cell loss could be directly due to the
cytopathic effect of viral infection, a PCR method for detection of splice HIV
mRNA trancripts could be designed. If HIV mRNA could be detected in CD8
lymphocytes it would rule out thymocyte infection as a mechanism of viral entry and
support infection of mature CD8 T cells. CD8 lymphocyte cultures could also be
used to compare cell loss in vitro and determine whether more cells were lost as a
consequence of HIV-1 infection.
It would also be interesting to monitor serial samples from individuals before
and during anti-retroviral therapy. The frequency of infection of different cell types
and cell counts could be compared as could the emergence of resistant mutants in
each cell type. This would give a greater insight into cell and virus turnover rates
in each cell subset.
It will be important to compare the viral load in memory and naive CD4 T
cells and CD8 lymphocytes with the observed loss of these cell fractions. The
emergence of anti-retroviral resistant mutants within these cell types would also be
useful. These results may help to explain the preferential loss of naive cells with
disease progression.
In attempt to look at the distribution of HIV in tissue, lymph node and
spleen samples from post mortem were gently manipulated in cell culture medium
to disaggregate cells. However very few viable cells were available for cell
separation and PCR. In addition if HIV was detected by PCR in a purified cell
fraction it would be impossible to determine whether the cells were from tissue or
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the peripheral blood supply. In situ PCR would allow the detection of HIV-1 DNA
in individual cells in tissue, which could be stained with monoclonal antibodies to
specific cell markers.
The high virus load in AIDS may facilitate infection of a wide range of cells
through a non-CD4 dependent mechanism. Therefore, it will be important to
determine the distribution of chemokine receptors on different cell subsets. This
will be easier to carry out when a panel of monoclonal antibodies to these receptors
are available. It will be useful to use immunohistochemistry to determine CD4 and
chemokine receptor expression on HIV infected cells.
It may be that the extensive sequence diversity of HIV amongst variants
recovered from PBMCs represents a combined contribution from a variety of
different population of infected cells. Therefore HIV from different cell types could
be sequenced, for example in the V3 region which has been linked with cell
tropism.
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CHAPTER 4 : Detection of HIV-1 mRNA in CD4
lymphocytes, CD8 lymphocytes and monocytes isolated
from the peripheral blood of seropositive individuals.
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INTRODUCTION
4.1 HIV-1 Messenger RNAs
In HIV-1 infection the full-length, polyadenylated transcripts provide both
genomes and mRNAs for the gag and pol genes. In addition single and multiple
splice events give rise to over 30 alternatively processed mRNAs that are translated
in the cytoplasm to produce the envelope glycoprotein and accessory proteins
(reviewed in Coffin, 1996; Luciw, 1996) (figure 4.1).
Splicing occurs after transcription and is a process which not only achieves
joining of the exons (figure 4.2 ), it also maintains them in the same order as the
template DNA (reviewed in Guntaka, 1993; Levy, 1993; Coffin, 1996; Luciw,
1996). Conserved sequences have been demonstrated at the exon-intron junctures,
GU at the 5' splice site, AG at 3' splice site and another short sequence called a
branch sequence, located 30 bases upstream of the 3' end of the intron. It is thought
that splicing enzymes recognise some common configuration of the mRNA and
with the help of small nuclear ribonucleoprotein particles, or snRNPs, catalyse the
cutting and splicing reactions. snRNPs are composed of RNA and protein and the
RNAs of these particles have nucleotide sequences complementary to those at the
exon-intron junctions or the branch sequences. Five different kinds of snRNPS are
involved in splicing and may act to align the splice sites by hydrogen bonding to the
sequence at the intron-exon boundaries. The RNA of a U1 snRNP base pairs with
the 5' intron junction and a cut is made. This reaction creates a loop or a lariat-
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Figure 4.1 : HIV-1 mRNA transcripts. represent the position of primers

























gag-pol vif (vif) vpr (vpr) tat-1 vpu,env tat-2 tev rev,nef nef
Figure 4,2 : HIV-1 exons. ▼represent the position of primers designed to detect
HIV-1 mRNAs. Splice donor and acceptor sites are numbered according to their























































shaped intermediate with the aid of a U2 snRNP. The newly formed 3' OH group
then cleaves the 3' splice site releasing the partly looped intron and at the same
time joining the two exons. These final steps are thought to involve a U5 snRNP.
In all retroviruses the spliced RNAs share 5' and 3' ends with the genome,
and most subgenomic RNAs share the same 5' donor, the major splice donor.
However, it has been demonstrated that following mutation of the major splice
donor, the kinetics of RNA and protein synthesis are slowed. It was shown that an
alternative cryptic major splice donor signal, four bases down stream was
activated. The efficiency of RNA splicing from this cryptic donor (AGA"
GUACGCC) may be lower than that from the major donor site (CUG'GUGAGUA)
and would explain the delayed replication and infection kinetics (Purcell et al.,
1993).
The splicing of HIV-1 RNA is complex because of the presence of both
constitutive and alternatively used 5' RNA splice donor and 3' splice acceptor
motifs. The varied use of these diverse splicing signals results in the synthesis of
several sets of structurally different mRNAs for protein, including the viral
envelope, regulatory and accessory proteins. Generally, the most highly spliced
forms of RNA, that exclude non-coding exons, are most common except in the case
of nef, in which the inclusion of a non-coding exon is favoured. Sixteen alternative
mRNAs may encode gpl60 in vitro. However, most of these exist at very low
levels and the most common env is the shortest possible transcript. If any of the
alternative splicing mechanisms were to occur in vivo, two determinants could
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control splice acceptor usage. Firstly, the different sequence structure of the
competing splice acceptor motifs in individual HIV-1 strains could alter the balance
of the splice acceptor usage. It has been confirmed that HIV-1 strains with different
sequences do have different splicing patterns. Or alternatively the activation status
or type of cell harbouring an HIV-1 provirus could also affect the balance of splice
acceptor usage.
4.2 Rev : A regulator of HIV-1 gene expression.
The ratio of spliced to unspliced viral mRNA is controlled by the regulator
of viral gene expression Rev which functions through a Rev-responsive element
(RRE) in full length transcripts. As Rev accumulates in an infected cell it increases
the cytoplasmic levels of unspliced and partially spliced HIV-1 mRNAs, resulting
in the efficient expression of the structural viral proteins (figure 4.3) (Slepushkin et
al., 1992).
The HIV-1 Rev protein binds viral RNA species that contain the Rev-
responsive element (RRE), located in the env gene, thereby promoting the export,
and possibly the stability and translation, of partially spliced and unspliced RNAs
from the nucleus into the cytoplasm for its translation and/or packaging into
progeny virions. In addition, the rev gene product may influence translation of
viral mRNA on cytoplasmic polysomes.
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4.3 Splicing Patterns and HIV-1 disease progression.
Numerous studies have demonstrated that a substantial proportion of HIV-
infected individuals have ongoing viral transcription in PBMCs (Schnittman et al.,
1991; Arens et al., 1993). In one particular study a high frequency of viral
transcription was seen regardless of whether the patients were asymptomatic or had
developed AIDS (Schnittman et al., 1991). Individuals who demonstrated disease
progression showed either a general increase in the amount of expression of all
transcripts or elevated levels of unspliced transcripts in late-stage disease
(Slepushkin et al., 1992). In contrast a study of long-term asymptomatic
individuals, undetectable or low levels of the three classes of HIV-1 transcripts
(unspliced, singly spliced and multiply spliced) were detected (Michael et al.,
1995).
A direct association between the presence of message for a structural protein,
and a more advanced immunosuppression has been demonstrated (Schnittman et al.,
1991). These findings are supported by a later study showing that the shift from a
predominantly spliced or regulatory viral mRNA pattern to a predominantely
unspliced pattern is associated with disease progression (Neumann et al., 1994).
It was therefore suggested that both HIV-1 cellular RNA load and splicing patterns
may be used to predict disease progression. However, Saltarelli (1996) found no
evidence for major changes in splicing patterns with disease progression within an
individual and concluded that HIV-1 transcriptional patterns are viral strain specific
rather than disease stage specific.
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4.4 Development of HIV-1 mRNA RT-PCR
(i) RNA extraction
Numerous RNA extraction methods have been documented for the extraction
of HIV-1 mRNA (Schnittman et al., 1991; Arens et al., 1993; Neumann et al.,
1994). In order to detect HIV-1 mRNA it was necessary initially to optimise
conditions. This was achieved by analysis of cells isolated from IIIB cultures and
HIV-1 negative controls. Serial dilutions of cells were extracted using various
methods including proteinase K (section 2.2), RNAzol, mRNA commercial
extraction kit (R&D systems), (section 2.5 iii) and a whole RNA extraction kit
(Stratagene). Primers spanning the HIV-1 V3 region (section 2.3) and the
constitutively expressed cellular genes P-actin mRNA (section 2.9) were used in
reverse transcriptase and PCR reactions (sections 2.8 i and 2.3) in order to
determine the optimal extraction method. The levels of HIV-1 RNA extracted using
each method could be compared as could the levels of HIV-1 proviral DNA
contamination from controls run with no RT. The whole RNA extraction kit
(Stratagene) gave the most consistent levels of RNA and a low level of DNA
contamination. To reduce non-specific bands from residual DNA, the extracted
RNA was treated with DNAse RQ1 (section 2.7 iv).
(ii) Primer design
In order to specifically amplify HIV-1 mRNA, primers complementary to
a region in the 5' LTR and the env region were designed (Nars, T5480, S5326, and
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S5327) (section 2.8) (figures 4.1 and 4.2). In designing primers nucleotides
complementary to conserved regions of at least 15 nucleotides were used with
melting temperatures between 55 and 72°C (G/C = 4°C, A/T = 2°C). The melting
temperature of primer pairs used in each PCR reaction were balanced as closely as
possible, and palindromes and GC runs were avoided.
(iii) RT-PCR
The RNA preparation and outer-antisense primer (S5326) were warmed for
90 seconds at 65°C to disrupt any secondary structure and to allow the primer to
bind to the complementary sequence on the RNA. The reaction buffer for the
reverse transcriptase reaction was then added and reverse transcriptase and PCR
reactions were carried out. Ten fold serial dilutions of cells from a IIIB culture
were analysed as described (section 2.8) and compared with the detection of RNA
by actin RT-PCR (section 2.10). Using these two PCR techniques in parallel it was
possible to optimise the HIV-1 mRNA RT-PCR as the actin control reactions
eliminated variations due to the efficiency of the extraction procedure. The optimal
reaction conditions are given in section 2.8.
The RT-PCR technique discussed above was then compared with the Access
RT-PCR system (section 2.10). The Access RT-PCR proved to be more sensitive
and primary product bands less diffuse. Separate RT and PCR methods were used
as it allowed limiting dilution analysis of the cDNA from the RT step, where the
Access PCR does not as the RT and PCR reactions take place in one step. A control
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amplification lacking RT was performed on each RNA sample to test for DNA
contamination of the RNA samples and another control lacking template was also
performed to monitor for contamination during processing. PCR product from
spliced transcripts could be detected as distinct bands of a size differing from that
of any contaminating proviral DNA or genome RNA.
The expected PCR products using the primers described, were vif ( 1431 bp),
vpr (900 bp), tat exon 1 (515 bp) and vpu-env (317 bp) (table 4.1). Molecular
weight markers (Promega) were used when analysing the PCR product on
agarose gels, to confirm that the PCR products were of the predicted sizes (figure
4.4). Band A is of a length similiar to the expected vpu-env product, and band B
is approximately 500bp in length, the product size expected from amplification of
tat exon 1. After limiting dilution PCR the non-specific bands are no longer
amplified and the most highly expressed mRNA is detected as a single band. In
later amplifications a product of approximatly 900bp was detected corresponding to
vpr mRNA.
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Figure 4.4 : An agarose gel illustrating HIV-1 mRNA transcripts amplified by RT
PCR. In each case MB cell cultures were used. pGEM molecular weight markers
were used to estimate the band lengths.
GEL A : Primary PCR product Lane( 1) HIV-1 negative PBMCs, (2) HIV
negative Hela cells, (3) HIV negative PHA stimulated PBMCs, (4) HIV-1 negative
plasma (5) IIIB stock control culture PBMCs (1 pi RNA in PCR reaction), (6) 1IIB
(0.1 pi RNA), (7) MB (0.01 pi RNA), (8) MB (0.001 pi RNA).
GEL B : Secondary PCR product. In lanes 9 to 12, 1 pi of primary product from
lanes 5 to 8 respectively were used in secondary reactions. In lanes 13 to 16, 0.1
pi of primary product from lanes 5 to 8 respectively were used in secondary
reactions.
Band A is approximately of the length expected for vpu-env transcripts. Band B is
approximately 500bp the product size expected for amplification of tat exon 1.













Table 4.1 : Product sizes expected from HIV-1 mRNA PCR
Position in HXB2 Product Size
Genome (base pairs)
5' Major splice junction 743 NAa
Primer T5480 693 NA
Pimer S5327 4912 NA
vif 3' Splice acceptor 6293 (vif) 1434
vpr 3' Splice acceptor 5388 (vpr) 900
tat exon 1 3' Splice acceptor 5777 (tat exon 1) 515
vpu-env 3' Splice acceptor 5976 (vpu-env) 317
a NA = Not applicable
(iv) Sequence analysis
From the dilutions of the extracted I1IB controls, the PCR-end point cDNA
from the RT step was diluted and serial PCR reactions carried out using a
biotinylated inner primer (Primer S5327 section 2.5 i). Diluting the cDNA meant
single mRNA molecules, or only one splice transcript product was amplified and
these single bands were sequenced using the primer T5480 (section 2.5 ii-v). In
each case the sequences obtained were of HIV-1 mRNA for tat, vpu-env (figure 4.5
A), or vif (figure 4.5 B) with the intron sequences spliced out. Only a small
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Figure 4.5 : Sequence analysis of HIV-1 mRNA products showing changes from
the HXB2 consensus, n represent any base. Figure 4 5 A: LTR-Vpu, env transcripts
sequenced from IIIB positive controls and CD4 lymphocytes isolated from S14.
Figure 4.5: LTR-Vpr transcripts sequenced from IIIB controls and CD8
lymphocytes isolated from SI4.
Figure4.5(A):LTR-VPU,EnvmRNASecaienc s
Position HXB27285159766052 HXB2GAGGGGCGGCGACTGSPLICEGAAGAAGCGGAGAC GC ACGAAGAGCTCATCAGAACAGTCA ACT ATCAAGCTTCT TATCAAAGCAGTAAGTAG 11IBSPLICEnnT....nnn. S14CDSPLICE..GAACA..Annn. Figure4.5(B):LTR-VPRmRNASequenc s Position HXB27515388472 HXB2GGCGACTGSPLICEGACTCT CTATAAGAAAGGCCTTATTAGGACACATAGTTAGCCCTAGGTC.TCAATATC AGCAGGA ATAACAG TA GATCTC * 11IBSPLICEnnnnnnnnnnnnnnnnnnnn S14CD8...SPLICE...nnnA.nA...A..GGTTTn
region of the tat exon 1 sequences could be read and these corresponded to positions
5791 to 5859 in the HXB2 genome.
4.5 Isolating RNA from cell subsets from the PBMCs of HIV-1
seropositive individuals.
CD4 lymphocytes, CD8 lymphocytes, and monocytes were isolated from
eight HIV seropositive individuals and HIV-1 negative control samples. Four
positive samples and one negative control were separated using the E-rosetting and
magnetic bead positive selection (section 2.1 iv and v), the remaining four HIV-
positive samples and a negative sample were separated using the miniMACS system
(section 2.1 vi). These separated samples were immediately stored as pellets in
liquid nitrogen to minimise RNA degradation and were previously used to determine
the level of proviral DNA (table 3.3 and 3.4). Whole RNA was extracted using the
Statagene isolation kit and RT-PCR was carried out using primers spanning the actin
intron and primers complementary to the HIV V3 region of the external envelope
glycoprotein. Control RT reactions were carried out in parallel to detect any
contaminating DNA.
Neither the cellular P-actin gene nor V3 HIV-1 genomic RNA could be
detected in the cell samples isolated using the E-rosetting technique. This cell
separation procedure takes many hours and it was concluded that any RNA present
may have been degraded during the separation procedure. However the miniMACS
cell separation method is considerably less time consuming and therefore RNAse
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activity was limited. Both HIV-1 V3 and actin mRNA were detected in these
samples. Cells isolated using the miniMACS procedure were used for all
investigations involving HIV-1 mRNA RT-PCR.
RESULTS
4.6 Detection of HIV-1 mRNA in CD4 and CDS lymphocytes and in
monocytes isolated from seropositive individuals
Previously stored aliquots of separated monocytes and CD4 and CD8
lymphocytes from individuals SI 1, S14, S21, and S22 (tables 2.2 and 3.4) with
previously determined HIV-1 proviral loads were extracted using the Stratagene
whole RNA isolation kit. When it was possible to isolate enough cells, nucleic
acids were extracted from ten replicates of ten-fold serial dilutions of each cell
subset (approximately 107 to 101 cell), DNAse treated, and RT-PCR reactions
carried out as optimised for IIIB above. The aim of this study was to estimate the
number of cells actively infected with HIV-1, therefore it was essential that the
dilutions were carried out before the RT-step, as one cell may express many copies
of HIV-1 mRNA.
In order to determine that the efficiency of the RNA extraction and RT step
was equal for each sample IIIB limiting dilution controls, with a known PCR cut¬
off were run in parallel with each study sample. Also, HIV RNA levels were
normalised to the levels of the constitutively expressed cellular genes P-actin
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(section 2.9). In each case P-actin present was detectable in reactions containing 106
to 10 cells but not when less than 10 cells were present in the PCR reaction. The
end-point of the I1IB dilutions was also constant throughout. Therefore although
this RT-PCR method cannot directly quantify the number of cells expressing HIV-1
mRNA, values calculated in each cell fraction can be compared.
CD4 counts from these four individual were 85, 354, 386, and 418 per ml
whole blood (table 4.2). Only one individual studied had a CD4 count less than 200
because in individuals with advanced disease too few CD4 cells could be isolated
to perform both PCR for HIV provirus and mRNA. Individual Sll had a CD4
count of 85 and an AIDS defining illness. HIV-1 mRNA was detected in all
individuals except S22, which had the lowest proviral load of the individuals
studied, in CD4 cells [contains CD4 lymphocytes, and DCs (section 3.9)]. HIV-1
mRNA was detected at a low level in only individual S14 when 106 cells were
present. In the isolated CD8 lymphocytes HIV-1 mRNA could be detected in
individuals Sll , S14, and S22 when a minimum of 104, 104, and 105 cells were
extracted respectively. In order to verify that CD8 lymphocytes are actively
infected with HIV-1 the PCR product was sequenced as described for IIIB (section


















































































































































































































4.7 RT PGR for HIV-1 mRNA
It proved difficult to accurately quantify the number of cells actively
infected with HIV-1 mRNA for a number of reasons. Firstly, it was difficult to
determine the level of RNA lost during the cell separation, RNA extraction and RT
reactions due to the action of RNAses. Secondly the RNA extraction and RT
reaction efficiencies may vary from sample to sample, and finally splice patterns
vary from individual to individual and perhaps between cell subsets within an
individual. These different splice patterns further complicate investigations as
longer RNA molecules are amplified less efficiently. Therefore, because the size
of the amplified band influences the overall amplification, reliable quantitations of
the different mRNAs can only be made by comparison to the same band of known
quantity. As shorter molecules are amplified more efficiently it is not possible to
compare levels of expression of different mRNAs.
In this study vpu-env, or vpu-env and vpr were the only splice products
detected in cells isolated from seropositive individuals. The vpu-env band was used
in the separated cells to determine the level of HIV-1 mRNA. Also the P-actin
mRNA PCR and IIIB controls normalised the extraction and RT steps and allowed
comparisons to be made between individuals semi-quantitatively.
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Previous reports have also noted that attempts to use RT-PCR for the
amplification and identification of all the HIV-1 mRNAs have not been fully
satisfactory for a number of reasons, including the generation of numerous PCR
artifacts and the nonlinear amplification of various mRNAs (Neumann et al., 1994).
In one study this group used combinations of cloned HIV-1 cDNAs of known
concentration as markers for the identification of the differently expressed mRNAs
and as standards to quantify HIV-1 mRNA in PBMCs (Neumann et al., 1994). This
may be a strategy to adopt in order to quantify mRNA in future investigations.
4.8 Detection of HIV-1 mRNA at all stages of disease progression.
In a previous study HIV-1 transcripts were detected in 94% of the 48
individuals studied (Arens et al., 1993). This level of detection was maintained
whether the PBMCs were isolated from asymptomatic individuals or those with
AIDS (Schnittman et al., 1991). The results from the four individuals studied
confirm that HIV-1 replication occurs throughout HIV-1 infection irrespective of
CD4 counts and disease progression.
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4.9 Productive infection of CD4 and CD8 lymphocytes in vivo.
The permissiveness of target cells to HIV-1 infection and replication are
linked to cellular proliferation, activation and differentiation. T cell activation is
required for completion of HIV-1 reverse transcription and integration. HIV
transcripts were detected in CD4 cells, CD8 lymphocytes and at a low level in
monocytes. In earlier studies infection of monocytes was thought to be by a slow
replicating virus when compared with HIV-1 replication in T cells. The findings
in this study confirm the finding that viral replication is indeed at a lower level in
the monocyte population than the T lymphocytes within the peripheral blood of HIV
seropositive individuals.
Provirus containing lymphocytes in PBMCs and lymph nodes are generally
transcriptionally inactive (Harper et al., 1986; Embretson et al., 1993). It is likely
that cells containing HIV-1 provirus but with no detectable virus replication
represent the small proportion of cells not destroyed in HIV infection, either because
of infection with a defective virus or because virus expression is inhibited. HIV-1
mRNA was detected in purified CD8 lymphocytes of three of the four individuals
studied. From sequence analysis it was evident that the resulting PCR products
were the spliced mRNAs vpu-env and vpr. Infection of both CD4 and CD8
lymphocytes with active viral replication, substantiates the theory noted in the
previous chapter that immune dysfunction and cell loss may be a direct consequence
of HIV-1 infection.
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A recent study suggested that infection of CD8 lymphocytes occurs in the
thymus when the cells express both CD4 and CD8 (Kitchen et al., 1997). Recent
reports suggest that HIV-1 infection involves continual rounds of viral replication,
cell destruction and cell replacement (Ho et al., 1995; Wei et al., 1995). The
detection of active replication in CD8 lymphocytes undermines thymic infection and
gives support to the possibility that HIV-1 infection occurs in the mature population
of CD8 lymphocytes in peripheral blood. If immature CD4 CD8 thymocytes were
infected with HIV-1 it is likely that activation of the virus would occur upon
stimulation of the CD8 T cells and the resulting virus replication would lead to the
destruction of the cell before it reached the peripheral circulation.
4.10 Future work.
In order to more accurately determine the relationship between HIV-1
mRNA levels in PBMCs and disease progression further samples must be analysed.
Combinations of cloned HIV-1 cDNAs of known concentration should be used so
quantitation of HIV-1 mRNA transcripts can be compared with these standards.
HIV-1 expression should also be investigated in dendritic cells and NK cells.
Provirus-containing lymphocytes in PBMCs and lymph nodes are generally
transcriptionally inactive. It will be interesting to investigate the distribution of
actively and latently infected cells in PBMCs. In particular, it will be useful to
differentiate memory and naive subsets in CD4 and CD8 lymphocytes as loss of
CD8 lymphocytes occurs predominantely in the naive, CD45RA subset. The
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distribution of actively and latently infected cells in the naive and memory subsets
of CD4 and CD8 lymphocytes will allow a more accurate evaluation of the
dynamics of infected cell turnover, and provide information on the mechanism of
lymphocte depletion upon disease progression.
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CHAPTER 5 : HIV-1 V3 sequence variation in




5.1 HIY-1 Genomic Variation
A striking feature of HIV infection is the diversity and rapid turnover of
sequence variants within an infected individual (Tersmette et al., 1988; Meyerhans
et al., 1989; Simmonds et al., 1990). The process of reverse transcription is error
prone, contributing to the high genetic variability of these viruses (Coffin, 1992).
Genetic variation of retroviruses is the composite of the mutation rate per replication
cycle, the number of replication cycles and the selective advantage or disadvantage
possessed by the virus variant. In addition, the rate of recombination in retroviruses
is high and greatly contributes to genetic variation (Berkower et al., 1991).
Considerable sequence diversity is observed between different HIV-1
isolates, particularly those from geographically distinct regions, where divergence
has taken place over a number of years. Sequence diversity is seen within isolates
from the same individual as well as between HIV strains infecting different
individuals (Levy, 1993). The level of HIV sequence variation is not uniform
throughout the genome, gag and pol genes are more conserved than env. In
particular, the region of the viral genome that encodes gpl20 shows an extremely
rapid rate of sequence change, concentrated into five hypervariable domains (VI to
V5) interspersed among less variable regions (CI to C4) (Levy, 1993). It has been
speculated that high rates of sequence change in these regions may have adaptive
value in allowing immunological escape from the initially effective antiviral immune
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response (Masuda et al., 1990; Wolfs et al., 1991; Wolfs et al., 1991; Zwart et al.,
1991).
5.2 Sequence variation in the V3 region of HIV-1 gp!20 and in vitro
phenotvpe.
V3, the third variable domain in the gpl20 subunit of HIV-1 contains 35
amino acids arranged in a disulfide loop (figure 5.1). This domain plays an
important role in governing several biological properties of the virus; cell tropism,
cytopathicity, and fusogenicity (Luciw, 1996). The tip of the V3 loop has been
designated the principal neutralising domain because virus neutralising antibodies
directed against this region block HIV-1 infection of primary lymphocytes and
macrophages. The GPGRAF motif (figure 5.1 amino acids 15 to 20), located at
the crown of the loop, is highly conserved among HIV-1 isolates, and sequences
near the cysteine residues at the bottom of the loop also show little variability.
Nucleotide sequence analysis of amplified DNA from the V3 hypervariable
region indicated that the initial virus population of acutely infected individuals were
completely homogenous in sequence contrasting with the high degree of variability
normally found in seropositive individuals and were similar to those associated with
macrophage tropism in primary isolates of HIV (see below) (Zhang et al., 1993).
These HIV variants with a non-syncytium inducing (NSI) macrophage tropic (MT)
phenotype predominate in early asymptomatic infection (Schuitemaker et al., 1992).
In the course of infection, HIV-1 isolates display increased replication rates,
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reduced macrophage tropism and a more cytopathic syncytium inducing (SI)
phenotype (Fenyo et al., 1988; Cheng-Mayer et al., 1989; Connor et al., 1994).
Initially, SI capacity of HIV-1 isolates was determined by scoring syncytium
formation upon inoculation of peripheral blood mononuclear cells (PBMCs) with
virus or co-cultivation of PBMCs with virus-infected cells. Alternatively the SI
capacity of HIV-1 was determined by using MT2 cells as an indicator, since MT2
cells selectively support replication of SI variants. Changes in the V3 loop have
been shown to influence the phenotype of variants of HIV-1 in in vitro culture
(Hwang et al., 1991; Fouchier et al., 1992; Andeweg et al., 1993; Boyd et al.,
1993). In particular, substitutions of basic amino acids change virus isolates from
NSI to SI isolates (de Jong et al., 1992; Fouchier et al., 1992) and may confer a
reduction in the ability of the virus to replicate in macrophages (Schuitemaker et al.,
1991; Chesebro et al., 1992).
Analysis of natural variants of HIV-1 coupled with studies on point
mutations introduced into V3 in molecular clones of virus, indicates that basic
amino acids in one or more positions 11, 24, 25, 29 and 32 (figure 5.1) confer a SI
phenotype, whereas hydrophobic amino acids in these positions correlate with a NSI
phenotype (Chesebro et al., 1992; de Jong et al., 1992; Fouchier et al., 1992;
Milich et al., 1993). Fouchier et al and de Jong et al (1992) found that in NSI
variants, the amino acid residue at position 11, 25 and 29 were uncharged or
negatively charged. The SI phenotype was associated with a change from serine
at position 11 into a naturally occurring arginine (S to R). In addition a naturally
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Figure 5.1 : The HIV-1 V3 loop. Amino acids are numbered 1 to 35. The
GPGRAF sequence at the tip of the loop is highly conserved between HIV-1
isolates and is designated the principal neutralising domain (PND).
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occurring mutation at position 25, aspatate to glutamine, (D to Q) or position 29,
aspartate to asparagine, (D to N) are required for full expression of the syncytium-
inducing, high replicating (SI) phenotype. Further inspection of sequences of viral
variants isolated from infected individuals indicates that SI, T-cell line tropic viruses
also generally have a non-acidic amino acid or alanine at position 32, whereas
macrophage-tropic viruses have either an acidic or neutral amino acid at this
position (Fouchier et al., 1992; Milich et al., 1993).
The SI phenotype correlates with increased V3 sequence heterogeneity with
a broad range of substitutions, insertions, and deletions at many positions between
the disulfide-bridged cysteine residues (Chesebro et al., 1992; Milich et al., 1993).
In contrast, V3 sequences from NSI isolates show few sequence differences from
each other or from a consensus sequence of 133 North American isolates (LaRosa
et al., 1990) that comprise predominantly subtype B variants of HIV-1 (Louwagie
et al., 1993). The V3 domain from different HIV-1 isolates may assume two
distinct conformations that determine preferential tropism for lymphocytes or
macrophages (Shioda et al., 1992). If the correlation between V3 sequence and
viral phenotype is based on a structure-function relation, several mechanisms can
be suggested. The charge and secondary structure of the V3 loop might influence
binding of the virion, resulting in altered syncytium induction and infectivity or the
processes subsequent to exposure of the V3 domain upon binding of gpl20 to CD4
might be influenced (Sattentau et al., 1991). Structure-function studies are
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complicated because sequence changes out with the V3 loop may also alter the
structure of V3.
5.3 Restricted sequence variability of HIV-1 V3 in vivo.
A highly restricted distribution of HIV was found in the body preceding the
onset of AIDS, with proviral sequences apparently confined to cells of the lymphoid
system (PBMCs, spleen, and lymph nodes). In contrast, those patients who died
from complications associated with AIDS showed significant infection of cells in the
central nervous system (CNS) and in lung and bowel tissues (Bell et al., 1993b;
Donaldson et al., 1994b). This apparent redistribution of virus upon disease
progression occurs at the same stage of disease as the apparent change from an NSI
to a SI phenotype. Therefore, while isolates become cytopathic and often non-
macrophage tropic in vitro, the redistribution of HIV in vivo involves organs such
as brains, lungs and other tissues in which the main targets of infection are reported
to be tissue macrophages, microglia (in the CNS), and other non-lymphocyte cell
types.
Donaldson et al (1994) directly sequenced the V3 loop of virus variants in
lymphoid and nonlymphoid tissues from a series of individuals who died while
asymptomatic or as a consequence of AIDS, with no prior cell culture. V3
sequences from both lymphoid and non-lymphoid tissues showed highly restricted
sequence variability and a low overall positive charge of the encoded amino acid
sequence compared with those of standard laboratory isolates of HIV-1. The low
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charge and restricted sequence variability were comparable to those observed with
isolates showing a NSI and macrophage-tropic phenotype in vitro (Donaldson et al.,
1994a). All patients were either exclusively infected or predominantly infected with
variants with a predicted NSI/macrophage-tropic phenotype, irrespective of the
degree of disease progression.
Most of the published sequences of SI variants used for sequence
comparisons were derived from isolates of HIV-1 that were passaged extensively in
cell culture, therefore it is possible that whatever selection constraints restricts
sequence diversity in vivo are absent in the conditions used for virus culture. It is
also possible that the V3 loop with a large positive charge confers a growth
advantage in vitro, leading to the selection of variants bearing such divergent
sequences from a hetergenous in vivo population. The isolation of SI variants from
patients progressing to AIDS is associated with increased virus load and therefore
with a greater likelihood that such extreme variants might by chance be present in
the initial PBMC culture.
Changes in the properties of isolates upon in vitro passaging are commonly
observed. Repeat passaging enables HIV to adapt to efficient replication in different
cell types, including permanently transformed T cell lines. It has also been shown
that in vitro culture leads to rapid loss of sequence variability in the env gene
(Kusumi et al., 1992) and often to the replacement of the predominant in vivo
variant with a minor population (Kuiken et al., 1992; Kusumi et al., 1992). To
investigate the underlying reason for the discrepancy between the frequent isolation
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of SI variants and the predicted NSI phenotype of variants in vivo, sequence
comparisons were carried out in the V3 region from between 10-20 single molecules
from PBMCs of 10 HIV infected individuals. Based upon the number of changes
from the LaRosa (LaRosa et al., 1990) consensus and the V3 loop charge
(Donaldson et al., 1994a), 3 samples could be classified as NSI only while 7
samples contained a varying proportion of more highly charged variants
corresponding the SI phenotype. However, upon in vitro culture, all but two of the
samples yielded SI isolates , in each case with evidence for the selection of the most
highly charged variant in the PBMC population previously sequenced (Strappe,
1997).
5.4 HIV-1 phenotvpe and co-receptor usage
The chemokine receptor family members that are currently implicated as co-
receptors in HIV entry include CCR5, CCR3, CCR2b and CXCR4 (section 3.2)
(Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; Doranz et al., 1996;
Dragic et al., 1996; Feng et al., 1996). While CD4 binds all Env proteins, CCR5
mediates viral entry into macrophages, whereas CXCR4 mediates entry into many
CD4-positive transformed T cell lines (Alkhatib et al., 1996; Choe et al., 1996;
Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996; Feng et al., 1996).
However, classification of SI T cell tropic and NSI macrophage tropic HIV-1
isolates according to CXCR4 and CCR5 co-receptor usage respectively is
complicated by the finding that macrophage tropic variants can also use CCR3,
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while dual tropic isolates use CCR5, CCR3, CCR2b or CXCR4 (Premack et al.,
1996).
Recent reports have indicated that the gpl20 V3 loop can influence the
ability of HIV-1 variants to use different chemokine receptors (Choe et al., 1996;
Cocchi et al., 1996). Speck et al (1997) demonstrated that the specific amino acids
in the V3 loop of the HIV-1 envelope protein that determine cellular tropism also
regulate chemokine co-receptor preference for cell entry by the virus. Comparisons
of variants with Q or E at position 25 in the V3 loop regulated the ability to use
CXCR4 for cell entry. The use of CCR5 was influenced by mutations at position
30.
5.5 In vivo V3 sequence variation in different cell subsets
Given the evidence for changes in the in vitro phenotype of virus isolated
from PBMCs at different stages of disease progression, it is clearly important to
investigate the V3 sequence of virus from different cell subsets isolated from
various individuals with varying CD4 counts. In this study I carried out detailed
sequence comparisons of the V3 loop and flanking regions of virus variants in CD4
and CD8 lymphocytes, as well as dendritic cells and natural killer cells isolated
from five HIV-1 seropositive individuals. For solid-phase sequencing, the second
PCR reaction was performed in a 100/xl volume using a biotin-labelled inner
antisense primer (307) and unlabelled sense primer (306). Biotinylated PCR
products were sequenced with the V3 sense primer (306) as described (section 2.6).
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Sequences were aligned manually and translated using the Simmonic program.
Comparisons of V3 charge and amino acid sequence diversity were made between
different cell subsets and individuals in this study. Rooted trees were constructed
using the MEGA (Kumar et al., 1993) package with the sequence HIV HXB2 as an
outgroup and Jukes Cantor method to account for multiple substitutions. The
bootstrap resampling method was used (100 replicates) to assess the robustness of
each branch in the tree constructed.
RESULTS
5.6 Amino acid Sequence variation in the V3 loop
HIV-1 DNA extracted from different cells were diluted until only 10-30%
of replicates gave a PCR product, thus ensuring that nucleotide sequences were
derived from single molecules of provirus (Simmonds et al., 1990b). HIV-1 V3
and flanking regions amplified from CD4 positive cells, CD8 lymphocytes,
dendritic cells, natural killer cells and unseparated PBMCs isolated from
individuals P6, P7, S4 (W4), S6(W6), and S24 (W5) (for patient details see tables
2.1, 2.2, 3.3 and 3.4) were sequenced and the corresponding amino acid sequences
analysed (figure 5.2 to figure 5.6).
None of the nucleotide sequences in the V3 loop or flanking regions
contained inactivating substitutions such as stop codons or frameshifts, supporting
the previous finding (Donaldson et al., 1994a) that there is little evidence for high
rates of defective genomes in vivo. Amino acid sequences were relatively conserved
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Figure 5.2 : V3 amino acid sequences and charges ofHIV-1 DNA amplified from
various cell subsets isolated from individual W5.
a Changes from the V3 loop LaRosa consensus sequence and flanking region HIV-
MN consensus are noted.
























































































































































































































































































































Figure 5.3 : V3 amino acid sequences and charges of HIV-1 DNA amplified from
various cell subsets isolated from individual W6.
a Changes from the V3 loop LaRosa consensus sequence and flanking region HIV-
MN consensus are noted.








































































































































































































































































































































Figure 5.4 : V3 amino acid sequences and charges of HIV-1 DNA amplified from
various cell subsets isolated from individual W4.
a Changes from the V3 loop LaRosa consensus sequence and flanking region HIV-
MN consensus are noted.





































































































































































































Figure 5.5 : V3 amino acid sequences and charges of HIV-1 DNA amplified from
various cell subsets isolated from individual P6.
a Changes from the V3 loop LaRosa consensus sequence and flanking region HIV-
MN consensus are noted.




























































































































































































































































































































































Figure 5.6 : V3 amino acid sequences and charges of HIV-1 DNA amplified from
various cell subsets isolated from individual P7.
a Changes from the V3 loop LaRosa consensus sequence and flanking region HIV-
MN consensus are noted.







































































































































































































































































































































































































































in both the V3 region and flanking regions within an individual and in different cell
subsets isolated from the same individual.
Amino acid sequences from individual W5 (S24) (figure 5.2) revealed
changes in the 3' flanking region which were exclusive to CD4 lymphocytes (valine
to glycine or serine) and natural killer cells (serine to valine). In S6 (figure 5.3)
a histidine to proline substitution occurs only in the V3 loop of virus isolated from
CD8 lymphocytes. A isoleucine to valine substitution at position 26 of the V3 loop
was only detected in CD4 lymphocytes from individual W6 (S6). However this
study provides no evidence for the existence of a shared determinant in the V3 loop
that governs the distribution of HIV-1 in different cell types.
Similar diversity of HIV-1 V3 sequences was observed irrespective of the
disease progression in the individuals studied. Indeed, P6 showed a relatively high
level of amino acid variation from the consensus sequence when compared to the
other individuals studied and P6 had the highest mean CD4 count. One of the most
striking features of this study is the low level of V3 amino acid diversity within each
individual. A much higher level of amino acid divergence from the consensus is
observed in the V3 flanking regions when compared with the V3 "hypervariable"
domain.
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5.7 Prediction of in vitro phenotvpe from V3 loop sequences.
To investigate the relationship between in vitro phenotype and V3 sequence,
the overall V3 charge and the degree of sequence divergence from the subtype B
consensus were calculated in a previous study for a series of isolates with known
biological properties. This studied showed that NSI macrophage-tropic isolates
consistently showed a lower charge and/or greater similarity to the subtype B
consensus than did SI and non-macrophage-tropic variants. When the number of
differences from the subtype B consensus is plotted against the V3 loop charge a
diagonal line separates the SI and NSI populations (figure 5.7) (Donaldson et al.,
1994a). This method of analysis was used to compare the in vitro phenotypes for
individuals with differing degrees of disease progression in CD4 and CD8
lymphocytes. Clearly the vast majority of sequences analysed segregate on the left
hand side of the dividing line and therefore have a predicted NSI macrophage tropic
phenotype (figure 5.8). This proves true for both CD4 and CD8 lymphocytes.
The 7 isolates segregated into the predicted SI section of the graph were all derived
from cells isolated from P6, who interestingly, was the individual with the highest
CD4 count. A plot of CD4 and CD8 lymphocyte V3 loop charges illustrates that
there is no charge variation between these two cell types (figure 5.9).
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Figure 5.7 : Comparisons of V3 loop sequence on the basis of predicted overall
charge and number of changes fronm a sutype B consensus of sequences with a





Figure 5.8 : Comparisons of V3 loop sequences from CD4 and CD8 lymphocytes
on the basis of predicted overall charge and number of changes from a subtype B
consensus.











Figure 5.9 : Comparisons of V3 loop amino acid charge in CD4 and CD8
lymphocytes.
















5.8 Phvlogenetic analysis of V3 nucleotide sequences from CD4 and
CDS lymphocytes.
Nucleotide sequences of CD4 and CD8 variants from five study subjects
were analysed phylogenetically. The data set included the sequence of a molecular
clone HXB2 to serve as an outgroup. The phylogenetic tree was constructed using
a distance based method and neighbour-joining as implemented in the MEGA
package (Kumar et al., 1993) (figure 5.10). Pairwise distances were calculated
using the Jukes Cantor method to account for multiple substitutions. Sequences
from each five individuals grouped separately. To assess the robustness of the
observed groupings bootstrap re-sampling was carried out using 100 iterations of
permuted data. Lineages containing variants from P6, P7, W4 and W5 showed high
bootstrap values indicating that variants within an individual were consistently more
similar to one another than they were between individuals. There was however little
bootstrap support for the existence of clearly distinct lineages within an individual
although this may have been caused by the shortness of the sequences analysed (less
than 300bp). Consistent with the inferred V3 amino acid sequences there was no
clear evidence for separate grouping of variants from CD4 and CD8 lymphocytes
although sequences from P6, W6, and to a certain extent W4 showed some evidence
for distinct variants. For example sequences from CD8 lymphocytes of W6 grouped
into a single claid that was distinct from all but two variants isolated from CD8
lymphocytes. Similarly sequences from the CD4 lymphocytes of P6 were
monophyletic although this claid also contained one CD8 lymphocyte.
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Figure 5.10 : Phylogenetic analysis of sequences in the V3 region of CD4 and CD8
lymphocytes isolated from HIV-1 seropositive individuals.
Filled circles represent virus isolates from CD8 lymphocytes. Open circles


















Scale: each — is approximately equal to the distance of 0.0025
DISCUSSION
5.9 Restricted sequence variation in the V3 region
In a previous study investigating HIV-1 V3 sequences from lymphoid and
non-lymphoid tissues it was observed that there was limited sequence variation in
the V3 loop of HIV-1 sequences amplified without prior cell culture (Donaldson et
al., 1994a). This study has also shown restricted V3 variation in CD4 and CD8
lymphocytes isolated from the peripheral blood of HIV-1 seropositive individuals.
This restriction was evident irrespective of the degree of disease progression and cell
type. It has been demonstrated that the primers used to amplify the V3 loop do not
preferentially amplify NSI variants (Donaldson et al., 1994a). Variants with a
predicted NSI phenotype have frequently been detected in previous studies analysis
viral sequences in vivo (Simmonds et al., 1990a; Holmes et al., 1992a; Kuiken et
al., 1992a; Milich et al., 1993a).
5.10 HIV tropism in vivo
This study does not indicate that there is a specific V3 loop sequence which
determines HIV-1 tropism for CD4 or CD8 lymphocytes in vivo. No single amino
acid change or changes were found in the V3 loop of a particular cell type in each
individual. However it is possible that V3 conformation is important in determining
cellular tropism and changes out with the V3 loop may affect the conformation.
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5.11 Phvlogenetic analysis of the V3 region from CD4 and CD8
lymphocytes.
The V3 region is not a particularly useful region for phylogenetic analysis
as this region is under both immunological and functional pressures which restrict
sequence variation. The V3 loop and flanking regions analysed were also too short
(approximately 300 bp) and very few robust groupings (bootstrap value >75) were
detected by re-sampling. However, there was some evidence for divergent V3
nucleotide sequences in CD4 and CD8 lymphocytes from phylogenetic analysis.
5.12 Future investigations
It is difficult to know whether the different sequences represent genuine
diversity of HIV within that cell type or whether each cell type purified consists of
a heterogenous population of cells at different stages of activation. For example
naive and memory lymphocytes may bear different HIV-1 variants. It would be
useful to isolated memory and naive CD4 and CD8 lymphocytes and analyse the V3
sequences derived from each. Future samples should be of a larger volume so a
greater number of cells and therefore more virus variants can be isolated for
sequencing and phylogenetic analysis.
157




Infection with HIV-1 is thought to be restricted to cell types expressing the
CD4 receptor. Cell types previously shown to be infected when isolated from the
peripheral blood of HIV seropositive individuals included CD4 lymphocytes,
monocytes and dendritic cells, all of which express cell surface CD4. However in
vitro results show a much wider cellular range with evidence for infection of CD4
and CD8 lymphocytes, dendritic cells, monocytes and natural killer cells. In this
study CD4 and CD8 lymphocytes, monocytes, B cells, dendritic cells and natural
killer cells were isolated from the peripheral blood of HIV infected individuals at
different stages of disease progression. A limiting dilution nested PCR technique
was used to quantify HIV-1 proviral DNA in each cell subset. HIV-1 DNA was
detected in CD4 and CD8 lymphocytes, monocytes, dendritic cells and natural killer
cells. PCR data and measurements of the relative frequency of each cell subset
were used to calculate the relative contributions of the individual cell subset to total
viral load. Surprisingly, not only are CD8 lymphocytes infected in vivo, they are
a major reservoir of HIV-1 within the peripheral blood of individuals with AIDS.
HIV infection of CD4 and CD8 lymphocytes was detected at all stages of
disease progression. Monocyte infection was detected only in a few individuals and
in these cases the level of infection was consistently low. This supports the theory
that differentiation into macrophages is required for in vivo infection. In general the
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frequency of CD4 lymphocyte and CD8 lymphocyte infection increased with disease
progression. However there appeared to be very little correlation between the level
of DC or monocyte infection with mean CD4 counts. A RT-PCR based method was
developed to detect HIV-1 mRNA transcripts in different cell subsets for which
proviral loads had previously been determined. HIV-1 vpu-env and vpr mRNA
transcripts were detected in CD4 and CD8 lymphocytes and at a low level in
monocytes isolated from the peripheral blood of seropositive individuals. This
finding suggests active replication of HIV in the mature CD8 lymphocyte population
in vivo even although they do not express CD4. These findings rule out the
possibility that CD8 lymphocyte infection is defective or that transcription is
inhibited in this cell type.
Sequence comparisons of the V3 region of the envelope gene indicated that
in some individuals, different virus populations may be present in CD4 and CD8
lymphocytes. This provides further independent evidence for HIV infection of CD8
lymphocytes. V3 amino acid sequences showed restricted variation and this was
evident irrespective of disease status and cell type. In the main the amino acid
sequences were indicative of a NSI-macrophage tropic in vitro phenotype.
Recent studies have shown by virus quantitation and mutation fixation rates
that the rate of CD4 lymphocyte turnover is close to the number of lymphocytes
expressing HIV-1 mRNA in the body (Ho et al., 1995; Wei et al., 1995),
suggesting that HIV-1 infection involves continual rounds of viral replication, cell
destruction and cell renewal. Rather than immune dysfunction or secondary to CD4
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lymphocyte loss, the immunodeficiency observed in AIDS may be a direct result of
the cytopathic effect of active HIV-1 infection. In AIDS a reduction in the cell
numbers and function of CD4 lymphocytes, CD8 lymphocytes, dendritic cells and
natural killer cells is observed. These were the principal cell types infected within
the peripheral blood of HIV seropositive individuals. CD4 and CD8 naive
lymphocytes are lost preferentially as total CD4 counts fall. It may be that the
stimulation of naive cells makes these cells susceptible to HIV infection and
destruction. HIV-1 DNA detected in memory cells may represent differentiated
naive cells with a defective infection. Preferential naive cell depletion may
contribute greatly to the immunodeficiency associated with HIV-1 as these cells are
required for all new T cell mediated immune responses and are memory cell
precursors.
This study provides evidence for the widespread infection of CD4-negative
cells within the peripheral blood of HIV seropositive individuals, indicating that
HIV has a broader tropism for cell types in vivo than described previously. Active
infection of CD4 and CD8 lymphocytes, dendritic cells and natural killer cells may




This study has given rise to many potentially interesting investigations.
Clearly, it would be useful to determine the possible mechanisms for HIV-1
infection of CD4-negative cells. Initial studies reported here show that CD8
lymphocytes up-regulate CD4 expression when stimulated with PHA. In order to
understand this phenomenon better CD8 lymphoctes should be stimulated under
more physiological conditions with for example anti-CD3. It is possible that
stimulation of CD8 T cells in vivo may up-regulate CD4 expression allowing
infection with HIV. Another possible mechanism for HIV-1 infection of CD4-
negative cells is using a second receptor, CCR5 or CXCR4 for example. A panel
of monoclonal antibodies against various cell markers including the chemokine
receptors implicated in HIV infection conjugated to flourescent dyes could be used
for immunocytochemistry or FACS analysis of PBMCs. Determination of which
cell subsets express chemokine receptors will be useful in investigating there role
in infection of CD4-negative cells. A mRNA RT-PCR technique with primers
complementary to nucleotide sequences of each of the chemokine receptors reported
to be involved in HIV infection would also help in determining the cellular
expession of these receptors.
Naive and memory CD4 and CD8 lymphocytes should be isolated from the
peripheral blood of HIV-1 seropositive individuals. PCR for HIV-1 DNA and
mRNA may give some insight into the reasons why naive cells are preferentially
depleted during HIV infection. It will be important to monitor serial samples from
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individuals before and during anti-retroviral therapy. The frequency of infection of
different cell types and cell counts could be compared as could the emergence of
resistant mutants in each cell type. This would give a greater insight into cell and
virus turnover rates in each cell subset.
Investigations of cell death, syncytium formation and functional assays for
CTL responses in CD8 lymphocytes from HIV-1 positive cultures and negative
controls will give an insight into the importance of HIV-1 infection of this cell type
and immune dysfuction. Similiar studies using monocytes and natural killer cells
would also help to determine the role of HIV-1 infection in cell loss.
Natural killer cells do not express CD4 or mRNA for CD4. Investigations
of proviral load and HIV-1 mRNA expression in natural killer cells would be useful
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(ii) Positively selected CD8 cell fraction isolated from the peripheral blood of
an HTV-1 seropositive individual using the miniMACS system.
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ORTHO TRIO PATIENT SUMMARY REPORT
(iii) Positively selected CD8 cell fraction isolated from the peripheral blood of
an HIV-1 seropositive individual using the miniMACS system.
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Frequent infection of peripheral blood CD8-positive T-lymphocytes
with HIV-1
W J Livingstone, M Moore, D Innes, J E Bell, P Simmonds, and the Edinburgh Heterosexual Transmission Study Group
Summary
Background Although lymphocytes expressing the CD4
surface receptor for HIV-1 have been identified as the
principal target of the virus, the extent to which infection of
^pther cell types of the immune system contributes to
immunodeficiency is unknown. We investigated the cell types
in peripheral biood infected with HIV and the relation of viral
load in different subsets to disease progression.
Methods The study group consisted of 16 HIV-infected
individuals, eight of whom had clinically defined AIDS with
CD4 cell counts less than 200/p,L blood. The main
component subsets of peripheral blood mononuclear cells
were purified by magnetic bead separation, and included CD4
and CD8 lymphocytes, B lymphocytes, monocytes, and
dendritic cells. HIV proviral sequences within these separate
populations were quantified by limiting-dilution nested
polymerase chain reaction.
Findings HIV-1 proviral sequences were detected in T-helper
cells, cytotoxic T cells, dendritic cells, and monocytes. CD4 T
lymphocytes constituted the main reservoir of HIV in all but
one of the symptom-free individuals studied (those with CD4
^ount >200/p.L). However, in all the individuals with CD4
counts of less than 200/|xL, most infected cells within the
peripheral blood mononuclear cell fraction were either
dendritic cells or CD8 lymphocytes. Infection of CD8 cells
accounted for between 66% and 97% of total proviral load in
five of the eight AIDS patients. A strong inverse relation
between total CD8 count and the frequency of CD8 T-
lymphocyte infection was found.
Interpretation This study provides evidence for widespread
infection of lymphocytes of the CD8 phenotype, indicating
that HIV-1 has a broader tropism for different cell types in vivo
than described for cultured virus. Infection of CD8 cells may
contribute to the decline of this subset upon disease
progression in HIV-infected individuals. Infection of CD8 cells
may or may not occur by a non-CD4-dependent mechanism of
virus entry.
%iancet 1996; 348: 649-54
See Commentary page 631
Introduction
The principal immunological defect occurring with
progression of HIV-1 infection is the loss of CD4 T-helper
cells, which have a central role in the immune response to
pathogens. Theories about the causes of this loss of CD4
cells range from their destruction or dysfunction directly
caused by viral infection to apoptosis resulting from
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defects in antigen presentation.1 Whether the defects in
many immune pathways, including the cytotoxic T-cell
response mediated by CD8 lymphocytes, are secondary to
the destruction of T-helper lymphocytes is similarly
unclear. For example, Macatonia and colleagues suggested
that infection of reticulodendritic cells with HTV
contributes to the defects in antigen processing and
presentation to T-helper cells found in AIDS patients.2
In this study, we used standard separation methods to
isolate subsets of cells involved in the immune response
and thereby to investigate the extent to which each cell
type is infected with HIV. It has hitherto been generally
accepted that the cellular tropism of HIV is determined
almost exclusively by the distribution of CD4, the cell-
surface receptor for HIV-1.3"5 After virus attachment, high-
affinity interactions between CD4 and the external envelope
glycoprotein (gpl20) of HIV-1 initiate conformational
changes, resulting in exposure of a fusogenic domain of
the transmembrane envelope protein (gp41) which allows
entry of the virus into the cytoplasm.1 CD4 is expressed on
T-helper cells, monocytes, and peripheral-blood dendritic
cells6-7 but not on B cells or mature cytotoxic T cells.
Although monocytes express CD4 and the activation
marker HLA-DR,1,8,9 there is little evidence for extensive
infection ofthese cells with HIV. Estimates of the frequency
of infected monocytes in the peripheral circulation have
ranged from zero to 100 per million of total cells.10"14
Previous reports have found little evidence for in-vivo
infection of mature cytotoxic T cells with HIV,10,15
although infection of CD8 T lymphocytes has been
achieved in vitro.6
Peripheral-blood dendritic cells, like monocytes, are a
heterogeneous population at different stages of
maturation." They are extremely potent antigen-presenting
cells and their infection by HIV could be critical in the
generation of immune dysfunction. Various groups have
isolated populations of these cells that can be infected in
vitro2,16'17 and HTV-1 has been isolated directly from
peripheral-blood cells with dendritic-cell characteristics.14,18
It is not known whether strains of HIV exist with
differences in tropism for different cell types found in
peripheral blood mononuclear cell populations. In vitro,
macrophage tropism is associated with a non-syncytium-
inducing viral (NSI) phenotype. Changes in phenotype
and tropism of virus isolates are known to occur during
disease progression,14,20 although no change in the relative
frequencies of the different cell types infected has been
Primer Sequence (5-3') Sense (+) or Position of 5'base
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Subset removed Monoclonal Cell phenotype
antibody
ER positive* CD3 CD4 CD8 CD16 CD19
E positive None 82-8 47-0 40-1 15-5 0-9
CD4 T cells CD4 54-4 1-7 54-5 14-5 ND
CD8 T cells CD8 120 4-4 4-2 12-7 ND
ER negativef CD3 CD4 CD14 CD21 HLA-
DR
E negative None 1-0 64-7 59-5 8-6 ND
Monocytes CDllb/CD14 10 37-8 3-7 ND ND
B cells CD19/CD21 1-0 43-5 3-7 ND 53-2
ND=not done. *ER-positive=T cells; mean frequencies of three separate purifications (or
two for CD8-depleted cells). fER -negative=non-T cells (B cells, monocytes, and dendritic
cells); results from a single sample.
Table 2: Purity of cell fractions by FACS analysis
shown. Although in-vitro studies15'20 suggest that HIV
isolated from patients with advanced immunodeficiency is
unable to replicate in the monocyte lineage, we have found
that disease progression is associated with the spread of
HIV from cells of the lymphoid system to peripheral sites
such as lung, brain, and gut,21 where many of the target
cells in these tissues are of the macrophage/monocyte
lineage, such as microglia in the brain.22
In this study, whole blood from HIV-1-positive
individuals was separated into component cell populations
and nucleic acid was extracted from CD4 T cells, CD8 T
cells, monocytes, B cells, and dendritic cells. Limiting-
dilution PCR was then used to quantify the amounts of
provirus in each cell type.
Patients and methods
Blood samples
20 mL samples of whole blood were collected from 16 HIV-
seropositive individuals in Edinburgh, UK. Immunological and
virological information on disease progression was available for 13
of the participants, whose risk factors for infection included
intravenous drug abuse and sexual contact with an HIV-positive
individual. CD4 counts were available for the samples studied and
for the same individuals every 1 or 2 months during the previous
6 months, so mean values could be calculated. These ranged from
less than one to more than 980 CD4 lymphocytes per |xL. Eight
of the patients had CD4 counts associated with late-stage
symptomatic disease (CD4 count <200/|xL), whereas the other
five had no symptoms and had CD4 counts of more than 200/p.L.
Absolute counts were also available for CD8 T cells, B cells, and
monocytes, as well as viral p24 antigen levels.
Cell separation
CD3, CD4, CD8, CD 14, and CD 19 monoclonal antibodies were
supplied by the Scottish Antibody Production Unit, Lanark, UK.
The CD21 monoclonal was obtained from the Binding Site,
Birmingham, UK, HLA-DR from American Tissue Culture
Collection, Rockville, Maryland, USA, and CDllb was donated
by Peter Beverley, University College, London, UK.
Blood samples were diluted with an equal volume of
phosphate-buffered saline and mononuclear cells were isolated by
density-gradient centrifugation (Lymphoprep, Oslo, Norway).
Dendritic cells were isolated from the mononuclear cells as
described previously,6 with modifications so that other cell types
could also be selected. Briefly, T cells were depleted by rosetting
with neuraminidase-treated sheep erythrocytes. Magnetic beads
coated with antibody to mouse IgG (Immunotech, Marseilles,
France) were incubated with various mouse monoclonal
antibodies, and then washed twice with phosphate-buffered saline
to remove unbound antibody. T cells, which bind to the treated
sheep erythrocytes (ER positive), and non-T-cell (ER negative)
fractions were serially incubated on ice with these antibody-coated
beads for 0-5 h and cells bound to the beads were removed by
means of a magnet. These selected cells were then washed twice
with the buffer. j
The ER-positive fraction was incubated first with anti-CD4 t^
select T-helper lymphocytes and then with anti-CD8 to select
cytotoxic T cells.
Cells of the ER-negative fraction were incubated with anti-
CD3-coated beads to remove any contaminating T cells, and then
monocytes were isolated by use of anti-CD lib and anti-CD 14.
B cells were depleted with anti-CD 19 and anti-CD21, from the
ER-negative monocyte-depleted fraction. Dendritic cells were
isolated from the fraction depleted of T cells, monocytes, and B
cells by use of beads coated with CD4 and HLA-DR.23 Viable
cells were counted by means of a haemocytometer, with trypan-
blue stain exclusion of dead cells.
For three samples, a different method for cell separation was
used. Peripheral blood mononuclear cells were incubated with
anti-CD4-coated beads as before, and CD8 cells were obtained
from the residual cells by use of monoclonal antibody cell sorter
(MACS) anti-CD8-conjugated beads (Miltenyi Biotec Ltd,
Camberley, UK).
Purity of Isolated subsets
The process of isolating subsets of mononuclear cells by antibodj
coated magnetic beads prevented analysis of the selected cells by
fluorescence-activated cell sorting (FACS) techniques. However,
the purity of cell fractions could be inferred by measurement of
the frequencies of different cell types in the residual cells after
removal of a particular fraction. Cell populations were stained
with mouse monoclonal antibodies conjugated to fluorescein
isothiocyanate or phycoerythrin for FACS (Becton-Dickinson,
Cowley, UK).
Quantification of HIV proviral sequences
Nucleic acid was isolated from cells and plasma by incubation in
proteinase K (1 mg/mL) for 2 h at 37°C in the presence of 0-5%
sodium dodecyl sulphate and poly A precipitant (40 |xg/mL),
followed by extraction with chloroform/phenol, and precipitation
with ethanol. Proviral sequences were quantified by a previously
described limiting dilution and nested PCR approach.24 Viral
genome was quantified by means of primers spanning the V3 loop
and gag region. The nucleotide sequences of the primers and the
position of the 5' base in the HXB2 genome25 are given in table L
Patient Risk group AIDS-defining CD4 count p(L) CD8 count p.(L) Monocytes p24 antigen
number illness
Sample used Mean 6 mo* Sample used Mean 6 mo*
(per pi) (pg/mL)
26 Het/IVD <1 0-5 70 105 160 64
22 Homo PCP <1 0 235 348 120 87
1 IVD PCP 2 4 571 875 270 <8
24 Het oc 7 14 372 552 280 53
2 Het/IVD 24 63 456 505 150 <8
3 Het PCP 31 80 336 524 284 <8
27 IVD 35 54 1951 2291 420 <8
4 Het/IVD 162 228 646 677 190 <8
5 Het/IVD 234 236 361 433 160 <8
30 IVD 238 279 1244 1430 740 <8
23 Het 385 305 764 764 530 <8
6 IVD 959 938 2204 1422 550 112
7 IVD 983 860 2102 1739 320 33
Het=heterosexual contact; IVD=intravenous drug user; Homo=male homosexual; PCP-Pneumocystis carinii pneumonia; OC=oesophageal candidosis.
*Mean CD4 and CD8 counts are an average of three to six results taken over 6-month period before sample was analysed.
Table 3: Risk group, CD4 and other cell counts, and blood virus load






Frequency of infection per 106 cells
CD4 cells CD8 cells Monocytes B cells Dendritic cells Total PBMCs
26 <1 >483 58 4 <10* 200 8
22 <1 >4882 110 40 <10 60 167
1 2 4873 4 <4 <7-2 180 ND
24 7 44 34 <10 <20 23 4
2 24 208 24 20 <2 60 ND
3 31 39 2 <1 <2 20 ND
27 35 85 6 4 <1 <10 10
4 162 400 400 <1 <1 700 ND
5 234 40 1 <0-25 <2-5 6 ND
30 238 2 <20 <1 <10 1099 41
23 385 117 <10 <10 <10 <10 49
6 959 2 <0-05 <0-8 <1 <1 ND
7 983 11 0-5 <0-05 <0-08 40 ND
ND=not done.
Kfor negative samples, cut-off for assay depended on number of cells extracted,
f able 4: Absolute cell counts and frequency of infection of 106 cells from different subsets of peripheral blood mononuclear cells
(PBMCs) with HIV
V3'primers provided equivalent quantification to primers in the
gag region.2'
Preliminary quantifications used serial ten-fold dilutions of
DNA and subsequently (with V3 primers) two-fold dilutions in
quadruplicate around the endpoint with between ten and 20
replicates. In addition to the selected subsets (CD4 T cells, CD8
T cells, B cells, monocytes and dendritic cells), PCR was also
used to quantify the provirus load in peripheral blood
mononuclear cells and the residual ER-positive populations after
depletion of CD4 and CD8 cells in seven patients. Residual cells
from this fraction could be unselected cytotoxic T cells or T-
helper cells in which CD4 receptors were down-regulated by
infection with HIV. For patients 2 and 5, up to 20 replicates of
the endpoint dilution were amplified in V3 to obtain single
molecules for sequencing. Quantification results were expressed
as proviral copies per million cells. All separations, extractions,
fcnd amplifications were carried out with parallel samples of
mononuclear cells isolated from buffy coat leucocytes derived
from HIV-negative blood to serve as negative controls.
Analysis of quantification results
The relative frequencies of CD4 T lymphocytes, CD8
lymphocytes, monocytes, and B cells in the original mononuclear
cell populations were estimated by the FACS method. To
estimate the numbers of cells used for PCR, cell concentrations
were compared before and after depletion with specific
monoclonal antibodies for each subset. The only exceptions were
samples from individuals with extremely low CD4 cell counts
(< 100/pL), where the low level of cells lost during magnetic
separation greatly exceeded the numbers of selected cells, and led
to a significant overestimate of the numbers of cells separated. For
these samples we therefore used the absolute CD4 cell counts
derived from the FACS analysis of the original blood samples to
estimate cell numbers, allowing for the loss of cells during the E-
rosetting step before CD4-depletion.
^ To ensure that all proviral sequences were accounted for by this
method of analysis, we compared the total number of provirus-
bearing cells from unfractionated peripheral blood mononuclear
cells with the sum of each of the component subsets analysed. For
example, the frequency of provirus in mononuclear cells from
patient 26 was eight copies per milion cells. This was similar to
the sum of the frequencies in the separate subsets. In this
particular case, the contribution to the proviral sequences in the
CD8 cells was 58 copies per million CD8 cells, multiplied by their
frequency in the total population (70 000/mL in a total
mononuclear cell concentration of 600 000/mL; 11-6%).
Therefore, CD8 cells contributed 6-8 (58X0-115) cells/mL to the
mononuclear cell virus load. The contributions of CD4
lymphocytes (2-1/10° cells), monocytes (1-1/10" mononuclear
cells), and dendritic cells (1-3/10" mononuclear cells) were
calculated similarly. The total of these individual contributions
was 11-3 cells/mL, close to the virus load measured by PCR on
Anfractionated mononuclear cells (eight copies/10" cells). This
analysis was carried out on six study individuals and yielded a
total ratio of mononuclear cell proviral load to total of the subsets
load of between 0-4 and 1-4. These results are consistent with the
accuracy of the methods used for cell counting and quantification
of HIV sequences, and independently validate the methods used
for quantification of cells and provirus.
To test for correlations between proviral load in each cell type
and markers of disease progression, non-parametric tests
(Spearman's rank correlation test) were performed.
Results
ER-positive cells contained a mean frequency (three
measurements) of 82-8% CD3 cells (table 2).
Contaminating cells included B lymphocytes (0-9% CD 19
cells) and natural killer cells (15-5% CD16 cells). Positive
selection for CD4 cells was shown by a reduction of CD4-
positive cells from a mean of 47-0% in the ER-positive
population to 1-7% in the depleted cells. CD4-depleted T
cells consisted of 54-5% CD8 cells, which were then
positively selected on CD8-coated beads. Residual cells
after CD8 depletion contained only 4-2% CD8 cells.
ER-negative cells (non-T cells) (table 2) contained less
than 1% CD3-positive T cells. Monocytes were effectively
removed by means of beads coated with CD lib and
CD14 (59-5% to 3-7%). The remaining cells were
depleted by use of CD19-coated and CD21-coated beads
to remove residual B cells. Less than 1 % of the resulting
population expressed CD3, 43-5% CD4, and 53-2%
HLA-DR, a phenotype consistent with dendritic cells.6-23
Magnetic beads coated with anti-CD4 and anti-HLA-DR
coated magnetic beads were then used to isolate the
dendritic cell fraction.
The virus load in different cell types isolated from
mononuclear cells of HIV-1 seropositive patients was
quantified by means of limiting dilution PCR and
compared with risk group, p24 antigen levels, and mean
CD4 and CD8 cell counts (tables 3 and 4). We used mean
CD4 cell counts taken over the previous 6 months as a
marker for immunosuppression and progression to AIDS.
HIV DNA was detected in the CD4 T cell subset of all 13
individuals studied (between two and more than 4882
provirus copies per 10" cells). Infection of non-CD4
lymphocytes was more frequent in AIDS patients (CD4
lymphocyte count <200/p.L) than in non-AIDS patients.
Infection was detected in monocytes of four individuals
with CD4 counts of 0, 24, and 35 per p.L. A similar
association was found with the infection of CD8
lymphocytes, which was present in all individuals with
CD4 counts less than 200/|iL, whereas infection of this
subset was at a low level (one virus copy per 10" cells, n=l)
or absent (n=4) among those with CD4 counts less than
Vol 348 • September 7, 1996 651
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CD4 983 959 385 238 234 162 35 31 24 7 2 0 0
count nL
Patient 7 6 23 30 5 4 27 3 2 24 1 22 26
number
CD4 Dendritic cells Monocytes CD8
Figure: Relative contribution of different cell subsets to proviral
load in peripheral blood mononuclear cells
Samples ranked by mean CD4 lymphocyte count, with highest value to left
(table 3).
200/pL). Viral RNA was detected in plasma from ten of 13
individuals. However, DNA was never detected in plasma.
Estimations of the frequencies of infected cells,
combined with their frequency in peripheral-blood
mononuclear cell populations, were used to calculate the
proportion of virus in each subset isolated (figure). The
proportion of CD4 lymphocytes infected with HIV
increased with disease progression (p=0-004; Spearman's
rank correlation), although their contribution to total virus
load in the mononuclear cell population showed a
downward trend. By contrast, both the frequency of
infection of CD8 lymphocytes and the proportion of HIV
in the mononuclear cell population contributed by CD8
cells increased with disease progression (p=0-04 and
p=0-03 respectively). There was a significant reduction in
the number of circulating CD8 lymphocytes in individuals
who had low CD4 counts (table 3; p=0-005). No
correlation was found between infection of dendritic cells
and monocytes with progression of disease.
Because the finding of HIV infection of CD8 cells was
surprising, we separated mononuclear cell subsets from
three HIV-infected individuals by a different method to
isolate CD8 cells, which allowed direct analysis of their
purity (table 5). First CD4 cells were removed from
mononuclear cells by incubation with anti-CD4-coated
magnetic beads. CD8 lymphocytes were then selected
from the depleted cells using anti-CD8-coated MACS
beads in a column, and these cells were used for FACS
analysis and for HIV PCR. MACS beads efficiently
selected CD8 cells. Frequencies of contaminating CD4
cells ranged from 0-5 to 1-3% in the three patients.
Sample %CD3 % Lymphocytes Proviral copies
number
CD4 B cell %NK cells per 106 cells
S04 97 1-3 0-2 2-4 1400
S05 94 1-2 0-4 0-2 84
S06 95 0-5 0-3 1-9 8-7
NK=natural killer.
Table 5: Detection of HIV proviral sequences in cells separated
by CD8-MACS beads
Frequencies of B cells and natural killer cells were similarly
low, with maximum levels of 0-4% and 2-4% respectively.
HIV proviral sequences were detected by PCR in the
CD8 cells separated by MACS beads from all three
patients (8-7-1400 copies per 106 cells; these values were
similar to those obtained by the original separation method
with Immunotech beads). The frequencies of proviral
sequences in the cells separated by incubation with CD4
beads (containing CD4 lymphocytes, monocytes, and
dendritic cells) were 128, one, and ten copies of DNA per
million cells for S04, S05, and S06, respectively. Each of
these frequencies was lower than those for the
corresponding CD8 cell samples, indicating that no level
of CD4 subset contamination of the selected CD8 cells
could account for the frequency of proviral sequence^
shown in table 5.
The use of monoclonal antibodies from different sources
in the two methods made it unlikely that cross-reactivzty
between the CD8 monoclonal antibody and cell-surface
proteins other than CD8 was responsible for the selection
of HIV-infected cells. Similarly, the very low frequencies
of contaminating CD 16 natural killer cells and CD4
lymphocytes made it unlikely that they were the source of
HIV proviral sequences in the isolated CD8 cells.
Discussion
We found HIV infection of a range of cell types within the
peripheral blood mononuclear cell populations. There was
remarkable variation in the frequencies of infected cells
within each subset, although there was some evidence for a
consistent change in the predominant CD4 T-helper
target cells upon disease progression.
A surprising finding was the frequent infection of CDS
lymphocytes from AIDS patients (as high as 400 provirus
copies per 10" cells in one case). For methodological
reasons we consider it unlikely that contamination from
HIV-infected CD4 cells could have accounted for the
provirus detected in CD8 cells. Levels of contaminating
CD4 lymphocytes were consistently low (table 5).
We subsequently carried out sequence comparisons of
the V3 region of CD8 and CD4 lymphocytes and of
dendritic cells isolated from two of the patients (2, 5).
Genetically distinct populations, predominantly of a
predicted NSI phenotype, were found in the CD4 and
CD8 cell types in both individuals, ruling out cross-
contamination as an explanation for the HIV sequences
detected in the CD8 lymphocytes.
Our findings tend to refute previous reports that CD8
cells were uninfected in vivo.10,15 This discrepancy may be
explained by the fact that a relatively insensitive PCFy
incapable of detecting low levels of infection, was used in
both of these earlier studies. However, Semensato and
colleagues26 have reported that CD8 lymphocytes from the
lungs of patients with AIDS show similar frequencies of
infection to those we found in the mononuclear cells.
Only four of the 13 patients tested harboured HIV
provirus in peripheral-blood monocytes, consistent with
previous reports of low frequencies of infection in this cell
type in vivo.10,14
Previous reports of the infection of dendritic cells are
contradictory. For example, Hsia and colleagues did not
detect HIV-1 provirus in 104 or 105 dendritic cells isolated
from the peripheral blood monocytes of seropositive
patients,14 whereas Patterson and colleagues detected HIV
provirus by PCR in lymphocytes and purified dendritiri
cells of all patients investigated and found that, in each™
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case, the viral load was similar for both cell fractions.18 We
detected HIV-1 provirus in the peripheral blood dendritic
cells of ten of the 13 patients. Independent evidence for in
vivo infection of dendritic cells was obtained by sequence
comparisons of the V3 region. Distinct populations of
HIV-1 variants were found in dendritic cells compared
with those found in CD8 and CD4 cells (data not shown).
Natural killer cells, which we found to be present in ER-
positive cells (15-5%; table 2) express low levels of the
CD8 receptor and can be infected with HIV in vitro.27
However, low frequencies of natural killer cells were
consistently found in the CD8-positive population selected
by MACS beads (table 5). Most cells expressed CD3 and
a maximum of 2-4% expressed CD16. Natural killer cells
kre therefore unlikely to be the source of the HIV proviral
Sequences detected in the CD8 population.
Although CD8 lymphocytes do not express CD4, in
vitro infection of CD8 lymphocytes with HIV-1 has been
achieved by co-culture with HIV-1-infected CD4 cells.28
The interaction between CD4 and CD8 cells occurring in
vivo as part of the immune response may transmit
infection to CD8 lymphocytes. An alternative explanation
is suggested by studies in SCID mice (ie, animals with
severe combined immunodeficiency), which indicate that
infection of human progenitor T cells may occur in the
thymus of infected animals during normal selection for
both antigen specificity and co-receptor (CD4 or CD8)
expression.29 Thus the peripheral CD8 cells we found to
be infected with HIV could have taken up virus within the
thymus while expressing CD4 during normal selection at
an immature stage. This hypothesis would explain why we
only see infected CD8 cells later in disease. An alternative
(jptplanation for widespread infection of CD8 cells is that
HIV can infect cells through a non-CD4-dependent
mechanism of virus attachment and entry. CD8
lymphocytes, in common with CD4 lymphocytes and
macrophages, express the CC-CKR-5 receptor (M Dittmar,
personal communication), which has been identified as a
second receptor for non-syncytium-inducing variants of
HIV-1.30,3' Infection of CD8 lymphocytes may therefore
occur through a different as yet unidentified atachment
protein, but there may be a common pathway for viral
phenotypes in cell fusion and entry. Our current
understanding of the tropism of HIV-1 is largely derived
from in-vitro investigation of the properties of virus
isolates. The more restricted tropism of these isolates for
CD4 cells could result from selection. For example, the
process of virus isolation and co-culture with primary
lymphocytes could preferentially stimulate CD4-tropic
firiants at the expense of variants with tropisms for cellpes no activated by phytohaemagglutinin. Most
laboratory strains of HIV lose their ability to replicate in
macrophages. Current methods of virus culture may also
select against variants that can replicate in certain cell
types such as CD8 cells in which a different cellular
receptor is used.
One of the factors contributing to the high frequency of
CD8-positive lymphocytes occurring only in late-stage
disease is loss of the CD4 T-cell population from
circulation. On the other hand, a substantial increase in
CD8 T-cell infection on disease progression may possibly
be related to the phenomenon by which HIV spreads to
non-lymphoid tissues during the later stage of disease,21
with loss of immune control.
a These results are also consistent with the possibility that
lie decline in CD8 T cells may be a direct consequence of
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the cytopathic effect of HIV on this subset and that HIV
has a broader cellular tropism than previously described.
These findings have important implications for
understanding of the pathogenesis of HIV and the design
of intervention studies.
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White-coat hypertension as a cause of cardiovascular dysfunction
Stephen K Glen, Henry L Elliott, Joan L Curzio, Kennedy R Lees, John L Reid
Summary
Background The increasing use of 24 h ambulatory blood
pressure monitoring has allowed diagnosis of white-coat
hypertension, in which blood pressures are higher on clinic
measurements than on ambulatory monitoring. Treatment is
not generally thought to be necessary for this disorder.
However, there is evidence that patients with white-coat
hypertension develop renal impairment and left ventricular
hypertrophy. We undertook this study to assess whether
white-coat hypertension, in the absence of cardiovascular
structural abnormalities, is associated with cardiovascular
functional abnormalities.
Methods Cardiovascular function was assessed by
ultrasonography in three groups of patients classified as
normotensive, persistently hypertensive, or white-coat
hypertensive (23, 20, and 22 patients, respectively) on the
basis of ambulatory blood pressure monitoring, carried out for
28 h with recordings taken every 15 min during the day and
every 20 min during the night, and clinic measurements,
made with a semi-automatic oscillometric device.
Results Similar abnormalities of diastolic left ventricular
function were identified in the patients with persistent
hypertension and those with white-coat hypertension; both
groups differed in these indices from the normotensive group
(E/A ratios 0-94 [SD 0-23], 1-06 [0-21], and 1-24 [0-31]
respectively; ANOVA p<0-005). In addition, the white-coat and
persistently hypertensive groups, when compared with the
normotensive group, showed similar abnormalities of
elasticity, compliance, and stiffness (stiffness index 4-32
[1-90], 4-53 [1-38], and 3-27 [0-95] respectively; ANOVA
p<0-05) of the large arteries.
Interpretation Functional cardiovascular abnormalities were
identified in white-coat hypertensive patients who had no
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identifiable structural abnormalities. Such functional
abnormalities can be reversed by antihypertensive treatment.
We propose that patients with white-coat hypertension might
benefit from antihypertensive treatment as well as those with
persistent hypertension. This hypothesis should be addressed
in prospective clinical trials.
Lancet 1996; 348: 654-57
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Introduction
Most clinical trials of antihypertensive treatment have
relied on conventional clinic measurement of blood
pressure to identify hypertensive patients and to
demonstrate the benefits of blood pressure reduction.1
However, 20-40% of individuals with borderline clinic
hypertension can be reclassified as normotensive during
daytime ambulatory monitoring,2 5 and these trials
inevitably included some such individuals with white-coat
hypertension. However, controversy remains about the
precise definition of white-coat hypertension. For example,
one definition is a raised diastolic pressure (90-104 mm Hg)
at clinic but normal daytime ambulatory blood pressure
(below the 90th percentile of a normotensive control
group)2 and another is a mean clinic blood pressure at least
6 mm Hg higher than the ambulatory mean.1 Nevertheless
the inclusion of white-coat hypertensive patients in the
studies cited did not prevent the demonstration of
significant reductions in cardiovascular disease.
Irrespective of the definition, and despite the recognition
that the presence of medical personnel influences blood
pressure," the general assumption is that the inclusion of
white-coat hypertensive patients may have diluted the
overall magnitude of the benefits of a drug treatment found
in previous studies. Another possibility is that the white-
coat hypertensive patients also benefited from active
treatment—this idea is the substance of our hypothesis.
The main aim of our pilot study was the non-invasive
measurement of a range of indices of cardiovascular
function in patients referred for evaluation of their
hypertension, to find out whether patients with white-coa4
hypertension differ from patients with hypertension or
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